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Summary
Cyclic AMP phosphodiesterases were studied in T lymphocytes from 
different maturation stages, tissues and species. Although cyclic AMP 
phosphodiesterases were characterised in lymphocytes isolated from murine 
spleens, human tonsils, a murine thymoma cell line and a human mature T cell line, 
the main focus of this study was cyclic AMP PDE activities from murine 
thymocytes. With the use of selective phosphodiesterase inhibitors, the relative 
contribution that particular phosphodiesterase isoforms made towards total 
phosphodiesterase activity in the cells was assessed. Thus, cyclic GMP stimulated,
PDE2 activity and cyclic AMP specific PDE4 activity were shown to provide the 
major cyclic AMP hydrolysing activities in murine thymocytes. PDE4 activity 
predominated (-80%  total) in the absence of cyclic GMP. However, on addition of 
low (10|iM) concentrations of cyclic GMP, PDE2 activity constituted the major 
PDE activity in thymocytes (-80% total).
The PDE4 selective inhibitor rolipram inhibited murine thymocyte PDE4 
activity in a dose-dependent manner (IC50 ~65nM). PDE2 activity was stimulated 
in a dose-dependent fashion (EC50 ~1|UM) by cyclic GMP and was selectively 
inhibited by the compound, EHNA (IC50 ~4pM), No calcium/calmodulin 
stimulated, PDEl activity or cyclic GMP-inhibited, PDE3 activity was found to be 
present in murine thymocytes. The non-selective PDE inhibitor IB MX elicited 
>98% inhibition of PDE activity in thymocytes indicating the absence of IBMX- 
insensitive, PDE7 activity in these cells. FPLC analysis confiiTned these findings, 
revealing a rolipram inhibited PDE4 activity and a cyclic GMP stimulated, EHNA 
inhibited, PDE2 activity, but no PDEl, PDE3 or PDE7 activity.
The selective inhibitors identified the profile of phosphodiesterase activities
in T cells from other sources. Thus, PDE2 activity was also found to be present in
i
1
murine splenic lymphocytes, proliferating T3.2 thymoma cell line derived from 
murine thymus and the human leukemic T cell line, Jurkat. In contrast to murine 
thymocytes, PDE3 appeared to be present in human tonsillar T  lymphocytes, the 
human T cell line Jurkat and the thymoma cell line, T3.2. Similar to murine 
thymocytes, PDE4 activities were found to be present in the murine thymoma cell 
line, T3.2 and the human T cell line, Jurkat. Moreover, primary lymphocytes 
isolated from murine thymuses, spleens and human tonsils did not contain 
Ca^+/CaM stimulated, PDEl activity. In contrast, the proliferating human Jurkat T 
cell line contained calcium/calmodulin-stimulated PDEl and an IBMX insensitive 
PDE activity. The differential distributions of phosphodiesterase activities within 
these lymphoid cells indicated species and possibly maturation-dependent 
differences of phosphodiesterase expression within these cells.
Upon ligation of the TCR/CD3 complex with either the mitogenic lectin 
phytohaemagluttinin or anti-TCR/anti-CD3 monoclonal antibodies, 
phosphodiesterase activities and cyclic AMP levels were found to be rapidly and 
differentially regulated in murine thymocytes. Within 5 minutes of challenge with 
PHA, there was a transient decrease (-83%) in PDE4 activity and in PDE2 activity 
(-40% ), returning almost to basal in 20 minutes. Both anti-CD3 and anti-TCR 
antibodies also caused an initial reduction in the PDE4 activity (-50%) which was 
then followed by a sustained increase in activity. In contrast to that observed with 
PHA, anti-TCR/CD3 antisera had little effect on PDE2 activity. Cyclic AMP levels 
were also differentially regulated upon stimulation of thymocytes with either PHA 
or anti-CD3 monoclonal antibodies. Hence, there was a transient 2-fold elevation 
in cyclic AMP levels upon stimulation of thymocytes with PHA, which reached 
basal levels again within 30 minutes. In contrast anti-CD3 antibody stimulation of ’
thymocytes led to a slow sustained elevation in cyclic AMP levels over a 30 minute 
period.
i
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PDE4 activity. Moreover, the protein kinase C selective inhibitor chelerythiine
Study of the mechanism controlling the anti-CD3-stimulated elevation in 
PDE4 activity in murine thymocytes revealed that the increase in this 
phosphodiesterase activity was dependent on protein tyrosine kinase and protein 
kinase C-mediated signals. This interpretation was based on findings that the 
tyrosine kinase inhibitor, genistein partially inhibited the TCR-mediated elevation in
Ï
blocked the rise of PDE4 activity and the phorbol ester, phorbol- 12-myristate, 13-
acetate caused an increase in PDE4 activity which was of a similar magnitude to the
.V:elevation seen in the presence of anti-CD3 antibodies. Interestingly, the elevation in 
PDE4 activity was blocked upon stimulation of thymocytes with TPA or anti-CD3 
antibody in the presence cyclohexamide or actinomycin D. This indicated that a 
rapid induction of PDE4 activity occurred in murine thymocytes upon crosslinking
of the TCR/CD3 complex. These data identify ‘crosstalk’ between cyclic AMP and
■
PKC mediated signalling pathways.
::A
.X X V I
CH A PTER 1.
INTRODUCTION.
1.1. T ceil development biology.
T lymphocytes provide the cellular arm of the immune system and are
.responsible for the helper (combating bacterial infection) and cytotoxic 
(protecting against viral pathogens) T cell functions of an immune response.
Mature T lymphocytes respond to antigen via cell surface T cell antigen receptors 
(TCR), which specifically recognise proteolytically processed peptide antigens 
bound in the grooves of self major histocompatability complex (MHC) proteins 
on antigen presenting cells (APCs).
'
Mature T cells which are tolerant to self antigen develop in the thymus.
Pre-T cells originating from haematopoietic sites such as foetal liver and adult 
bone marrow enter the thymus at the cortico-medullary junction/subcapsule of the 
thymus via the blood. These cells express a very low concentration of the co­
receptor CD4, which is quickly lost thus giving the CD47CD8" or “double 
negative” phenotype. Immature thymocytes rearrange and express TCRp which 
promotes the development of thymocytes (Mallick etaL,  1993; Raulet etaL,
1985). The positive selection of cells expressing a productive TCRp avoids the 
accumulation of thymocytes with nonproductive TCRp rearrangements. TCRp is 
expressed on the surface of immature T cells with a surrogate a  chain (gp33)
(Groettrup et al., 1993). These peptide chains ate linked by disulphide bonds to 
form a pre-T cell receptor (pre-TCR) in association with the CDSySe complex (a 
collection of non-covalently associated proteins involved in receptor assembly, 
membrane trafficking and transduction of transmembrane signals in lymphocytes, 
see section 1.2.1). Further maturation occurs via signalling through the p chain, 
the CD3 complex and the non-receptor protein tyrosine kinase (PTK) (see 
section 1.4).
p chain expression promotes maturation of CD4VCD8" thymocytes 
beyond this “double negative stage” (Kishi ei at., 1991). Following expression 
and allelic exclusion of TCRp, the cells are selected for clonal expansion and 
maturation, with the induction of CD4 and CDS co-receptor expression producing
I
the CD4+/CD8+ “double positive” phenotype (Boyd and Hugo, 1991). At this 
stage T C R a rean'angement can occur, and gp33 expression is down-regulated, *
allowing for the expression of the mature TCR/CD3 complex (Groettrup et al., 
1993). CD4VCD8^ cells may temporarily become TCR negative at this transition, 
because p chains can only be exported to the surface in a a p  dimeric 
conformation. However, once productive a  chains are formed, the a p  
heterodimer is expressed.
At the CD4^/CD8* stage, negative selection leading to the deletion of 
auto-reactive clones occurs (Boyd and Hugo, 1991; Boyd etal., 1993) (fig. 1.1). 
Indeed, programmed cell death (apoptosis) during negative selection plays an 
important role during thymic education since the vast majority of cells (95%) die 
in the thymus and only 5% are rescued from cell death and are positively selected 
(Bill and Palmer, 1989; Hueber et aL, 1994; Kaye and Ellenberger, 1992; Swat et 
a l ,  1991) (see section 1.4.1), In addition, clonal anergy can also occur, whereby 
the cells do not react upon recognition of a peptide antigen (Nossal, 1994).
Positive selection for self MHC restriction, and functional maturation of 
the cells also occurs at the CD4+/CD8+ stage. This selection procedure occurs in 
order to produce a T cell repertoire that only recognises foreign peptide antigen in 
the context of self MHC. The essential event during this process is the binding of 
apT C R  to self MHC molecules (Bill and Palmer, 1989). Binding rescues the 
short-lived CD4‘*'/CD8'  ^ thymocytes from cell death, and in doing so, signals 
whether CD4 or CD8 co-receptor will be down-regulated. Generally, this 
determines the class of effector cell to which they will differentiate and specificity 
for MHC class-I or II molecules. Positive selection is associated with the 
termination of TCR retirrangement as gene rearrangement of the a  gene locus 
continues until the cell is positively selected or the cell dies. Thus positive 
selection not only selects cells with functional self restricted antigen receptors, but 
also rescues cells from programmed cell death.
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Figure 1.1. Simplified scheme of T cell development from stem cell 
to mature T lymphocyte.
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As a result of positive selection, CD4+/CD8+ thymocytes up-regulate their 
TCR levels (Borgulya et a l ,  1991; Ohashi et a l ,  1990). The development from 
the CD4+/CD8+ stage to the expression of CD4 or CDS “single positive” cells is 
also thought to be dependent on TCR-M H C interaction (Scott et a l ,  1989; S ha et 
a l ,  1988). If the TCR is not ligated within 4-5 days, the cells simply die (Egerton 
et a l ,  1990). CD4 or CD8 is down-regulated before entry into the periphery, via 
the medulla or cortico-medullary vascular sites (Savino et al., 1993).
1.2. T ceil antigen receptor/CD3 complex.
The TCR/CD3 molecule can be subdivided into three units; the clonotypic 
a p  heterodimer, responsible for mediating antigen recognition, the CD3 complex 
and the Ç family (made up of Ç and fr subunits) responsible for transmitting the 
signals from the a p  heterodimer inti-acellularly (Weiss, 1991).
Antigen recognition for T lymphocytes is effected through the variable 
domains of TCR molecules. Genes that encode these variable regions are 
assembled during the early stages of T cell differentiation from germline variable 
(V), diversity (D) and joining (J) gene segments by a process known as V(D)J 
recombination. This allows the production o f a maximal number o f  receptors 
from a relatively small amount of genetic m ateria l. V(D)J recombination occurs 
at four different gene loci a , p, y, and Ô (Davis and Bjorkman, 1988). For a  or y, 
one of many domain-sized V regions is juxtaposed to one of several short J gene 
segments; while for the other chains, P or 5, an additional short D segment is 
interposed between the V and J segments. Imperfect joining o f recombining gene 
segments with the loss or gain of nucleotides (under the action of terminal 
deoxytransferase (TdT)) enhances the vtuiability of TCR proteins and 
superimposes junctional diversity on to combinatorial diversity (Strominger, 
1989). Initial P chain rearrangement and expression is followed by a termination 
o f P gene reaiTangement, which contributes to allelic exclusion. The a  chain then 
rearranges, but is not allelically excluded (Raulet et a l ,  1985; Snodgrass et a l ,
1985). The recombinase-activating gene (RAG) genes are required to anneal 
DNA regions together in this recombination event (Mombaerts et a l ,  1992; 
Shinkai et aL, 1992). These genes are found to be expressed in early lymphocyte 
progenitors, with their expression levels tightly regulated (Neale et a l ,  1992). 
Knockout mutations of RAGl, RAG2, or TCRp in murine models lead to an 
accumulation of immature TCR7CD47CD8" thymocytes. Thus demonstrating 
the importance of these genes during T cell maturation (Mombaerts et a l ,  1992; 
Shinkai e t a l ,  1992).
1.2.1. Structure of TCR/CD3 complex.
The TCR homodimer of the TCR/CD3 complex is composed of a 
clonotypic antigen recognition unit (aP  or y6  heterodimers). Following ligand 
binding, signals are transmitted to one or more of the CD3 components. The CD3 
complex consists of two CD3e chains, one CD35, one CD3y. The invariant, non- 
covalently associated CD3 (Ô, y, e) and Ç, family (Ç and r\) chains are involved in 
receptor assembly, membrane trafficking and the transduction o f transmembrane 
signals (Weiss, 1991) (fig. 1 .2 ). This multicomponent structure has no intrinsic 
catalytic activity, but non-receptor PTKs are found to be recruited to the receptor 
complex, via specialised motifs contained within the TCR/CD3 complex. The 
CD3 structure facilitates the transmission of signals from the membrane to the 
nucleus of the cell, via multiple and complex signalling cascades (Weiss and 
Littman, 1994).
The aPTCR comprises a disulphide-linked heterodimer, the a  (40-50kDa) 
chain being more acidic than the P (35-47 kDa) chain (Marrack and Kappler,
1987). Each polypeptide chain comprises two immunoglobulin-like domains of 
approximately 110  amino acids, which are anchored into the plasma membrane by 
a transmembrane peptide and a short cytoplasmic tail. The amino acid sequence 
polymorphisms reside in the N-terminal domains of a  and p polypeptides, which 
are homologous with the variable domains of immunoglobulins (Davis and
Figure 1.2. Schematic representation of the T cell antigen 
receptor.
The diagram shows the components of the TCR: the clonotypic 
heterodimer, CD3 chains (5, e and y), and the Ç family (Ç and t]). 
Associated with these molecules are the non-receptor tyrosine kinases 
p7Qz^^ and p59^^(^). The co-receptors CD4, CDS and CD2 are also 
represented with the tyrosine kinase p56^ <^  ^associated to CD4/CD8.
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Bjorkman, 1988). It is this domain that is responsible for conferring antigenic 
specificity to the T cell activation process.
The CD3-y(25-28kDa), -e (21kDa), and -5 (21kDa) components are non- 
polymorphic, and are therefore not involved in the generation o f diversity which 
is associated with the apTC R  component of the receptor complex (Tan et al.,
1991). The cytoplasmic tails of invariant chains are considerably longer that the 
a  and p tails (40 to 100 residues as opposed to 5 residues) of the heterodimer, 
suggesting that they play a role in coupling the antigen receptor to the signal 
transduction machinery. The CD3y, 5 and e chains are the products of three 
closely linked genes and are related in their primary sequences.
The Ç family is a related, but genetically distinct group from CD3. It 
consists of three polypeptides Ç and T], which are products of a single gene and the 
y chain. Ç and r\ differ at their C-terminal ends, due to alternative splicing. The Ç 
chain is expressed as a homodimer or as a heterodimer with r\ (Samelson et al.,
1985). Ç (16kDa) andrj (21kDa) chains comprise a small extracellular domàin of 
only nine residues, a transmembrane segment and a large cytoplasmic tail. The C- 
terminal end of x\ is about 40 amino acids longer than that of Ç The Ç and r\ 
polypeptides exist at the cell surface, as disulphide linked dimers (C™Ç, and 
Ç-T|) (Baniyash et al., 1988), and have been postulated to have different functions 
at distinct developmental stages (Bauer et a l ,  1991).
There appears to be a certain amount of redundancy between CD3 chains, 
since chimeric molecules of cytoplasmic regions of CD3e, Ç, t | and FceRIy joined 
to extracellular and transmembrane domains of cell surface receptors, such as 
CD4, CD8 or CD 16 results in the initiation of early and late signalling pathways, 
independently of TCR (Irving and Weiss, 1991; Le tourneur and Klausner, 1991; 
Romeo and Seed, 1991). This redundancy has been explained by the presence of 
a recurrent functional m otif of about 2 0  amino acids which exist in the 
cytoplasmic domain of the CD3 and ^ family chains (Weiss, 1993). This motif 
consists of six conserved amino acid residues spaced precisely over a 26-amino
acid sequence (D/EX7D/EX2YX2LX7YX2L) (where X corresponds to a variable 
residue). It is common to each of the CD3 proteins (y, e, 5) and Ç family, and has 
come to be known as the immunoreceptor tyrosine-based activation motif (ITAM) 
(Cambier, 1995; Reth, 1989) (fig. 1.3). This consensus sequence can be found in 
the cytoplasmic tail of CD3-Ô, CD3-e, CD3-y and TCR-Ç family subunits 
(Wegener etah, 1992). Furthermore, TCR-Ç polypeptide appears to be unique 
among this set of signalling molecules as it displays three copies of the ITAM 
motif (Irving and Weiss, 1991). These sequence motifs are essential for 
intracellular signalling in T cells (Weiss and Littman, 1994), enabling the 
recruitment of signalling components such as non-receptor PTKs to the T cell 
receptor. The number and exact sequence of ITAMs that are present in the 
cytosolic domain appears to have a direct bearing on the efficiency and specificity 
of signal transduction (Irving et al., 1993). It has become clear recently that 
ITAM motifs are not however, completely redundant. Indeed, analysis of 
chimeric receptor signalling indicates that there are distinct differences in their 
capabilities. For example, TCR-Ç and CD3e chimeras mediate partially distinct 
protein tyrosine phosphorylation responses (Letourneur and Klausner, 1992).
1.2.2. Non receptor protein tyrosine kinases.
Associated with the TCR/CD3 complex are three members of the src- 
related kinases, p607^^ and p59^ "^^ '^^  of which, p56^‘^* is the best 
documented. These each contain a unique N-terminal region with a myristylation 
site for membrane association (Resh, 1994), a catalytic tyrosine kinase domain 
(SH I domain), single SH2 and Src-homology-3 (SH3) domains and a negative 
regulatory C-terminal tyrosine (Mustelin and Burn, 1993). They associate with 
the cytoplasmic regions of the TCR/CD3 complex, being critical for T cell 
development (see section 1.4), and have been implicated in the regulation of TCR 
signal transduction, and p72’*^^are two related non-receptor tyrosine
kinases (zeta chain associated protein family (ZAP-70 family)) that are distinct
I
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Figure 1.3. Diagrammatic representation of the oligomeric TCR.
The black rectangles represent the ITAMs present in the 
cytoplasmic domains of the Ç and CDS chains. The ( YXXL )2  motif is 
shown, with on each of the ITAM domains, with a schematic 
illustration of p70^^P binding via its N-terminal SH2 domains upon 
TCR ligation and phosphorylation of tyrosine to give Y(P0 4 )XXL 
sequence.
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from other src~ related kinases in possessing two tandem N-terminal SH2 
domains. However, they lack the unique N-terminal region with myristylation 
site, SH3 domain and negative regulatory C-terminal tyrosine phosphorylation 
site (fig. 1.4). These molecules have also been shown to strongly associate with 
the cytoplasmic region of the zeta chain upon ligation of the TCR/CD3 complex 
and may play a role in TCR-mediated intracellular signalling (Chan et a l ,  1991; 
Chan et a i ,  1992).
SH2 domains are sequences of about 100 amino acids originally identified 
in cytoplasmic tyrosine kinases v-Src and v-Fps (Pawson, 1988; Sadowski et al.,
1986). SH2 regions recognise and bind to phosphotyrosine containing peptide 
sequences (generally denoted as Y(P0 4 ')"X-X-L/I) (Valius and Kazlauskas,
1993). SH3 regions are small protein modules of about 60 amino acids that are 
found in intracellular signalling proteins such as cytoplasmic PTKs as well as in 
cytoskeletal and adaptor proteins (Koch et al., 1991; Pawson and Gish, 1992), 
which bind to proline-rich peptides of about 10 amino acids (generally denoted as 
X-X-X-P-P-X-P-X-X-) (Ren e ta l ,  1993; Yu e ta l ,  1994). Proteins containing 
these domains have been shown to be critical for recruiting specific proteins to 
receptors, so that they can take part in signalling cascades, and allowing signalling 
networks to be built within the cell (Pawson, 1995; Valius and Kazlauskas, 1993). 
SH2 and SH3 domains vary slightly around the consensus sequences outlined 
above, thus bestowing specificity to a particular protein-protein interaction 
(Songyang et a l ,  1995),
These protein binding domains have been found to play an essential role in 
the organisation within the cell upon TCR/CD3 complex ligation. SH2 and SH3 
domains enable multimeric signalling complexes to form, recruiting PTKs (p56^‘^ \ 
pjQzap^ to the receptor complex. Proteins which act as adaptor molecules 
displaying no intrinsic catalytic activity, such as grb-2  and guanine nucleotide 
exchange proteins or guanine-nucleotide releasing factors for p2 F"-  ^ such as 
p l20^^^ and Vav, as well as phosphatidylinositoI-3-kinase (PI-3-K) and
11 I
Figure 1.4. Comparison of the structure of src and ZAP-70 family 
kinases.
The structure of and p596 '«('U ^re compared with that of 
p]Qzap andp724X^. The diagonal lined area in all of the kinases 
represents the catalytic (SHI) domain. The vertical lined area in 
p5 6 L/: and is the regulatory site, which when phosphorylated
by pSO^ -y^  is inhibitory to the catalytic activity of the kinases.
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phospholipase C-7 I (PLC-yl) are integi*al proteins within these signalling 
complexes. The interactions between these molecules, appear to link T-celi 
receptor activation to downstream signalling pathways such as PLC-yl and the 
p21^‘“/mitogen activated protein kinase (MAPK) cascade.
has been shown to be essential for normal signal transduction
/ kthrough the TCR (Strauss and Weiss, 1992). p56*  ^ was found to be associated to 
the cytoplasmic region of CD4 and CD8a  in mature T cells (Barber ertz/., 1989;
/ kRudd et al., 1988). The interaction between CD4 and p56 was mediated by
associations of and p59^^^-^ do not require stimulation of the cell. plO^^P 
is a 70kDa protein expressed exclusively in T cells and NK cells (Chan et al,.
13
cysteine motifs present in the unique N terminal domain of p56^ *^  ^in the sequence 
CXCP (Turner et al., 1990). On the other hand, p59^ *^^ ^^  was found to be 
associated directly with TCR-Ç chain and the CD3 y, Ô, 8 chains through its N- 
term inalregion (Samelson etal.,  1990; Timson-Gauen etal., 1992). The
1992), which is found associated to the tyrosine-phosphorylated Ç chain of the 
TCR/CD3 complex. However, unlike and p59^ "^ "^^ , the interaction of pTO^ '^  ^
requires receptor ligation (Chan et al., 1991; Wange et al., 1992). p72'"^  ^is 
preferentially expressed in B cells and myeloid cells (Law et al., 1994; Taniguchi 
et al., 1991) but it is found to be expressed in low levels in thymocytes and at 
even lower levels in mature T cells (Hutchcroft et al., 1992).
A third class of PTK associated with TCR activation is responsible for 
phosphorylating the C-terminal regulatory tyrosine residue of p56^^* (Y^OS) and 
^^gfyn(T) (-Y528) and thus down-regulating them activities. pSO^ **^  resembles the src 
family kinases in possessing the kinase domains, SH2 and SH3 domains. 
However, it lacks the N-terminal membrane-attachment motif, tyrosine 
autophosphorylation site and a C-terminal regulatory sequence (Okada et al., 
1991).
i
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1.2.3. TCR/CD3 complex ligation.
Ligation of the TCR by antigen leads to the production of interleukin-2 
(IL-2), and the proliferation of that specific T cell clone (Altman et al., 1990). 
Immediately following crosslinking of the TCR/CD3 complex there is an increase 
of tyrosyl phosphorylation in cytoplasmic and membrane bound proteins within 
the cell (Hsi et al., 1989). Targets include the Ç and e chain of the TCR/CD3 
complex, and PLC-yl. The phosphorylation of tyrosine residues within ITAM 
domains of the TCR/CD3 chains is essential for signalling. Indeed mutation of 
these tyrosine residues for a non-phosphorylatable residue results in a lack of 
signalling. Following tyrosine phosphorylation of the ITAMs, signalling proteins 
are able to associate with the TCR via their SH2 motifs. pTO^*  ^appears to require 
the modification of both tyrosines in the ITAM domain of TCR-Ç, as the SH2 
domains of will only bind to tyrosine-phosphorylated TCR-Ç when the 
phosphorylated residues are present in tandem (Howe and W eiss, 1995) (fig. 1.4).
A problem arises when one considers that an activated kinase is required 
in order to phosphorylate the TCR/CD3 complex, thus initiating the signalling 
cascade. The PTPase, CD45 plays an essential role in T cell signalling, having a 
positive role in T cell signal transduction processes, regulating the activities of 
opposing p59‘^ ''* (Biffen et al., 1994; Ledbetter et al., 1988). 
CD45 appears to mediate its effects by dephosphorylating the negative regulatory 
tyrosine phosphorylation site in the C-terminal of 5rc-homologous kinases. In a 
CD45“ cell line, the TCR/CD3 complex was found to be completely uncoupled 
from intracellular pathways (Koretzky etal.,  1991), showing CD45 to have an 
obligatory role in lipid signalling and activation in T cells.
With these considerations, a model has emerged regarding the initiation of 
T  cell signalling. Upon TCR/CD3 ligation of MHC bound antigen, CD4 or CDS 
form a ‘bridge’ between these molecules and the MHC molecules increasing the 
stability of the interaction. (Parnes, 1989). It is evident that co-crosslinking of 
CD4/CD8 with TCR/CD3 enhances the effectiveness of T cell stimulation, thus
14
suggesting that the increased avidity and signalling capability in the presence of 
these co-receptors are critical in the response to antigen (Emmrich, 1988; Saizawa 
et a l ,  1987). This interaction possibly localises CD4- or CD8 -associated at 
the cytoplasmic domains of the TCR/CD3 complex (Diez-Orejas e t a l ,  1994), 
thus enabling the phosphorylation of ITAM motifs in the Ç and e chains. These 
phosphorylation events would promote the recruitment of to the TCR/CD3 
complex. Upon binding, this kinase could become a substrate for and this 
phosphorylation could activate p70^^/' (Weiss, 1993). In support of this model, 
Chan et a l  (1992) demonstrated that association of activated p70^°f' with TCR-Ç 
is dependent on the co-expression of pSô^ *^  ^or p59^"^^ Indeed, pdd^ *^  ^has been 
found to be associated with p70^^^ (Duplay et a l ,  1994), but to date no 
phosphorylation of p70^^/' has been described.
Tyrosine phosphorylation events are essential for T cell activation (June 
et a l ,  1990b). Upon activation of PTKs, there are a series of signalling cascades 
which are activated, ultimately leading to transcriptional activation of the IL-2 
gene, and T cell proliferation. The main signalling pathways recruited are 
highlighted below (fig. 1.5).
1.2.4. Phosphoinositide signalling.
TCR ligation causes a rapid increase in phosphatidylinositol-4,5- 
bisphosphate (PIP2)-specific PLC-yl activity (Imboden and Stobo, 1985). This 
elevation of activity is observed within 30 seconds of stimulation, and is due to 
tyrosine phosphorylation of PLC-yl. It is this event which is associated with 
functional coupling of the TCR to the inositol phospholipid pathway (Mustelin et 
a l ,  1990; Secrister n/., 1991; Weiss e ta l ,  1991). p56^^^has been found to be 
associated with PLC-yl in stimulated T cells, suggesting that p56^ (^  ^plays a central 
role in coupling the TCR to phosphoinositide signalling (Weber et a l ,  1992). 
Activation of PLC-yl elicits the hydrolysis of PIP2 to generate the second 
messengers, inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), leading
15
Figure 1.5. Signalling pathways activated upon ligation of the 
TCR/CD3 complex.
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to the release of calcium from intracellular stores and the activation of PKC (Rana 
and Hokin, 1990) (fig. 1.5). Rapid, sustained increases in intracellular calcium 
levels [Ca^+li, are achieved initially by the release of intracellular calcium stores. 
Their depletion signals calcium influx across the plasma membrane through 
calcium channels (Cardenas and Heitman, 1995). This elevation in [Ca^+]i is 
thought to influence calcium/calmodulin-dependent events, such as the activation 
of the calcium-dependent phosphatase, calcineurin resulting in the modulation of 
transcription factor activities, such as NF-AT (Clipstone and Crabtree, 1992), 
which in turn conti’ols transcriptional activity of promoter regions of genes such 
as IL-2 .
DAG stimulation of PKC isoform(s) results in the activation of most of 
these serine/threonine protein kinases (Berridge and Irvine, 1989; Nishizuka,
1988). In total, twelve mammalian isoforms of the PKC family have so far* been 
identified, all varying in their tissue distribution, primary amino acid sequence, 
effector sensitivities and substi’ate specificities in vitro (Dekker and Pai'ker, 1994; 
Hug and Sarre, 1993). Pharmacological evidence has shown that PKC is very 
important in T  cell signalling, promoting the induction of IL-2 receptor expression 
and IL-2 production and initiation of DNA synthesis via the modulation of 
activator protein-1 (AP-1) activity (Gupta a/., 1991; Hirano e t a l ,  1984; Isokov 
and Altman, 1987) (see section 5.1).
1.2.5. p21"" signalling pathway.
p2F"'^ is a member of the family of low molecular' weight GTP-binding 
proteins (G proteins), which also includes Rho and Rac. The proteins bind GTP 
and have an intrinsic GTPase activity that catalyses GTP to GDP. The GTP- 
bound form of p21"^ is the biologically active form (Satoh et aL, 1992), therefore 
upon hydrolysis of GTP, p2 1 ^^ inactivated. By virtue of its GTPase activity, 
p2 iray functions as a molecular switch in signal transduction.
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This protein appears to be a very important signalling component in T 
cells (Downward et al.., 1992). It is apparent that GTP-bound p2F^“ can 
accumulate after TCR crosslinking, via phytohaemagglutinin (PHA) or anti-CD3 
stimulation, through a tyrosine kinase linked activation which is independent of 
calcium and PKC (Izquierdo et a l ,  1992). This is important, as it indicates that a 
second tyrosine kinase controlled signalling pathway originates from the TCR 
involving the p2K'^ GTPase (Downwai'd et aL, 1992; Downward et al., 1990)
(fig. 1.6). The activity of p21^‘“ is regulated by the rate of hydrolysis of bound 
GTP and the rate of exchange of bound GTP (Downward, 1992). Proteins which 
are responsible for GTPase activity include p i20^^^ and neurofibromin 
(McCormick, 1989). Proteins which control guanine nucleotide exchange in T 
cells include the mammalian homologue of the Drosophila son o f  sevenless gene 
(SOS) (Shou etal., 1992), She and Vav whose activity is known to be stimulated 
by tyrosine phosphorylation (Gulbins et at., 1993; Schlessinger, 1993). In 
fibroblasts, Grb-2 (an adaptor molecule, which contains two SH3 domains and 
one SH2 domain (Lowenstein et aL, 1992)) has been shown to localise SOS to the 
cell membrane via the C-terminal SH3 domain of Grb-2. This complex associates 
with tyrosine phosphorylated motifs, and promotes an increase the activity of
(Buday and Downward, 1993; Gale et aL, 1993) (fig. 1.6). This signalling 
complex formation has also been identified in a B cell line, where Shc/Vav and 
Grb-2 are required for p21™'^  activation (Gulbins et aL, 1994; Kumar et aL, 1995). 
However, in T cells She is substituted for Vav (Gupta et aL, 1994; Ramos- 
Morales et aL, 1994).
p21™' activation leads to the activation of the MAPK or extracellular 
signal regulated protein kinase (ERK) cascades (Pelech and Sanghera, 1992; 
Robbins et aL, 1992). T lymphocytes express at least two MAPKs, ERK l and 
ERK2, that are stimulated in response to TCR ligation (Nel et ai., 1991; 
Whitehurst et aL, 1992). Two intracellular pathways for ERK2 regulation co­
exist in T cells: one is mediated by p2 and the other by PKC (Izquierdo et aL,
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Figure 1.6. Schematic representation of p2F^^/Raf-l/M APK  
signalling pathway upon ligation of the TCR/CD3 complex.
19
Plasma
membrane TCR
S H 3 /7 7 :
Grb2
1
Raf-1
MEK
t
ERK2
NF-AT, c-jun, c-myc 
gene transcription
1993). The TCR stimulates both PKC and p2K^'^, but upon stimulation of the 
TCR in cells transfected with the inhibitory p2R^-^ mutant, N17r<3.s', which 
prevents activation of p2R^^, TCR does not activate ERK2 (Izquierdo etaL,
1993). This indicates that p 2 F ^  and not PKC couples the TCR to MAP kinase 
regulation.
A down stream effector of p2F^ ‘^ , raf-1 (a serine threonine kinase) 
physically associates with GTP-bound p2R “-* via its N-terminal regulatory 
domain, causing raf-1 activation (Avruch etaL,  1994; Hallberg e t a l ,  1994).
Recently, raf-1 has been reported to be physically linked to the T cell receptor, 
associating with S and y chains of the CD3 complex in unstimulated cells (Loh et 
al., 1994). Raf-1 (in some cells it is identified as MAPKKK) is responsible for 
activating MAPKK (MEK), which upon phosphorylation stimulates ERK2. The 
activation of p2T ‘^  appears to mediate the action of the transcription factors NF- 
AT, c-Jun, and c-Myc via the MAPKs thus linking this GTPase with the 
transcriptional activation of the IL-2 gene (Northrop et aL, 1993; Pulverer et aL,
1991; Seth et aL, 1992; Woodi'ow et aL, 1993) (fig. 1.6).
-In addition to activation by p2L^^, PKC has also been shown to 
phosphorylate and activate raf-1 in T lymphocytes (Siegel et aL, 1990; Whitehurst
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et aL, 1995), opening up the possibility of p2 L'^^-independent activation of the 
MAPK cascade in T lymphocytes (fig. 1.6). Raf-1 has also been shown to be 
regulated negatively by cyclic AMP in fibroblasts, PC12 cells and T cells (Chen 
and Iyengar, 1994; Lange Cai'ter and Johnson, 1994; Whitehurst et aL, 1995).
'The implications of this will be discussed in section 1.6.1.
1.3. C o-receptors of the TCR/CD3 complex.
Accessory molecules play an essential role during T cell interactions with,
'1'and activation by APC. They have been shown to augment the biochemical 
signals provided by the TCR, as well as being implicated in T cell adhesion. The 
role of CD4/CD8 has been discussed previously (see section 1.2.3).
•fî'
1.3.1. CD28.
CD28 is a 90kDa homodimeric glycoprotein located on the surface of T 
cells. It has been identified as the major co-receptor in T cell signalling, 
interacting with the B7/B11 ligand on the surface of APCs (Linsley et aL, 1990).
Anti-CD28 monoclonal antibodies are known to induce synergic activation of T 
cells upon co-stimulation of the cells with PHA, phorbol- 12-myristate, 13-acetate 
(PMA) (Martin etaL, 1986; Pierres etaL, 1988; Weiss etaL,  1986b) or CD2 
antibodies (van Lier et aL, 1988) to produce enhanced amounts of IL-2, TN F-a,
IFN -yand GM-CSF (Thompson etaL, 1989). CD28 stimulation appears to 
provide a secondary signal which is necessary for T cell proliferation, and 
prevents the induction of anergy (Schwartz, 1992). This is supported by reports 
that ligation of CD28 can reverse anergy in peripheral T cells and T cell clones
-(Harding et aL, 1992; Sommer et aL, 1993),
PI-3-K is a heterodimeric enzyme containing an 85kDa regulatory subunit 
and llO kD a catalytic subunit. This kinase has been implicated in CD28 
signalling, with the observation that D-3 phosphoinositides are formed in T cells 
on ligation of the CD28 receptor (Rudd et aL, 1994; Ward et aL, 1993). This was 
supported by the discoveiy o f a binding motif for PI-3-K in the cytoplasmic tail of 
CD28 (Prasad et aL, 1994). Binding of PI-3-K to CD28 is found to be necessary 
for T cell signalling (Pages et al., 1994), Interestingly, CD28 co-clustering with 
CD45 inhibits proliferation (Ledbetter et al., 1988), which may dephosphorylate 
the phosphotyrosine residue in the cytoplasmic tail of CD28 (Pages et aL, 1994), 
thus hindering the binding of PI-3-K and downsti’eam signalling events.
f
1.3.2. CD2.
The CD2 antigen is a 50kDa glycoprotein originally defined as the human 
T-lymphocyte antigen T11/sheep red blood cell receptor. This cell surface 
molecule appears to have an important role during thymic differentiation. The
'natural ligand for CD2 has been identified as lymphocyte function-associated
li;
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aantigen 3 (LFA-3/CD58) (Selvaraj etal., 1987), which is present on thymic 
epithelial cells (Springer er n/., 1987).
Upon crosslinking of CD2 with specific pairs of monoclonal antibodies, it 
is possible to induce T cell activation, ultimately resulting in the proliferation of 
lymphocytes: this is known as the ‘alternative’ pathway of T cell activation, 
which is independent of TCR ligation although dependent on the CD3 complex 
(Alcover et ah, 1987; Mener et a i ,  1984). The activation of this pathway induces 
the same events as those stimulated by TCR/CD3. These include IL-2 secretion, 
increased [Ca^+Ji, PIP2 hydrolysis, p2L^‘^ activation (Graves et aL, 1991), 
increases in cyclic AMP production (Caixera et aL, 1988; Hahn et aL, 1991) and 
opening of voltage sensitive Ca^+ channels (Alcover et aL, 1986). However, CD2 
does not appear to be essential for T cell activation, where following the ligation 
of TCR/CD3 complex in the absence of CD2, IL-2 production has been noted 
(Moingeon etaL, 1988a).
CD2 also functions to facilitate cellular adhesion upon interaction between 
T lymphocytes and its natural ligand LFA-3 on APCs. Upon elevating cyclic 
AMP levels, there is an increase in avidity between cells, mediated by CD2. This 
regulation of CD2 avidity is dependent on the presence of an asparagine residue in 
the cytoplasmic region of CD2, as amino acid substitution of this residue leads to 
cells that are incapable of avidity regulation. The role of adhesion by CD2 is 
found to be independent of CD3 surface expression, however CDS is essential for 
T cell activation (Hahn e ta l ,  1993; Rabin etal., 1993). This suggests that the 
signalling and adhesion pathways mediated by CD2 are separate. It is clear that 
synergy exists between anti-CD2 and anti-CD3 stimulated pathways, as CD2 can 
have an active signalling role, and also aid in the interaction between the T cell 
and the APC (Yang et aL, 1986). Increases in avidity enhance the T cell 
activation by a mechanism that does not require the signalling through CD2 
(Moingeon et al., 1988b). Interestingly, it has been demonstrated that CD2 is 
associated with TCR/CD3 complex on the surface of T cells (Brown et aL, 1989).
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1.4. Signalling during T cell development.
One of the central problems yet to be resolved in T cell signalling is how 
the TCR/CD3 complex transduces differential signals in a maturation state- 
dependent manner (Hueber et aL, 1994). In mature T cells, ligation of the 
TCR/CD3 complex can lead to proliferation and differentiation into effector cells, 
whereas in the thymus, the immature T cell must undergo rigorous selection 
procedures in order to produce a T cell repertoire that recognises only foreign 
peptide antigen in the context of self MHC. Auto-reactive clones are thus selected 
with TCR-derived signals in developing T lymphocytes. This can result in their 
proliferation (selection) into mature lymphocytes, or apoptosis (deletion) 
depending on the antigen specificity of the TCR (see section 1.1).
CD2 is one of the earliest cell surface markers to be expressed on the 
immature T cell, shown to be present on 85-95% of all developing T cells in the 
thymus (Lanier etal., 1986; Sewell et aL, 1986). The interaction of CD2 on 
thymocytes with LFA-3 on thymic sti'omal cells is considered to be of major 
importance in the expansion and differentiation of immature thymocytes which 
lack TCR/CD3 complex expression, and in providing IL-2-dependent 
proliferation signals (Alcover et aL, 1986; Denning et aL, 1987; Reem etaL,
1987). This activation can be mimicked with the use of monoclonal antibodies 
directed against CD2, causing the TCR/CD3 negative subset to express IL-2R, but 
not to proliferate. This pathway of thymocyte activation is thought to come under 
the regulation of the CD3-mediated signalling in the later stages of maturation 
(Alcover etal.,  1988; Blue et aL, 1987; Fox etal., 1985; Ramarli et aL, 1987).
At the CD4VCD8" stage of thymocyte development, the [3 chain has 
rearranged and expressed on the surface of the immature thymocyte with a 
surrogate a  chain, gp33, and the CDS complex (see section 1.1). It was thought 
that signalling through the pre-TCR may reveal some distinct signalling 
characteristics in this immature subset of cells. Crosslinking of this pre-TCR with 
either anti-CD3e or anti-TCRp antibody results in an increased level of
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intracellular calcium, similar to that seen in mature cells (Groettrup and von 
Boehmer, 1993; von Boehmer, 1992). However, in CD4’^ /CD8"** cells it has been 
proposed that the TCR may be partially uncoupled from PTK activation and thus 
the subsequent activation of PLC-yl and calcium mobilisation (Finkel et aL,
1991; Sancho et aL, 1992). Ultimately this will lead to immunological 
unresponsiveness due to a lack of IL-2 receptor (IL-2R) expression, IL-2 secretion 
and proliferation. The reason for this unresponsiveness has been suggested to be 
due to differences in the signalling network present in immature T cells. Thus it 
appears that calcium mobilisation is regulated in a developmental state-dependent 
manner.
p56^ *^  ^appears to be essential for T cell maturation as pSô^ *^ * deficient 
murine thymocytes are developmentally blocked at the CD4"/CD8" stage (Molina 
et aL, 1992). In these cells TCR|3 is rearranged, but not the T C R a chain (Levin et 
aL, 1993b). In contrast, overexpression of pSô^ *^ * leads to an inhibition of p- but 
not a-gene rearrangement (Abraham et aL, 1991; Anderson et aL, 1992). These 
studies strongly suggest that the p56'(^  ^signal transduction pathway plays a crucial 
role in thymocyte development regulating, either directly or indirectly, allelic 
exclusion of the TCR-p gene and activation of a TC R -a gene rearrangement.
This property is specific to p56^^^, as cannot be utilised as a substitute
(Cooke etaL, 1991).
Interestingly, p56^^  ^signalling at the CD47CD8" stage of development 
occurs in the absence of the co-receptors CD4 or CD8 and therefore via a different 
mechanism to that ascribed to p56^‘^''^  in mature cells (Anderson and Perlmutter,
1995; Levin etal., 1993a; Palmer et aL, 1993) and section 1.2,2). Indeed, if the 
cysteine motif (which is essential for p56^^^ association to CD4 or CD8 ) is 
removed in mature T cells (Turner et aL, 1990), the activity of the kinase is the 
same as that observed in wild type p56^‘^*, indicating that this region is of no 
importance at this developmental stage.
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As development progresses, pSô^ '^ * is found to be associated with CD4 and 
CD8 (Nakayama et aL, 1993) and the expression of the non-receptor PTK 
p59^”^  ^ increases. p59^^^) does not appear to have a central role in T cell 
development. This is observed in mice lacking p596’«(^ '^  which display normal 
ratios of all thymocyte and peripheral T cell populations. Nevertheless, TCR- 
induced thymocyte proliferation is compromised, suggesting a role for this kinase 
(Appleby eta l., 1992). Indeed, hyper-responsiveness to TCR activation was 
induced in models that overexpressed p59^'^^) (Cooke et aL, 1991). The 
involvement of the Ç chain is also apparent (Nakayama et aL, 1989; Vivier et aL, 
1991). Indeed it is noted that TCR-Ç chain is hyperphosphorylated in vivo in 
CD4“^ /CD8‘*' thymocytes undergoing differentiation and selection (Nakayama et 
aL, 1989).
Interestingly, p70^^^ is found to be constitutively associated with the 
tyrosine phosphorylated TCR-Ç in CD4+/CD8+ thymocytes, and TCR ligation 
induces tyrosine phosphorylation of p70^^^ (van Oers et aL, 1994). This indicates 
that this PTK may play a central role in T cell signalling during development.
This is supported by evidence that a rare human severe combined 
immunodeficiency (SCED) model is associated with genetic mutations in the
gene (Arpaia eta l., 1994). In these p70^^^ deficient models, there is a lack 
of CD47CD8’^ lymphocytes in the circulation, suggesting that this PTK is 
involved in the regulation of positive selection of CD 8  ^cells (Arpaia eta l., 1994). 
Indeed, a recent study, where it has been shown that mice lacking p70^^ lack 
CD4 and CD8 single positive populations (Negishi et aL, 1995), with T cell 
development being blocked at the CD4+/CD8'*' thymocyte stage. This implies 
that p70^‘^ '^ is essential in determining the fate of thymocytes for both CD4 and 
CD8 lineages.
Therefore it appears that although the same pathways exist in immature as 
mature T cells, there are some subtle differences in the network that allows the 
differing signals to prevail in either environment. These include: (i) the
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expression of a pre-T cell receptor which has a different a  chain (gp33) from that 
seen on mature T lymphocytes; (ii) the signalling of p56^^^ in the absence of 
CD4/CD8 association;(iii) the possibility of partial uncoupling of the TCR from 
PTK activation at the CD4"^/CD8+ stage of development; and (iv) the 
constitutively hyperphosphorylated TCR-Ç chain which recruits plO^^P to the 
TCR.
1.4.1. Signalling pathways involved in apoptosis.
Cell death occurs by two processes, necrosis and apoptosis. Necrosis 
leads to rapid damage to the plasma membrane, as cells tend to swell and lyse 
releasing the cell contents into the extracellular space and inducing an 
inflammatory response (Kerr et al., 1972). Programmed cell death or apoptosis is 
a process by which cells actively commit suicide (Wyllie, 1980). During 
apoptosis cells shrink, the chromatin becomes condensed and then degrades to 
oligonucleosome-length, giving a characteristic DNA laddering pattern, before 
loss of plasma membrane integrity (Wyllie, 1980; Wyllie et aL, 1984). The
remnants of the dead cells are recognised and rapidly phagocytosed by
neighbouring phagocytotic cells in the tissue, thus avoiding any inflammatory 
response. This process inflicts minimal damage on tiie surrounding tissue and, 
during T cell development, is an important option as it enables auto-reactive 
clones to be disposed of without injury to neighbouring cells (Wyllie, 1980). 
Programmed cell death occurs on a massive scale within the thymus during 
negative selection with only 5% of the cells being exported to the periphery 
(Murphy eta l., 1990; Swat era/., 1991).
Apoptosis can be induced in thymocytes by ligation of the TCR 
(McConkey eta l., 1989b; Shi eta l., 1991; Smith eta l., 1989), Fas/Apo 1 
activation (Itoh etal., 1991; Rouvier era/., 1993), or neglect (Collins and Lopez 
Rivas, 1993). The mechanism by which programmed cell death manifests itself 
has been studied, and it is apparent that there are multiple routes towards
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apoptosis. These include calcium-, glucocorticoid-dependent or cyclic AMP-
■
induced apoptosis (McConkey e ta l ,  1989a; Wyllie, 1980). Glucocorticoids have
'long been recognised as activators of cell death, as seen by their activation of a 
calcium- and magnesium-dependent endonuclease (Cohen and Duke, 1984;
Wyllie, 1980). Endonuclease activity is responsible for cleaving DNA in linker 
regions between nucleosomes. Such endonulease activity leads to the DNA 
fragmentation patterns associated with apoptosis. Mature lymphocytes also 
contain this endonuclease activity, but its activation is not coupled to 
glucocorticoid stimulation, implying that its activity may be developmentally 
regulated. The activation of endonuclease by glucocorticoid, and thus cell death, 
has been shown to be dependent on a sustained elevation in [Ca]i (McConkey et 
aL, 1989a). As mentioned above, apoptosis occui's following crosslinking of 
TCR/CD3 complex in CD4+/CD8+ thymocytes in organ culture (Smith et aL,
1989) and in vivo (Shi et aL, 1991). Endonuclease activation and cell killing are 
dependent upon the sustained increase in [Ca]i, mostly from extracellular origin 
(McConkey et aL, 1989b). Interestingly, activation of PKC inhibits this calcium- 
mediated mode of apoptosis.
Agents that elevate cyclic AMP such as E-series prostaglandins or cyclic 
AMP analogs have also been shown to induce apoptosis in murine thymocytes 
(Kaye and Ellenberger, 1992; McConkey et aL, 1990a). As cyclic AMP is known 
to exert its effects through cyclic AMP-dependent protein kinase (PICA) (see 
section 1.5.4) (Taylor et aL, 1990), it is interesting to note that agents that 
suppress TCR-mediated apoptosis via PKC, such as phorbol ester and IL-1 
(McConkey et aL, 1990b) also block DNA fragmentation in response to cyclic 
AMP, indicating that ‘cross-talk’ exists between these two signalling pathways.
The proto-oncogene bcl-2 was the first gene studied in the context of 
apoptosis regulation during lymphocyte development (Bakhshi et al., 1985). It 
has been found that when bcl-2 is overexpressed, it has the ability to block
apoptotic pathways which are triggered by, for example, ionising radiation or
glucocorticoids (Strasser et al., 1991). When overexpressed in lymphoid tissue, 
bcl-2  can cause a disruption in the normal lymphocyte cell development process 
(Hockenbery et at., 1990). However, bcl-2 largely fails to inhibit TCR-mediated 
apoptosis signals, suggesting the existence of b d -2 -resistant and -sensitive 
pathways of apoptosis. Recently, it has been noted that bcl-x, a gene which is 
homologous to bcl-2, is elevated in CD4+/CD8+ thymocytes, and negligible in 
CD4"/CD8~ thymocytes and single positive cells (Boise etal., 1993). This is in 
direct contrast to the expression pattern of bcl-2 (Ma et al., 1995). Bcl-x deletion 
appears to shorten the survival of CD4+/CD8+ thymocytes, whilst not affecting 
the survival of single positive thymocytes or peripheral T  cells, indicating that 
b d “X plays a critical role in regulating the survival time of thymocytes in the 
absence of selection (Ma et al., 1995).
1.5. Cyclic nucleotide signalling.
Since their discovery, the cyclic nucleotides, adenosine-3’,5’-cyclic 
monophosphate (cyclic ANIP) and guanosine-3’,5 ’-cyclic monophosphate (cyclic 
GMP) have been found to play a central role in signal transduction (Sutherland, 
1972; Sutherland and Rail, 1958). These intracellular second messengers are 
generated by adenyiyl cyclase and guanylyl cyclase, respectively (Goldberg and 
Haddox, 1977; Krebs eta l., 1987; Sutherland et al., 1968), in response to external 
stimuli, such as hormones or neurotransmitters. Cellular responses of such agents 
are mediated through the activation of protein kinases, causing the 
phosphorylation of target proteins within the cell, leading to a physiological effect 
(Kuo and Greengard, 1969; Taylor, 1989). In comparison to cyclic AMP, 
substantially less if known about cyclic GMP and the way that it mediates its 
actions within the cell. However, cyclic GMP is considered to be of great 
importance within the field of signal transduction especially with the finding that 
it can be elevated in response to niuic oxide (NO) (Moncada et al., 1991). Cyclic 
GMP appears to interact with several intracellular receptor proteins, including
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protein kinases (Francis et al., 1988; Lincoln et al., 1988), cyclic nucleotide 
phosphodiesterases (Charbonneau et al., 1986) and cyclic GMP gated ion
channels (Kaupp et al., 1989; Lincoln and Cornwell, 1993).
-
Adenyiyl cyclase is coupled to cell surface receptors via GTP binding 
proteins (G proteins) that either stimulate (G J or inhibit (GJ adenyiyl cyclase
'Iactivity (Gilman, 1987) (fig. 1.7). Cyclic AMP has been shown to bind with high 
affinity to the regulatory subunits of a protein kinase, thereby activating the
enzyme (Taylor, 1989). This enzyme has since been named cyclic AMP-
■dependent protein kinase (PKA). Binding of cyclic AMP to the PKA-holoenzyme
causes the dissociation of the two regulatory subunits from the two active 
catalytic subunits (Krebs and Beavo, 1979; Taylor, 1989). The catalytic subunits 
are now free to phosphorylate serine/threonine residues of target proteins, either in 
the nucleus where they are believed to bind to DNA and alter gene transcription 
and in the cytoplasm where the subunits may alter post-transcriptional events 
(Kammer, 1988; Krebs and Beavo, 1979). The modulation of transcription factor 
activities, such as cyclic AMP responsive element binding protein (CREB) or 
activation transcription factor (ATF) families, is thought to occur via 
phosphorylation, under the control of protein kinases such as PKA (Meek and 
Street, 1992) (fig. 1.7). This regulation controls the stimulation or repression of 
specific gene expression (Comb e ta l ,  1986; Montminy et al., 1986). Cellular 
cyclic AMP homeostasis is maintained not only by regulating its synthesis by 
adenyiyl cyclase (Cooper et al., 1994; Taussig and Gilman, 1995), but also by 
conü'ol of its degradation, through the action of the cyclic nucleotide
phosphodiesterases (PDFs) (Beavo eta l., 1994; Conti eta l., 1995b).
■7|
1.5.1, Receptor-G-protein coupling.
The receptor-adenyiyl cyclase complex consists of three components: the 
receptor, G proteins and the catalytic subunit of the cyclase (fig. 1.7).
Heterotrimeric GTP-binding proteins (G proteins) are a subset of a superfamily of
. ■
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Figure 1.7. Diagrammatic representation of cyclic AMP 
metabolism.
Cyclic AMP levels can be regulated at the level of; (i) adenyiyl 
cyclase, via receptor coupling through inhibitory G proteins (Gi) or 
stimulatory G proteins (Gg); (ii) cyclic AMP phosphodiesterase, by the 
regulating the level of breakdown of cyclic AMP.
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proteins which bind GTP with high affinity (Neer, 1995). They consist of three 
distinct subunits, a, P and y, and are generally defined by the nature of their a  
subunits (Gilman, 1987; Kaziro et aL, 1991). a  is the guanine nucleotide binding 
component whilst Py subunits form a tightly, although non-covalendy, associated 
complex. In the inactive state, heterotrimeric G proteins are bound to the inner 
leaflet of the plasma membrane via fatty acid modifications such as palraitylation 
and myristylation (Spiegel et al., 1991; Thissen and Casey, 1994), To date, about 
twenty subtypes of a  subunits, five P subunits and seven y subunits have been 
isolated (Milligan, 1995). They are recognised to play a central role in signal 
transduction, as they couple a diverse array of receptors to intracellular effectors.
Ail G protein-coupled receptors consist of a single polypeptide chain with 
seven putative transmembrane domains. Upon agonist binding to the receptor, it 
is thought that the conformation of the receptor changes, allowing the association 
of the G protein with cytoplasmic regions of the receptor. Receptor activation and 
subsequent binding of the G protein, promotes the exchange of GTP for GDP. 
Upon binding GTP, py subunits are released as a heterodimer, leaving the a  
subunit to interact with and modulate the activity of effectors such as adenyiyl 
cyclase (Gilman, 1984). It has become increasingly evident that py subunits play 
a role in signal transduction, having the ability to modulate the activity of certain 
classes of adenyiyl cyclase (see below) (Tang and Gilman, 1991; Tang et al., 
1991), PLC (Camps et al., 1992) and ion channels. The a  subunitieffector 
interaction is terminated by an intrinsic GTPase activity which hydrolyses the 
terminal phosphate of GTP, returning the a subunit in its inactive GDP-bound 
state. In this state, it re-associates with the Py complex fomiing the heterotrimeric 
conformation once more, which is required for receptor interaction.
1.5.2. Adenyiyl cyclases.
Adenyiyl cyclases are a group of membrane bound proteins with 
molecular weights ranging from 120-150kDa, responsible for catalysing the
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generation of the second messenger cyclic AMP from ATP (Casey and Gilman, 
1988; Gilman, 1987) (fig. 1.8). The initial isolation of a cDNA encoding a 
polypeptide with adenyiyl cyclase activity (Krupinski eta l., 1989), termed type-I, 
was followed by the isolation of multiple other forms of adenyiyl cyclase 
(Bakalyar and Reed, 1990; Cali et a l ,  1994; Feinstein et al., 1991; Fremont et a l ,  
1992a). There are now over eight genetically distinct mammalian adenyiyl 
cyclase isoforms originating from separate genes. Adenyiyl cyclase consists of a 
single polypeptide, which is predicted to have six transmembrane helices, a large 
cytoplasmic loop, another six transmembrane helices and a long intracellular tail. 
This structure is similar to that predicted for transporter species and ion channels 
(Krupinski et al., 1989). The conservation of primary sequence between species 
is very high (>90%), but dissimilar between subtypes (overall homology amongst 
the various isoforms is about 50%). Therefore it appears that these adenyiyl 
cyclase isoforms have evolved differently. Alternatively spliced transcripts
(Wallach eta l., 1994) and partial sequence identity of novel adenyiyl cyclases 
(type-VII) (Krupinski et al., 1992) are evident, however the extent of molecular 
diversity within this family is unresolved as yet. Although each isoenzyme family 
displays different properties of regulation by calcium, PKC, Gi (Gjai, Giai and 
Giocs) and py subunits of G proteins (Taussig and Gilman, 1995), all the adenyiyl 
cyclase activities are stimulated via G proteins Gg (Pieroni et al., 1993) and by the 
diterpene forskolin (Seamon eta l., 1981).
1.5.2.1 Type-I, -III, and -VIII adenyiyl cyclases.
The expression of these isoforms is largely restricted to the nervous 
system. Changes in intracellular calcium have profound effects on type-I adenyiyl
cyclase activity, being stimulated by nanomolar concentrations of 
calcium/calmodulin, thus causing an increase in cyclic AMP concentrations 
within the cell. Stimulation by calcium/calmodulin is also seem in the type-III 
and type-V ni isoforms . Type-III adenyiyl cyclase is found to predominate in
Figure 1.8. Diagram showing the action of adenyiyl cyclase and 
cyclic AMP phosphodiesterase on ATP and cyclic AMP 
respectively.
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olfactory neuroepithelium and is stimulated by PKC isoforms a  and Ç (Jacobowitz 
et al., 1993), however, type-I activity is unaffected by PKC-activation 
(Yoshimura and Cooper, 1993). The type-I iso-enzyme is also directly regulated 
by py subunits of the G protein, if the level of Py subunits increases, then adenyiyl 
cyclase activity decreases. At present this is the only isoform which is inhibited 
by py subunits (Tang and Gilman, 1991).
I.5.2.2. Type-II and -IV adenyiyl cyclases.
Type-II and -IV isoforms are regulated in a very similar manner: in 
contrast to type-I, py subunits stimulate adenyiyl cyclase activity in type-II (Tang 
and Gilman, 1991) and type-IV isoforms (Gao and Gilman, 1991). Adenyiyl 
cyclase activity is conditionally stimulated by these subunits, i.e. Py subunits by 
themselves having no effect, but in the presence of Gsa subunits, cyclase activity 
is enhanced 5-10 fold (Pieroni et al., 1993). Stimulation of these cyclases 
requires substantially higher concentrations of py than of G^a, and the source of 
these subunits is thought to be from Gi or Gq.
-
,Evidence is emerging to suggest that the activity o f these isoforms can be 
stimulated by PKC-mediated phosphorylation (Yoshimura and Cooper, 1993), 
although this is not widely accepted. However, the inhibition of type-II adenyiyl 
cyclase activity mediated by Gi, has been reported to be suppressed by phorbol 
ester treatment (Chen and Iyengar, 1993). This indicates that there is cross-talk 
between adenyiyl cyclase and Gj-linked receptors at the level of cyclic AMP 
generation. In addition type-II and type-IV isoforms are insensitive to calmodulin 
regulation.
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I.5.2.3. Type-V, -VI and -VII adenyiyl cyclases.
The type-V isofoim of adenyiyl cyclase has been shown in vitro to be 
stimulated by phosphorylation mediated by PKC (Kawabe et al., 1994). This 
effect is specific to the PKC isoforms a  and 5 (Jacobowitz et al., 1993).
Feedback inhibition of type-V and -VI adenyiyl cyclase by PKA-mediated 
phosphorylation has been studied. Type-VI adenyiyl cyclase is found to be 
present in the S49 lymphoma cell line and contains two PKA phosphorylation 
sites. Phosphorylation of these sites in vitro causes inhibition of this isoform 
(Premont et a l,  1992b). A consensus site for phosphorylation by PKA is also 
present in the type-V enzyme, the major isoform in the heart. It has recently been 
shown that this isozyme is inhibited by PKA-dependent phosphorylation (Iwami 
e t a l ,  1995).
Although these isoforms are both insensitive to micromolar concentrations 
of calmodulin, they can be inhibited by calcium at low micromolar concentiations 
(Ishikawa et a l,  1992; Yoshimura and Cooper, 1992). Indeed inhibition of cyclic 
AMP production resulting from elevations in calcium has been correlated with the 
expression of type-V or type-VI adenyiyl cyclases in some cell types (Ishikawa et 
a l,  1992; Yoshimura and Cooper, 1992),
A type-VII adenyiyl cyclase activity has been identified in the membranes 
of S49 lymphoma cell line, but has only been isolated as a partial sequence 
(Krupinski et a l ,  1992). However it has been shown that its activity is modestly 
enhanced by jJy subunits.
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1.5.3. Guanylyl cyclases.
It is now known that the regulation of synthesis of cyclic GMP can occur 
via two routes. Some agonists cause calcium-dependent synthesis of membrane- 
permeant free radicals such as NO (see section 4.3.4), which are able to stimulate 
the cytoplasmic guanylyl cyclase (Furchgott and Zawadski, 1980; Meilion et a l,  
1981; Rapoport and Murad, 1983). Other agonists interact directly with an 
extracellular domain of a membrane-spanning guanylyl cyclase, hence increasing 
its activity (Garbers, 1993). Three mammalian isoforms of plasma membrane 
guanylyl cyclases have been cloned. They have been designated GC-A, GC-B 
and GC-C (Lowe et a l,  1989; Schulz et a l,  1989). Further analysis has revealed
I
A
that two of these cyclases are natriuretic peptide receptors GC-A and GC-B, found 
expressed in the brain (Chinkers etal., 1989).
A cytoplasmic form of guanylyl cyclase has been known to exist for some 
years as a heterodimer (Kamisaki et a l,  1986). The activity of this guanylyl 
cyclase is dependent on the co-expression of the a  (70kDa) and P (82kDa) 
subunits, as no detectable cyclase activity is found associated with the monomers 
(Buechler et a l,  1991). However from cloning experiments, it appears that each 
subunit possesses a catalytic domain (Nakane et a l ,  1990). Soluble guanylyl 
cyclase in vascular smooth muscle is the target for nitric oxide (NO), resulting in 
the vasodilation of this muscle (Furchgott and Zawadski, 1980).
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1.5.4. Cyclic nucleotide dependent protein kinases.
Cyclic GMP- and cyclic AMP-dependent protein kinases were the first 
protein kinases that were purported to be related proteins (Lincoln and Corbin, 
1977). These kinases are members of a much larger group of protein kinases 
which phosphorylate serine/threonine residues (reviewed in (Edelman et a l,  
1987)). Since its discovery, cyclic AMP-dependent protein kinase (PKA) has 
been found to be the only protein (apait from cyclic AMP phosphodiesterases) 
that binds to cyclic AMP with such high affinity, in eukaryotic cells. This has led 
to the suggestion that all the downstream effects of cyclic AMP are mediated 
thi'ough protein phosphorylation via PKA (Taylor et a l,  1990).
PKA exists as two major isoforms, type-I and type-II, that differ with 
respect to their regulatory (R) subunits, as identified by their differing molecular 
weights, antigenicity, amino acid sequence and affinity for cyclic AMP analogues. 
Isotypes of each of these regulatory domains have also been identified, RI (a  and 
(3) and RII (a  and P) subunits, as well as the catalytic (C) (a, p and y) subunit. 
These vaiy between tissues, with type-II PKA being present in all cells, whereas 
the tissue distribution of type-I PKA is more restricted (Corbin e ta l ,  1977; Rubin 
et a l ,  1972). Intracellular localisation also varies, with RI isoforms found
primarily in the cytosolic compai’tment of the cell, although it has been located to
isoforms are activated by cyclic AMP and cyclic GMP, although a greater
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A:the membrane of erythrocytes (Rubin et a l,  1972), and found associated with the 
T cell receptor of activated lymphocytes (Skalhegg et a l,  1994). The RII 
isoforms are generally particulate, with up to 75% of the cellular RH pool being 
associated with the plasma membrane and cytoskeletal compartments (Nigg et a l ,  
1985; Salavatori et a l ,  1990). In all cases, the inactive holoenzyme form of PKA 
is a tetrameric conformation, consisting of two R subunits and two C subunits 
(R2C2) (Taylor, 1989) (fig. 1.7). However upon binding of four cyclic AMP to
the regulatory subunits (two per R monomer), the active catalytic subunits are 
released and can migrate through the cytoplasm and to the nucleus (Meinkoth et 
a l,  1990). These subunits are able to phosphorylate their physiological substrates 
(serine in the context X-R-R-X-S-X) witliin a number of cytoplasmic and nuclear
proteins. Both catalytic and regulatory subunits have been postulated to have a 
role in the transcriptional regulation of cyclic AMP-responsive genes, however it 
appears that the catalytic subunits are both necessary and sufficient for this 
response.
In a similar manner to PKA, there aie two classes of cyclic GMP- 
dependent protein kinase (PKG) present (type-I and type-II forms). PKG is found 
predominantly in cerebellar Purkinje cells, heart and lung tissue (Lincoln and 
Keely, 1980; Lohmann et a l ,  1981). Interestingly, PKG is absent from many 
regions of the brain where cyclic GMP is produced, indicating that it is not the 
sole modulator of cyclic GMP effects (Lincoln and Cornwell, 1993). Type-I PKG 
is a homodimer consisting of subunits of approximately 78kDa, whereas type-II 
PKG is a monomer with a mass of 86kDa. The type-II enzyme is not widespread, 
being found only in intestinal epithelial cells (deJonge, 1981). However, the 
type-I class is more widely distributed, consisting of two closely related isoforms 
type l a  and 1|3, (Lincoln et a l, 1988). These differ in their N-terminal region, 
indicating that they may be alternatively spliced (Francis et a l ,  1989). Both
concentration of cyclic nucleotide is needed to activate the (3 isoform (Landgraf et 
a l ,  1992). Binding o f cyclic GMP to PKG results in enzyme activation. This 
enzyme appears to be predominantly cytosolic, although platelets and type-II 
PKG from intestinal brush border appear to be membrane bound. The consensus 
sequence which is phosphorylated appears to be, R-L-R-S-R-L-G. This site is 
very similar to that of PKA and, not surprisingly, these protein kinases can 
phosphorylate the same sites (Lincoln and Corbin, 1977), although specificity 
determinants may exist for cyclic GMP kinase. This has been demonstrated, 
where phenylylalanine residues ai’e placed on the C-terminal end of the target
serine residues, enhancing the selectivity for PKG compared with PKA (Colbran
■■■e t a l ,  1992).
1.5.5. A-kinase anchoring proteins.
In order to perform specific phosphorylations that are necessary in the 
tight regulation of cellular metabolism one might expect that the activation of a 
kinase would be compartmentalised, in some way, to ensure targeting and 
specificity of phosphorylation of the desired substi’ate. The proposal of selective 
activation of PKA-pools, which ai’e co-localised with key substrates, may provide 
the opportunity for this to occur. The type-I PKA isoenzyme has shown to be 
associated with the TCR/CD3 complex upon TCR ligation (Skalhegg et a l ,  
1994). Interestingly, type-II PKA holoenzyme has been found to be tethered to 
specific subcellulai’ localisations via an interaction with specific A-Kinase 
Anchoring Proteins (AKAPs) (Scott and Cair, 1992). The binding to these 
adaptor proteins is maintained via high affinity interactions. RII dimérisation 
appears to be required for these interactions to take place (Luo et a l,  1990; Scott 
et a l ,  1990).
A number of different AKAPs specific for type-II PKA have been 
identified in the literature by virtue of their molecular weights, subcellular 
localisation and differential hormone induction (CaiT et a l,  1993; Carr et a l.
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1992; Keryer et a l ,  1993; McCartney et a l ,  1995). Interestingly, these AKAPs
■do not appear to anchor PKAU alone, but have recently been reported to bind the 
protein phosphatase calcineurin (Coghlan et a l ,  1995). It has been noted that the 
first 5 amino acids of each RII subunit are critical for AKAP interaction (Hausken 
et a l ,  1994). However, it appears that AKAPs contain additional binding sites
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possibly responsible for targeting them to cellular structures, such as DNA 
binding domains (Coghlan e ta l ,  1994) and cytoskeletal binding domains (Glantz 
et a l ,  1993). This added control to a dynamic system, may allow the 
redistribution of PKAII to occur in response to external stimuli. The ability of 
signalling molecules to grouped around AKAPs (Coghlan et a l ,  1995) may allow 
tight regulation of the phosphoiylation state and thus activity of key substrates.
J-y1.5.6. N uclear signalling of PKA.
As well as the rapid effects that are associated with PKA in 
phosphorylation of key signalling molecules, PKA activation also has long-term 
effects, resulting in the regulation of transcription of specific genes (Lalli and 
Sassone-Corsi, 1994). The nuclear targets for PKA are transcription factors 
which bind to palendtomic DNA sequences called cyclic AMP-responsive 
elements (CREs) (TGACGTCA), (Comb e ta l ,  1986; Montminy e ta l ,  1986). 
The transcription activation factors involved include CRE-binding protein
(CREB), and different members of the activation transcription (ATE) family 
(Weng et a l ,  1993; Yamamoto et a l, 1988). CREB/ATF regulatory proteins are
characterised by a leucine-zipper domain and a basic DNA binding domain that 
recognise the CRE site. These proteins have an important role in regulating basal 
gene transcription or induced gene transcription in response to cyclic AMP 
elevation. This family of transcription factors also share a certain degree of 
homology with members of the activator protein-1 (AP-1) family, Fos/Jun 
proteins (see section 5.1.2). Indeed, hetero-dimerisation can occur between the
'
families as well as homo-dimerisation, which creates enormous complexity,
P
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leading to a higher order of regulation, involving cross-talk between lipid and 
cyclic nucleotide signalling at the level of gene transcription (Altschul e ta l ,
1990; Hai and Curran, 1991; Landschulz et a l ,  1988). CREB/ATF proteins are 
the targets for several protein kinases including PKC and PKA, with 
phosphorylation of these factors stimulating or repressing transcription (de Groot 
eta l., 1993; Yamamoto eta l., 1988). Different forms of CREB/ATF proteins 
bind to different CRE sites, or even the same sites, with differing affinities 
following phosphorylation by such kinases. This control allows a convergence of 
signals to occur from different signalling pathways, at the level of gene
,.P
transcription. Attenuation or inhibition of cyclic AMP-stimulated gene 
transcription requires dephosphorylation of transcription factors to occur, 
representing a key mechanism in the negative regulation of CREB activity. It 
appears that protein phosphatase 2A (PP2A) and PP l oppose the action of PKA 
(Hagawara et al., 1992; Wadzinski et al., 1993). The PPTs involved may be 
dependent on the cells being studied.
Another class of transcription factors involved in the transduction of cyclic 
AMP effects on transcriptional regulation are CRE-modulators (CREM) (Meyer 
and Habener, 1993). The complexity of the CREM protein repertoire is enhanced 
by alternative splicing mechanism giving rise to various forms o f CREM which 
can be activators or repressors of transcription (Foulkes and Sassone-Corsi, 1992).
Cyclic AMP inducible transcription factors (ICERs) have now also been 
identified, which are involved in the repression of transcription (Molina et al.,
1993). The kinetic expression of these transcription factors is characteristic of an 
early response gene, such as c-fos, c-Jun and c-rel (Verma and Sassone-Corsi,
1987), with induction being rapid and transient. These are the first transcriptional
repressor in the cyclic AMP signalling pathway whose functions are regulated by 
the modulation of its own intracellular levels and not by phosphorylation. It is 
thought to be important in the phenomenon of down-regulation of gene activity 
after a first burst of activation by cyclic AMP.
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î1.5.7. Cyclic nucleotide phosphodiesterases.
The degradation of the second messengers cyclic AMP and cyclic GMP is 
achieved solely by cyclic nucleotide phosphodiesterases (PDEs). These elicit the 
hydrolysis of the 3 ’ phosphate ester bond to give the corresponding 5 ’ nucleoside 
monophosphate, thus rendering the signal inactive (Butcher et al., 1961; Butcher 
and Sutherland, 1962) (fig. 1.8). This activity is provided by a diverse group of 
enzymes with complexity resulting from the presence of both multiple genes 
together with alternative splicing (reviewed in (Beavo et al., 1994; Bolger, 1994; 
Conti et al., 1995b; Houslay and Kilgour, 1990; Reeves and England, 1990)).
Cyclic nucleotide hydrolysing PDEs exhibit distinct biochemical 
characteristics and can be divided into at least seven functional classes (table 1.1): 
(i) PD E l, which can hydrolyse both cyclic GMP and cyclic AMP and whose 
activity is stimulated by calcium/calmodulin (Ca^^/CaM); (ii) PDE2 hydrolyses 
of cyclic AMP and cyclic GMP, with the activity being stimulated by micromolar 
concentrations of cyclic GMP; (iii) PDE3 specifically hydrolyses cyclic AMP in 
a manner which is inhibited by micromolar concentrations of cyclic GMP; (iv) 
PDE4 enzymes are cyclic AMP specific PDEs which are insensitive to cyclic 
GMP, and are selectively inhibited by the selective inhibitor rolipram; (v) PDE5 
and PDE6 enzymes specifically hydrolyse cyclic GMP, but differ in their 
structure and tissue distribution; (vi) PDE7 specifically hydi'olyses cyclic AMP 
and is insensitive not only to cyclic GMP but also to the non-selective PDB 
inhibitor isobutylmethylxanthine (IBMX) and the PDE4 selective inhibitor 
rolipram.
The PDE enzyme family shows a diverse range of properties that are 
exemplified by their differential sensitivity to phosphorylation by various kinases
(Beltman et al., 1993; Degerman et a i,  1990; Houslay and Kilgour, 1990; Kilgour 
et al., 1989; Manganiello et al., 1990a; Pyne et al., 1989; Swinnen et al., 1989b), 
their inhibitor specificities and cofactor requirements (Degerman et al., 1990; Hall
4 .
Table 1.1. Summary of cyclic nucleotide phosphodiesterase 
isoforms.
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Isoenzyme Type Effectors Substrate Specificity Selective Inhibitor
PDEl
formerly Type-I, 
Ca2+/CaM- 
stimulated PDE
Stimulated by 
calciurn/calmodulin
Differing Km for 
cAMP and cGMP 
depends on the 
tissue
vinpocetine
PDE2
formerly Type-II, 
cGMP-stimulated 
PDE
cAMP activity is 
stimulated by low 
(pM) [cGMP]
High Km for both 
cAMP and cGMP
EHNA
PDE3
formerly Type-III,
cGMP-inhibitied
PDE
cAMP activity is 
inhibited by low 
(pM) [cGMP]
Low Km for both 
cAMP and cGMP
milrinone
cilostamide
amrinone
PDE4
formerly Type-IV, 
cAMP- 
specific PDE
Specific for cAMP Low Km for cAMP 
only
rolipram
Ro20-1724
PDE5
formerly Type-V, 
cGMP-binding 
cGMP-specific PDE
Specific for cGMP 
located in the 
periphery eg. heart 
or lung
Isofoims with high 
and low Km for 
cGMP only
zaprinast
dipyridamole
PDE6
formerly Type-V,
Photoreceptor
PDE
Specific for cGMP 
Located in rods and 
cones of visual 
system
Micromolar Km for 
cGMP
dipyridamole 
M&B22 948
PDE7
formerly Type-VII, 
c AMP-specific 
rolipram-insensitive 
PDE
Specific for cAMP Very low Km for 
cAMP only
None reported 
Insensitive to 
rolipram and IBMX
1
I
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1.5 7.1. Structure of cyclic nucleotide PDEs.
1.5.7.11. Catalytic domain of cyclic nucleotide PDEs,
It has become apparent that PDEs are multidomain proteins, with distinct
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and Hill, 1992; Houslay and Kilgour, 1990; Moore et a l ,  1991; Reeves and 
England, 1990; Swinnen etal., 1989b), their hormonal regulation (Conti et al., 
1995b; Sette et al., 1994b; Swinnen et al., 1991), their differential expression 
patterns (Engels et al., 1995; Engels et al., 1994; Lobban et al., 1994), and their 
intracellular localisation (Lobban et al., 1994; Shakur et a l ,  1993), Members of 
this diverse family thus have the potential to modulate cyclic AMP metabolism to 
the specific requirements of the cell, including being able to integrate regulatory 
signals from lipid, tyrosyl and NO signalling pathways.
catalytic and regulatory regions. The comparison of the two mammalian PDEs, 
Ca^+ZCaM-stimulated cyclic nucleotide PDE from bovine brain and cyclic GMP- 
stimulated PDE genes from bovine heart indicated that these were unique 
gene products (Charbonneau e ta l ,  1986). However as amino acid sequences 
have been determined, it has become clear that there is a conserved region of 
about 270 amino acids (35kDa) present in nearly all PDE isoenzymes, displaying 
as much as 90% within and about 30% sequence identity between PDE families 
(Charbonneau et a l ,  1986) (fig. 1.9). The homology of tliis region appears to 
have been conserved through evolution as deduced by comparing mammalian 
PDE sequences with sequences of low K ^ yeast PDE2 (Sass et a l,  1986) and 
Drosophila dunce{dnc) genes (Chen et a l, 1986) (fig. 1.9). However, this domain 
is not present in the higher Km PDE enzyme of yeast or in the Dictyostellum  
discoideum  PDE (Lacombe et a l ,  1986; Sass et a l, 1986), although these 
enzymes do show some homology to each other, indicating that there at least two 
major PDE families from an evolutionary stand-point. Interestingly, yeast PDE2 
enzyme is functional in mammalian cells, indicating that this enzyme family is 
very highly conserved (van Lookeren Campagne et a l ,  1990).
V 'i î .
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Figure 1.9. Schematic representation of the catalytic and 
regulatory domains of cyclic nucleotide phosphodiesterases.
The diagram compares (from top to bottom), Ca^+ZCaM- 
stimulated, PD E l; cyclic GMP-stimulated, PDE2; cyclic GMP- 
inhibited, PDE3; cyclic AMP-specific, PDE4 and cyclic GMP- 
specific, PDE5. The black area indicates the conserved catalytic 
domain of about 270 amino acid residues between almost all 
PDEs. PD E l contains a CaM binding domain in the N-terminal 
region of the PDE (horizontal lines). PDE2 and PDE5 contain a 
homologous non-catalytic cyclic GMP binding domain (wavy-lined 
area). PDE3 has a 44 amino acid insert within its catalytic domain, 
unique to this class of PDEs. PDE4 is shown to contain upstream 
conserved regions (UCR-1 and UCR-2) upstream of the conserved 
catalytic domain unique to this class of PDEs.
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The conservation o f this 270 amino acid region led to the proposal that this 
was the catalytic domain, which has been supported by a number of studies. The 
region was shown to contain a motif (Glu-Leu-Ala-Leu-Met-Tyr-Asn) which is 
also found in the regulatory subunits of cyclic AMP-dependent protein kinases. 
This was suggested to be a cyclic AMP binding sequence motif (Scott, 1987). 
Limited proteolysis of different PDE isoenzymes such as PD El and PDE2 has 
revealed that the catalytic domains of these enzymes are separate from the 
regulatory domains (Kincaid eta l., 1985; Stroop e ta l ,  1989). A 35-40kDa 
fragment was produced in this way, which had a cyclic AMP hydrolysing activity, 
but could no longer be regulated by cyclic GMP of Ca^^/CaM respectively. Site- 
directed mutagenesis of residues within the conserved domain has revealed that 
selected amino acids are essential for catalysis (Jin et al., 1992). Among these are 
a number of invariant histidine residues are highly conserved in the catalytic 
region of PDEs obtained from divergent sources (Charbonneau, 1990; 
Charbonneau eta l., 1986; Francis et al., 1994). These amino acids appear to be 
important in sustaining enzymatic activity, as mutation of these residues abolishes 
PDE activity (Jin et a l ,  1992).
1.5.7.12. Regulatory domains of cyclic nucleotide PDEs.
The primary sequence towards the N- and C-terminal area of PDEs appear 
to be more divergent between gi’oups, sharing little homology. However, within 
groups there still appears to be a similarity of 60-80% extending throughout the 
entire coding region. This has led to the suggestion that these regions of PDEs 
may be involved in modulating the function of PDEs. Non-catalytic conserved 
regions have been reported in all PDE groups, some of which are involved in the 
modulation of catalytic activity, for example CaM binding site on PD E l. 
Meanwhile, other conserved sequences are of unknown function such as upstream 
conserved regions (UCR) identified in PDE4 enzymes.
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The binding of CaM to PD El causes at least a 4 fold stimulation in PDE 
activity (Cheung, 1967). Peptides derived from PDEl were tested for their ability 
to bind CaM and it was revealed that the CaM binding site is in N-terminal region 
of these PDEs (Charbonneau eta l., 1991) (fig. 1.9). Limited proteolysis of PD El 
produced a 36kDa fragment which is constitutively active and independent of 
regulation by CaM (Charbonneau et al., 1991). In support of this, PDE1A2 
(61kDa) and P D E lA l (59kDa) have been shown to have similar substrate 
specificities, but differ in molecular weight and affinity for CaM (Hansen and 
Beavo, 1986). These PDEs appear to have identical primary sequences except for 
the N-terminal portion of tiie enzyme which incorporates the CaM binding site 
(Novack etal., 1991).
PDE2, PDE5 and PDE6 all possess a conserved domain which is separate 
from the catalytic domain (Charbonneau et al., 1989) (Eg. 1.9). The degree of 
homology in this region is high (30% between PDE2 and PDE6) (Gillespie and 
Beavo, 1989b; Stroop and Beavo, 1991). Studies using limited proteolysis on 
PDE2 have shown that cyclic GMP binding can be separated from the catalytic 
activity and is localised to a 60kDa chymottyptic fragment (Stroop and Beavo, 
1991). PDE2 binds cyclic GMP with high affinity (Martins et al., 1982) via an 
allosteric domain and a catalytic domain (Charbonneau et al., 1986; Emeux et al., 
1985; Yamamoto et al., 1983b). This results in the display of complex kinetics 
due to actions mediated through the cyclic GMP-binding regulatory site (Erneux 
e ta l ,  1982; Manganiello era /., 1990b; Pyne e ta l ,  1986; Stroop e ta l ,  1989). 
Indeed, hydrolysis of cyclic AMP by PDE2 isolated from hepatocytes shows 
positive cooperativity, with a Hill coefficient greater than unity observed (about 
1.9), indicative of positive homotropic interactions occurring between the 
regulatory and catalytic sites (Pyne et a l ,  1986). However, removal of the 
regulatory site by limited proteolysis has been shown to abolish the cooperativity 
of catalysis of cyclic AMP (Stroop and Beavo, 1992). This implies that the 
regulatory and catalytic domains are separate.
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Conserved regions has recently been identified in the N-terminal of PDE4 
(Bolger et al., 1993). These domains, UCR-1 and UCR-2 appear to be distinct 
features of the PDE4 family and are strongly conserved between organisms as 
evolutionarily divergent as Drosophila melanogaster and mammals. However, no 
other close homologs appear to be present in other sequences in GenBank or 
EMBL databases (Bolger eta l., 1993). UCR-1 and UCR-2 are distinct from each 
other and are separated by a region of low homology. It has been found that 
UCR-1, but not UCR-2, undergoes alternative splicing (Bolger, 1994). The strong 
evolutionary conservation of these domains suggests that they may have particular 
functions.
There is increasing evidence that N-terminal domains of PDEs can have 
important effects on the localisation and activity of the enzyme. Indeed, on 
removal of the N-terminal domain of PDE4A (RDI) an increase in PDE activity 
was observed (McPhee et al., 1995; Shakur et a l,  1995). This elevation in PDE 
activity has also been observed in PDE4B (DPD) and PDE4D upon cleavage of 
the N-terminus (Jin et a l,  1992; Pillai et a l ,  1993). Studies carried out on 
PDE4A also revealed that the extreme N-terminus of this PDE is important in 
conferring membrane association on the PDE (Shakur et a l ,  1993). Removal of 
this domain caused the protein to become soluble. A membrane binding domain 
has also been found in PDE3 enzymes which appears to be isolated in the N- 
terminal domain (Meacci et a l,  1992; Taira et a l,  1993).
I,
I.5.7.2. PD E l, calcium/calmodulin-stimulated PDE.
PD El was first described in bovine brain and rat brain, as a cyclic AMP 
hydrolysing activity which was elevated in the presence o f CaM and Ca^+ 
(Cheung, 1967; Kakiuchi and Yamazaki, 1970). This PDE activity was later 
isolated from the heart (Teo and Wang, 1973). PD El appears to be expressed in a 
wide range of tissues with the exception of, for example human peripheral blood 
lymphocytes (Thompson et a l, 1976) and monocytes (Thompson et a l, 1980).
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Ca^+ZCaM stimulated PDEs have been found at high concentrations in Purkinje
■cells and pyrimidal cells of the cerebral cortex (Kincaid e ta l ,  1987), heart
■ ■ ■ I(Hansen and Beavo, 1982), lung (Sharma and Wang, 1986b) and testis (Rossi et
regarding their kinetics, structure, tissue distribution and modes of regulation 
(Hansen and Beavo, 1986; Sharma and Wang, 1986a; Sharma and Wang, 1986b).
use of monoclonal antibodies (Hansen and Beavo, 1986; Sharma e ta l ,  1984).
%a l ,  1988).
The isozymes of this group of PDEs are the product of at least three genes 
PD EIA  (59Z61kDa), PDE IB (63kDa) and PD E IC  (70kDa). They differ
Different isoforms of this group were distinguished in the brain and heart by the
Indeed the amino acid sequence of the PDE1A2 (61kDa) and PDE IB 1A (63kDa) 
from bovine brain tissue have since been determined by direct sequencing of the
protein (Charbonneau et a l ,  1991) and sequencing of cDNA clones (Bentley et 
a l ,  1992; Repaske et a l ,  1992). A comparison of these isoform sequences 
suggested that although they were homologous they were the products of different 
genes. PDEIB 1A also differs with respect to kinetic properties, having a higher 
Vmax for cyclic GMP than cyclic AMP. Comparing the sequences from the 
PDE1A2 protein and a P D E lA l (59kDa) Ca^+ZCaM-stimulated PDE from bovine 
heart tissue revealed them to be identical except for the N-terminus (thought to 
provide the CaM binding domain (Chai'bonneau et a l,  1986)), implying that these 
two isozymes are generated from alternatively spliced genes (Novack et a l,  1991; 
Sonnenburg et a l ,  1993). Moreover, these isozymes appear to differ in their 
ability to hydrolyse cyclic AMP and cyclic GMP, and their affinity for CaM 
(Hansen and Beavo, 1986; Sharma and Wang, 1986b). This is of interest, as the 
brain splice variant is less sensitive to CaM than the enzyme from heart in vitro 
(Mutus et a l ,  1985) although the concentrations of CaM in the brain are elevated 
when compared to the heart. This may be due to the regulatory effect the N- 
terminal tail modulating the catalytic activity of the enzyme.
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The other PDE identified in this group is the larger isoenzyme, PD EIC
■
(70kDa) present in the lung (Sharma and Wang, 1986b), which has a distinct
mode of interaction with CaM, associating with CaM independently of calcium
-
concentrations. Interestingly a novel enzyme in this group which is a Ro20-1724 
sensitive, Ca^+ZCaM-stimulated PDE which exhibits a high affinity for cyclic 
AMP. This enzyme is poised to have a major effect on cyclic AMP 
concentrations within the cell in the event of increasing [Ca^+li (Rossi et al.,
1988). The PDE has been found to be expressed in monocytes o f atopic 
dermatitis sufferers. Cyclic AMP PDE activity is elevated in leukocytes from 
patients with atopic disease (such as atopic dermatitis or asthma) (Grewe et al., 
1982). It has been proposed that this PDE activity may be the cause of defective 
cyclic AMP metabolism in these cells (Chan etal., 1993).
The initial work carried out on this group of enzymes was misleading, as 
these proteins are highly susceptible to proteolysis, thus producing a PDE activity 
which is constitutively active, and independent of regulation by CaM (Cheung,
1971; Moss et al., 1978). Purification of this enzyme activity in the past gave 
contaminated samples upon DEAE anion exchange chromatography, as it eluted 
with the cyclic GMP-specific, PDE5 activity, hence giving misleading kinetics 
and inhibitor preferences. PD El isoforms appears to exist as homodimers, which 
have the ability to hydrolyse cyclic GMP and cyclic AMP with varying affinities 
depending on the isoform within the group which is being studied. PD E l activity 
can be selectively inhibited by nicardipine (Matsushima eta l., 1988) and 
vinpocetine (Hidaka and Endo, 1984) at micromolar concentrations.
ffi
!I.5.7.2.I. Regulation of PD El.
It has become apparent that this group of PDEs is regulated by 
phosphorylation in vitro. The PDE1A2 and the PDEIB 1A isoforms in brain can 
be phosphorylated by PKA and CaM-dependent protein kinase (CaMPK)
(Hashimoto et al., 1989; Sharma and Wang, 1986a) respectively in the N-
■2
.49
terminal domain, in the vicinity of the CaM binding domain (Florio et al., 1994; 
Sharma and Wang, 1985) These phosphorylation events cause a decrease in the 
sensitivity of the PDE to CaM and require an elevation in calcium for optimal 
stimulation of activity. Dephosphorylation of these isozymes by calcineurin 
restores normal CaM affinity and Ca^+ sensitivity (Sharma and Wang, 1986a; 
Sharma and Wang, 1985). As yet, phosphorylation events in these enzymes have 
not been reported in intact cells.
A rapid and transient induction of PD El activity has recently been 
reported in CHO cells via a PKC-mediated process (Spence et al., 1995). It is 
possible to envisage this group of PDEs playing a linking role in the regulation of 
calcium/phospholipid pathways and cyclic nucleotide signalling.
I.5.7.3. PDE2, cyclic GMP-stimulated PDE.
PDE2 was isolated initially from liver cytosolic fractions (Beavo et al., 
1970) and particulate fractions of other rat tissues such as thymocytes (Franks and 
MacManus, 1971) and brain (Beavo et al., 1971). This isozyme was first purified 
to homogeneity from bovine adrenal glands and heai't tissues (Martins et al.,
1982), and has now been identified in a number of other tissues (Erneux et al., 
1981; Pyne et al., 1986; Yamamoto et al., 1983a). PDE2 has now cloned from 
bovine brain and adrenal glands (Sonnenberg et al., 1991; Tanaka et al., 1991), rat 
brain libraries (Yang et al., 1994) and from rat liver mRNA (Repaske et al.,
1993). Two distinct subfamilies of this enzyme e x is t, PDE2A1 the heart/ 
adrenal isoenzyme (Martins et al., 1982), PDE2A2 the membrane bound form 
(Yamamoto et al., 1983a) and the PDE2B1 liver form (Pyne eta l., 1986) which 
may be a proteolytic product of PDE2A due to its smaller molecular size. 
Although the PDE2 enzyme has thus far only been identified as the product of one 
gene, there is evidence of two potential splice products. These appear to be 
different at the 5 ’ end of the protein (Yang et al., 1994).
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The native enzyme is a homodimer of about 220KDa (Le Trong et aL,
1990). Both cyclic AMP and cyclic GMP are hydrolysed by PDE2, although at 
physiological concentrations of cyclic nucleotides its preferred substrate is cyclic 
AM P (Moss et a l ,  1977). PDE2 differs profoundly from all other known cyclic 
AMP PDE families in that as well as having a catalytic site, they also have a 
distinct regulatory site (Charbonneau et a l ,  1986; Charbonneau et a l,  1989) (see 
section 1.5.7.1.2). Cyclic GMP binds to PDE2 with high affinity (Martins e ta l .
1982) via an allosteric domain and a catalytic domain (Charbonneau et a l,  1986;
Em eux et a l ,  1985; Yamamoto et a l, 1983b). PDE activity of PDE2 can be 
stimulated up to 50 fold by micromolar cyclic GMP concentrations. This may 
have physiological relevance as cyclic GMP may reach these levels in cells 
following stimulation by atrial natriuretic factor (ANF) or treatment of the cells 
with sodium nitropmsside (Hamet e ta l ,  1984; Trembly e ta l ,  1986).
Both cyclic AMP and cyclic GMP can be hydrolysed by PDE2 
isoenzymes, although cyclic AMIP is the preferred substrate (Moss et a l,  1977),
Members of this enzyme family display complex kinetics due to actions mediated 
through the cyclic GMP-binding regulatoiy site (Erneux e ta l ,  1982; Manganiello 
et a l ,  1990b; Pyne et a l,  1986; Stroop et a l ,  1989). Thus, in the case of the 
soluble type-H enzyme from hepatocytes, hydrolysis of cyclic AMP shows 
positive cooperativity, with a Hill coefficient greater than unity observed (about 
1.9). This is indicative of positive homoti'opic interactions occurring between the 
regulatory and catalytic sites (Pyne et a l ,  1986). Indeed removal of the regulatory 
site by limited proteolysis has been shown to abolish the cooperativity of catalysis 
of cyclic AMP (Stroop and Beavo, 1992). Cyclic AMP can also bind to the
... ... .regulatory site and stimulate activity, although much more weakly, leading to a
.
complex kinetic behaviour (Erneux et a l ,  1982; Pyne e ta l ,  1986). For these 
reasons, it has been difficult to find effective inhibitors against this enzyme 
activity, as inhibitors capable of interacting at both sites might stimulate as well as 
inhibit cyclic GMP-stimulated PDE activity (Erneux et a l ,  1982; Pyne et a l.
’:îI'
1986; Yamamoto et a l ,  1983b). To date, only one inhibitor has been found 
abrogate PDE2 enzymatic activity, the adenosine deaminase inhibitor erythro-9- 
(2-hydroxy-3-nonyl)-adenine (EHNA) (Mery e ta l ,  1995; Pages e ta l ,  1994; 
Podzuweit et a l ,  1995). This is discussed in section 3.1.
Studies focusing on PDE2 regulation by phosphorylation have shown that 
the particulate brain isozyme is phosphorylated by PKA in vitro. However, this 
modification does not alter the kinetic properties of the enzyme (Whalin et a l,  
1988) and, to date, in vivo phosphorylation of this enzyme activity has not been 
shown.
Thus, members of this enzyme family are placed in the unique position of 
being able to tailor cyclic AMP metabolism to the specific requirements of 
different cell types. This PDE family may also has the ability to integrate 
regulatory signals from NO signalling systems, as well as modulating the effects 
o f cyclic nucleotides in both heart and adienal tissues (Hartzell and Fischmeister, 
1986). This PDE may be the molecular basis for the opposing actions of cyclic 
AMP and cyclic GMP seen in some biological systems, such as lymphocytes, as 
an elevation in cyclic GMP levels reduces cyclic AMP (Hadden, 1988).
I.5.7.4. PDE3, cyclic GMP-inhibited PDE.
This group of PDEs was identified, along with PDE4 (see below) as the 
low K,n PDEs due to their ability to hydrolyse cyclic AMP with high affinity 
(Weber and Appleman, 1982),. However it was soon realised that this group 
consisted of two separate activities, one which was inhibited by cyclic GMP and 
cilostimide, and the other which was sensitive to Ro20-1724. This was the basis 
of the separation of the low K^ PDE group into two separate PDEs, cyclic GMP- 
inhibited, PDE3, and cyclic AMP-specific, PDE4 (Yamamoto e ta l ,  1984).
PDE3 isoforms have been shown to occur as both membrane bound (liver 
and adipose enzyme) (Heyworth et a l ,  1983; Pyne et a l,  1987a) as well as 
cytosolic (platelet isoform) (MacPhee e ta l ,  1988) species. They are expressed in
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a wide array of tissues, such as human platelets (Grant and Coleman, 1984),
■
bovine heart (Harrison et al., 1986), rat liver (Pyne et a l,  1987a) and bovine and 
rat adipocyte tissue (Degerman et a l ,  1987; Degerman et a l,  1988). Some 
variation has been found upon analysis of the molecular weights of PDE3 
isoforms. Generally it has been shown that PDE3 are polypeptides in the 110- 
135kDa range, although endogenous proteolysis produces fragments in the 44- 
90kDa range in adipocytes, platelets and cardiac tissue (Degerman et a l ,  1987;
I
Degerman et a l ,  1988; Harrison et a l,  1986; MacPhee et a l ,  1988). However, 
the 'dense-vesicle' rat liver cyclic GMP-inhibited PDE has a smaller molecular 
weight (62 kDa) (Marchmont et a l ,  1981; Pyne et al,, 1987a) and this is proposed 
to be the native molecular weight of this PDE. Evidence also suggests that this 
PDE may exist as a 1 lOkDa dimer in situ (Pyne et a l,  1987a).
Differences in molecular weights may also be accounted for because
.
PDE3 enzymes are found to consist of separate gene products or alternative splice 
valiants. To date, molecular cloning studies have revealed that the PDE3 family 
is derived from at least two distinct gene families isolated from human cardiac 
(PDE3A) and rat adipocyte (PDE3B) cDNA libraiies (Meacci et a l,  1992; Taira 
et a l ,  1993). These two groups are structurally very similar, including the 44
-,amino acid insert in the catalytic domain, which is a feature of this gi'oup of PDEs 
(fig. 1.9). However, the N-terminal regions aie very divergent, with a possible 
membrane binding role for this region (Meacci et a l, 1992; Taira et a l ,  1993).
Activities in this group of isoenzymes are inhibited by micromolar cyclic 
GMP. PDE3 have a high affinity (low K^) for both cyclic AMP and cyclic GMP 
(O.l-O.SjrM range) (Degerman et a l ,  1987; Grant and Coleman, 1984; Pyne et a l,
1987a). However, cyclic AMP is much more readily hydrolysed (Vmax rado 
cyclic AMP/cyclic GMP < 10). As a result, cyclic GMP serves as a potent 
competitive inhibitor of cyclic AMP hydrolysis (IC50 > IpM  for PDE3 from 
human and bovine platelets (Grant and Coleman, 1984; MacPhee et a l ,  1986)).
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This enzyme is believed to play an important role in allowing 'cross-talk’ between 
cyclic AMP and cyclic GMP signalling systems.
activity (Alvarez et a l ,  1981). In human platelets, PKLA is reported to mediate a 
phosphorylation event which leads to an increase in this cyclic GMP-inhibited 
PDE activity (MacPhee et a l ,  1988). The heart isozyme has been found to be a 
very good substrate for PKA in vitro (Harrison et a l ,  1986). This 
phosphorylation event may mediate a negative feedback mechanism which aids in 
the restoration of resting cyclic AIVIP levels within the system (Manganiello et at., 
1990a). The increase in cyclic AMP phosphodiesterase activity may play an 
important role in the desensitisation of platelets to further exposure to adenylyl 
cyclase agonists.
It has been shown by several investigators that many of the metabolic 
effects of insulin on carbohydrate and lipid metabolism are mediated at least in 
part by a cyclic GMP-inhibited PDE activity. Pretreatment of adipocyte and 
hepatocytes with insulin, or agents that elevate cyclic AMP, stimulates the 
phosphorylation of the membrane bound (or dense-vesicle) PDE3B (Gettys et at., 
1987; Heyworth et a l,  1983; Loten and Snyed, 1970; Smith eta l., 1991). This 
has lead to the theory that this isoform is an integral part of these two signalling 
pathways, and the regulation of glycogenolysis and gluconeogenesis. In 
hepatocytes it has been suggested that PKA is responsible for this phosphorylation 
event (Kilgour et a l, 1989). The phosphorylation of, and subsequent increase in, 
PDE3 activity mediates a depression of cyclic AMP levels in hepatocytes. This
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1,5.7,4.L Regulation of PDE3.
Hormonal regulation of PDE3 has been investigated and well 
characterised in rat adipocytes (Anderson et a l ,  1989), in 3T3-L1 adipocyte cell 
line (Manganiello et a l ,  1983) and in hepatocytes (Heyworth et a l,  1983). 
Treatment of intact rat or human platelets with prostaglandin Ei or cyclic AMP 
elevating agents, such as forskolin stimulates cyclic AMP phosphodiesterase
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study also suggested that an unidentified kinase phosphorylated PDE3, without 
causing a change in PDE3 activity, but preventing activation and phosphorylation 
of the PDE by PKA (Kilgour et al., 1989). A possible candidate for this ‘silent’ 
kinase was 5 ’AMP kinase, as it has been previously shown that this kinase 
prevents PKA from phosphorylating acetyl-CoA carboxylase (Monday et al.,
1988).
A similar scenaiio is seen in adipocytes, where lipolysis is modulated by 
agents that increase cyclic AMP concentrations such as adrenaline (Anderson et 
al., 1989) and antagonised by agents that decrease cyclic AMP levels, such as 
insulin (Manganiello eta l., 1992; Smith eta l., 1991). Cyclic AMP levels appear 
to be modulated by the regulation of PDE3, which is found exclusively associated 
with the endoplasmic reticulum subfraction (Anderson et al., 1989). It appears 
that phosphorylation in this case occurs at two distinct sites on PDE3 allowing a
■ïïi„greater degree of control of PDE activity, and promoting synergy between the two 
phosphorylation events (Degerman et al., 1990; Smith et al., 1991).
Isoproterenol-induced phosphorylation occurs via a PKA-dependent mechanism 
promoting lipolysis, but it is thought that a different kinase is responsible for the 
insulin-induced phosphorylation. Indeed, this phosphorylation occurs mainly on 
serine/threonine residues, therefore implying that the phosphorylation event is not 
a direct result of insulin receptor phosphorylation mediated events. Incubation of 
adipocytes with okadaic acid (a potent inhibitor of protein phosphatase- 1 and -2A) 
reproduced the hormone action (Shibata et al., 1991).
The identity of this ‘insulin-activated kinase’ is unknown, however it acts 
in a similar manner in adipocytes and liver (Shibata and Kuno, 1990a; Shibata and 
Kuno, 1990b). The cyclic GMP-inhibited PDE activity in platelets (PDE3A) is 
also activated upon phosphorylation with the ‘insulin-activated kinase’ (Lopez et 
al., 1992; Lopez-Aparicio eta l., 1993). Interestingly, it has been suggested that 
there may be a link between insulin activation of the PDE3 activity through PI-3- 
K, as wortmannin abolishes the phosphorylation event. However, this is not
%
thought to be direct, suggesting that the action of PI-3-K is upstream of PDE3 
(Rahn et al., 1994).
Due to their well documented hormonal regulation, PDE3 isoforms are 
important targets for therapeutic agents in disease models. There are several 
inhibitors of this class of PDEs, including the cardiotonic agents amrinone, 
milrinone and cilostimide, which are described in more detail in section 3.1 
(Reeves and England, 1990).
I.5.7.5. PDE4, cyclic AM P-spedfic PDE.
This group of PDEs is the probably the most intensely studied of the PDE 
enzymes, encompassing a diverse group of proteins that are important regulators 
o f intracellular signalling. In the past they have been often referred to (along with 
PDE3) as low-Km PDEs due to their ability to hydrolyse cyclic AMP specifically 
and with a high affinity (Km in the micromolar range). Purification of this PDE 
was initially achieved from dog kidney, and revealed a PDE enzyme of between 
48-60kDa which was specific for cyclic AMP, insensitive to inhibition to cyclic 
GMP (Thompson et al., 1979a) . Prior to molecular cloning technology the 
isolation of PDE4 isoforms proved to be difficult because of various factors, 
including the PDE4 isoforms being present only in trace amounts, they can be 
compartmentalised within the cell, and like other PDEs are unstable and easily 
proteolysed. Despite this, PDE4 isoforms have been isolated from a vaiiety of 
tissues and species including human heart (Reeves et al., 1987) and rat liver and 
hepatocytes (Lavan et al., 1989; Marchmont etal., 1981). However, as with 
PDE3 isoforms there was a difference of opinion on the size of this PDE, ranging 
from 52kDa for the peripheral, membrane bound rat liver PDE4 (Marchmont et 
al., 1981), to 60kDa species isolated from human lung (Moore and Schroedter,
1982). This may be due to proteolysis, however it has become evident that the 
PDE4 family encompasses different gene products (table 1.2).
I
56 ■i
Table 1.2. Summary of the properties of the PDE4 isoenzyme 
family.
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PDE4 enzymes were found to have a high sensitivity to what is now 
widely accepted to be PDE4 selective inhibitors, such as 4-{3-(cyclopentoxyl)-4- 
methoxyphenyl)-2-pyrrolidone (rolipram) and [4-(Butoxy-4-methoxybenzyi)-2- 
imidazolidinone] Ro20-1724 (Nemoz e ta l ,  1985; Watchel, 1983a) (see section 
3.1). They differ from other cyclic AMP PDEs in that their activities are 
unaffected by Ca^+ZCaM, or cyclic GMP (Beavo and Reifsnyder, 1990; Weishaar 
e ta l ,  1985).
I.5 .7 .5 .I. M olecular cloning of PDE4 isoenzymes.
Studies in Drosophila melanogaster led to the isolation of a region in the 
X  chromosome which encodes the dnc gene (Davis and Kauvar, 1984). It was 
established that mutations within this locus led to a variety of behavioural defects, 
disrupted cyclic AMP metabolism and caused sterility in adult females. The dnc 
mutants showed a phenotypic learning defect, revealing shortened memory of 
conditioned behaviour (Tulley and Quinn, 1986). The abnormal cyclic AMP 
metabolism was due to a mutation in a PDE gene, leading to an absence or greatly 
reduced PDE activity and an elevated cyclic AMP concentration within the cells 
(Byers et a l ,  1981; Davis and Kiger, 1981), indicating that dnc was the structural 
gene for cyclic AMP PDE (Davis and Kauvar, 1984). The connection between 
cyclic AMP metabolism and learning was supported by the fact that such features 
were characteristic of a number of lesions in the cyclic AMP pathway in dnc 
mutants (Chen e ta l ,  1986). The dnc gene was isolated by the chromosome 
walking technique which generated six RNAs subsequently reported as dnc gene 
products (Davis and Davidson, 1984). The dnc locus of Drosophila was cloned 
and sequence analysis of revealed a 45kDa protein exhibiting cyclic AMP-specific 
PDE activity. Comparison of its sequence with partial protein sequences from 
other PDEs revealed a conserved domain believed to contain the active site 
(Charbonneau e ta l ,  1986; Chen e ta l ,  1986). A dnc gene cDNA probe was used 
to obtain mammalian counterparts by low stringency cross hybridisation screening
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rat brain cDNA libraries (Davis et a l ,  1989). This procedure identified a series of 
cDNAs termed rat dnc-like-l (RDI), RD2, and RD3, which corresponded to a 
single gene, containing 75% identity in the conserved domain. RDI was found to
be full length, and RD2 and RD3 thought possibly to be splice variants, with |
alterations in their N-termini (Davis et al., 1989). IThe dnc gene cDNA was also used to screen rat testicular cDNA libraries, %
in order to identify PDE4 enzymes which may be important in gametogenesis ■;2
(Conti and Swinnen, 1990; Conti et al., 1992; Swinnen etal., 1989a). This 2.
:
resulted in the isolation of two groups of cDNA clones, differing in nucleotide
2 ;sequences, ratPD El and ratPDE2, Further screening of a Sertoli cell cDNA
,:Uy
library, using rat PDE2 probe uncovered ratPDE3 and ratPDE4 (Swinnen et al.,
1989a) (table 1.2). There was a highly homologous coding region in the middle i Iof the proteins, but the sequence diverged at the N- and C-termini. Sequence analysis showed that ratPDE2 was the same as the RDI gene. When cDNA 
clones from the four different groups were used to probe specific tissues, multiple f
transcripts were found of different sizes, some of which were organ specific 
(Swinnen et al., 1989a; Swinnen et al., 1989b), indicating that alternate RNA 
processing or the differential use of transcriptional start sites leads to the 
expression of multiple proteins from a single gene (Qui et al., 1991).
The genes for two major PDEs of Saccharomyces cerevisiae had also been 
cloned, a high affinity and a low affinity form (Nikawa et al., 1987; Sass et al.,
1986), on the basis of the gene products ability to suppress phenotypes associated ' •
with a ras2''‘*^'^  ^mutation. Ras proteins are regulators of adenylyl cyclase and 
consequently cyclic AMP production in yeast. The ras2"'‘^ ‘^  ^mutation lead to an 
elevation of cyclic AMP levels as a consequence of acute sensitivity to heat- 
shock. Selection was performed on the basis of rescue of heat-shock sensitivity, 
by a lowering of cyclic AMP levels. A rat brain cDNA clone was isolated by 
virtue of these cross-hybridisation studies, by expressing a rat brain cDNA in 
yeast containing a mutation (Colicelli et al., 1989). This led to the I
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isolation of a further PDE gene, DPD (dunce-like phosphodiesterase), which was
'characterised as a PDE4 and shows high homology to dnc, with 90% homology to
RD I in the catalytic domain (Colicelli etal., 1989). Dictyostellum discoideum  
was also found to contain a PDE4 activity, which has been sequenced by Kessin
'.'fand colleagues (Lacombe eta l., 1986).
Sequence analysis of the mammalian cyclic AMP-specific PDEs shows 
that they are encoded by four different genes. These have been designated as four 
separate subclasses, PDE4A, B, C and D. Figure 1.10 shows the peptide sequence 
alignments of rat PDE4 isoforms. The sequences are of PDE4A1 (RDI),
■f
PDE4B2 (ratPDE4), PDE4C1 (RPDE36) and PDE4D1 (rat PDE3.1). A
conserved domain is evident between residues 220-500, which is thought to be the 
catalytic domain (see section 1.5.7.1.1) (Charbonneau eta l., 1986; Jin etal,,
■y
1992). Using the rat brain cDNA probes, two human homologs of the cyclic 
AMP PDE were isolated from a human monocyte cDNA library (Davis et al.,
1989). The sequence homology resulted in one of these being designated a 
PDE4B isoform (hPDE4B) and the other a PDE4A (hPDE4A) (Livi et al., 1990;
McLaughlin et al., 1993). There was a conserved region of about 270 residues in 
hPDE4A and hPDE4B, but the N- and C-term ini diverged considerably. cDNAs
for four human genes have recently identified (DPDEl to DPDE4) (Bolger et al.,
1993). The deduced amino acid sequences are homologous to ûïq Drosophila dnc 
proteins, containing not only the conserved catalytic domain, but also two amino- 
terminal regions extending upstream of the catalytic domain , upstream conserved 
regions (UCR-1 and UCR-2), which lack homology with each other (see section 
1.5.7.1.2). The UCR domains appear to be unique to the PDE4 and are highly 
conserved throughout the evolution of this family from Drosophila to mammals 
(Bolger et al., 1993). Although UCR motifs aie of unknown function, it has been 
suggested that they may have critical roles in the regulation of this family, as 
these regions are conserved through evolution between splice variants (Bolger,
1994).
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Figure 1.10. Comparison of primary amino acid sequences of 
rat PDE4A, B, C, and D.
The peptide sequences of rat PDE4 isoforms have been 
aligned. The PDE sequences are as follows from top to bottom: 
PDE4A1 (RDI) (Accession Nos: M26715, J04554); PDE4B2 
(ratPDE4) (Accession Nos: M25350, M28413); PDE4C1 (RPDE36) 
(Accession No: L27061); and PDE4D1 (ratPDE3.1) (Accession Nos: 
M25349, M28412). • denoted an identical amino acid residue in 
both sequences. Note the area of conservation in the middle of the 
proteins, the catalytic domain, (residues 220-500) and the two conserved 
regions N-terminal to this UCR2 (residues 176-200) and U CRl 
(residues 94-130).
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Figure 1.10. Comparison of primary amino acid sequences of 
rat PDE4A, B, C, and D .
(continued)
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The complexity o f this family is now being appreciated, with it becoming 
apparent that four dnc gene homologs have been uncovered in human and rat 
(Bolger et al., 1993; Davis et al., 1989; Swinnen et al., 1989a). All mammalian 
homologs of the dnc gene that have been tested have biochemical and 
pharmacological properties typical of the PDE4 class of PDEs (Beavo and 
Reifsnyder, 1990). This includes high specificity for cyclic AMP and inhibition 
by a specific class of compounds, such as the antidepressant rolipram (Colicelli et 
al., 1989; Henkel-Tigges and Davis, 1989; Swinnen et al., 1989b). The rat 
PD E4B1 (DPD) cDNA was shown to encode a protein with a high degree of 
amino acid sequence identity (-80% ) with the cognate Drosophila dnc species 
within the conserved region. The homologies within the conserved domain 
between the isoforms are very high, for example PDE4B2 (ratPDE4) shows 90% 
homology with PDE4A1 (RDI), but diverges considerably at the N- and C- 
term ini (fig. 1.10). However, up to 50% of identical amino acid residues within 
the conserved domain utilise alternative codons, which suggest that the two 
cDNA clones are encoded by distinct but related genes (Swinnen et a l ,  1989a).
The conservation of PDE4 isoforms between species is remarkable, with a greater 
homology being observed in group members (>98% in PDE4D members) 
between rat and human, than between groups from the same species (Bolger etal.,
1994). This coixespondence of sequences of PDE4 genes between different 
mammals has been further supported by mapping of human and mouse genes 
(Bolger et al., 1994; Milatovitch et al., 1994). The similarity between PDE4A 
sequences derived from rat and human is shown in figure 1.11. These sequences
Ï
appear to be approx. 80% homologous throughout the entire sequence. It may be 
tempting to suggest the existence of four dunce gene homologs in all mammals.
1,5,7.5.2. Distribution of PDE4 isoenzymes.
It has been demonstrated that PDE4A, B, C and D genes aie expressed in 
specific tissues such as liver, kidney, lung, lymphoid cells (Engels et a l ,  1994),
■fl
Figure 1.11. Comparison of primary amino acid sequence between 
PDE4A (RDI) and PDE4B (h6.1).
The sequences have been aligned, and h6.1 is above the RD I 
amino acid sequence. • denoted an identical amino acid residue in 
both sequences. Note the area of conservation throughout almost the 
entire protein.
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Figure 1.11. Comparison of primary amino acid sequence between 
PDE4A (RDI) and PDE4B (h6.1).
(continued)
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and in selected regions of the brain such as the olfactory system, hippocampus 
and cerebellum (Engels eta l„  1995). PDE4C appears to have a more restricted 
expression, compared to the other isoforms, being absent from human or rat 
lymphoid cells (Engels et a i ,  1994). The leukem ic T cell line Jurkat was found to 
express only PDE4A in the resting state, but upon long-term stimulation of the 
cells with dibutyryl cyclic AMP, the expression of PDE4A and PDE4D was up- 
regulated (Engels et al., 1994).
The complexity of the PDE4 family has been further complicated by the 
existence of over twenty splice variants (Bolger, 1994). The importance of such a 
large family could be to enable cells to maintain a high degree of regulation on 
cyclic AMP degradation. Each PDE4 locus appeal's to have distinct tissue 
distribution, suggesting that these alternatively spliced transcripts have specific 
and subtle differences in regulation and sub-cellular targetting which enable the 
tailoring of these PDEs to a specific job. In support of this, investigations carried 
out on rat PDE4A (RDI), have shown that the N-terminal domain targets RDI for 
plasma membrane association (Shakur et al., 1993). This association may be with 
a specific anchor protein, as opposed to a nonspecific binding with the lipophilic 
bilayer, due to the nature of the extreme N-terminus (lacks hydrophobic amino 
acids), and its punctate distribution around the inner leaflet of the membrane 
(Shakur eta l., 1995). Indeed this N-terminal sequence has been shown to confer 
membrane association on a normally cytosolic protein chloramphenicol 
acetyltransferase (Scotland and Houslay, 1995) indicating that the N-terminal 
domain o f RDI contains structural information that targets proteins to the 
membrane. Membrane association ceases upon cleavage of this region of PDE4A 
(McPhee et a l,  1995; Shakur e ta i ,  1995).
Splice variants of the PDE4B locus are targeted to different regions of rat 
brain (Lobban et al., 1994), indicating that differential splicing may contribute to 
tissue specific- as well as subcellular-localisation of these enzymes (Houslay et 
al., 1995). PDE4B1 (DPD) was found to be exclusively cytosolic and was
J:.
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selectively expressed in hippocampal, cortex, hypothalamus and striatum regions, 
whereas PDE4B2 (ratPDE4) was located at the membrane o f all brain regions 
with the exception of the midbrain (Lobban et al., 1994). The restriction of these 
activities to specific regions of the brain may have selective effects upon brain 
function. Indeed, it has been found recently that many of the alternatively spliced 
mRNAs transcribed from rat dnc homologs have different patterns of expression 
in the brain (Bolger et al., 1994). Moreover, mRNAs from the dnc loci can be 
initiated from independent transcriptional start sites (Qiu and Davis, 1993), each 
o f which may be regulated independently (Monaco etal., 1994).
to basal occurs despite the constant presence of hormone due to an activation of
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1.5,7,5.3. Regulation of PDE4,
PDE4 isoforms have been shown to be regulated via phosphorylation. In 
rat liver, there is a peripheral membrane bound PDE4 which is subject to 
phosphorylation in response to insulin (Marchmont etal., 1981; Marchmont and 
Houslay, 1980a). Phosphorylation causes PDE activation in intact hepatocytes 
(Heyworth et al., 1983) as well as in isolated plasma membranes (Marchmont and 
Houslay, 1980b) and has been demonstrated to occur through a cyclic AMP- 
dependent pathway in vitro (Marchmont and Houslay, 1980a). Upon phospho- 
amino analysis of this enzyme, it was shown that phosphate was incorporated on 
the serine and tyrosine residues of the enzyme depending on whether membranes 
or intact cells were studied, respectively (Marchmont and Houslay, 1980a; Pyne et 
a l,  1989).
Cyclic AMP has also been shown to play a role in the regulation of 
PDE4D splice variants (PDE4D3.1, -D3.2 and -D3.3), via PKA. In the FRTL-5 
thyroid cell line PDE4 activity is elevated in response to thyroid stimulating 
hormone, which is known to elevate intracellular cyclic AMP (Sette et a l,  1994a). 
This hormone dependent cyclic AMP regulation in FRTL-5 cells involves an 
initial rise in cyclic AMP which returns to basal level within minutes. This return
'ï
PKA and subsequent phosphorylation and activation of PDE4D. This
■investigation demonstrated that splice variants from the same locus could be 
differentially regulated on stimulation of the cell by a particular hormone (Sette et 
aL, 1994b). Differential regulation led to short-term activation of PDE4D3.3, via 
changes in phosphorylation status and long-term regulation by stimulating de 
novo protein synthesis of two other splice variants PDE4D3.1 and PDE4D3.2. In 
addition an elevation of cyclic AMP has also been demonstrated to cause to an 
increase in ratPDE3 (PDE4D) expression in immature Sertoli cells on stimulation 
with follicle stimulating hormone (FSH) (Monaco e ta l ,  1994; Sette eta l., 1994b; 
Swinnen et aL, 1991) and in cardiac myoblasts (Kovala et al., 1994).
Clearly PDE4 enzymes are extremely important for the regulation of 
cyclic AMP signalling pathway, with close safeguards on their regulation 
evolving to ensure that the action of PDE4D is controlled and specific.
1.5.7.6, PDES, cyclic GMP-binding, cyclic GMP-specific PDE.
Recently the cyclic GMP-specific PDEs were divided into two distinct 
groups PDE5 and PDE6 , as it became clear that the photoreceptor PDEs (PDE6 ) 
are quite different from cyclic GMP hydrolysing PDE activities expressed, for 
example, in the lung (Beavo et a l ,  1994).
PDE5 was first noted in the supernatants of lung extracts, as a cyclic GMP 
binding activity (Lincoln et a l,  1976). Primary amino acid sequence differences 
have aided in the identification of splicing or post-translational modifications of 
the lung PDE5 activity (McAllister-Lucas et a l ,  1988). As well as its presence in 
the lung (Coquil et a l ,  1985), type-V PDE is also found to be present in platelets 
(Coquil et a l ,  1980), having similar native molecular weights (177kDa).
Studies of this group of PDEs have been hampered through co-elution 
with Ca^*^/CaM-stimulated PDE, therefore giving some misleading results (Beavo, 
1988). PDE5 enzymes have an almost complete inability to hydrolyse cyclic 
AMP. This group of PDEs possess an allosteric, high affinity cyclic GMP
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binding site associated with the enzyme, similar to that seen on the cyclic GMP- 
stimulated PDE although a function has not yet been clearly attributed to this 
region (Charbonneau era/., 1989; Coquil e ta /., 1980; Francis eta l., 1980). 
Interestingly, the binding capacity of this site may be increased by IB MX (Coquil 
et al., 1985). Phosphorylation may also contribute to this effect (Tremblay et al., 
1985). PDE5 isoenzymes have been observed to resemble zinc hydrolases, as 
they contain conserved histidine residues which bind zinc (Francis et al., 1994) 
and the removal of zinc greatly decreases the PDE activity.
The lung PDE5 is a substrate for PKA and PKG (Thomas et al., 1990) 
and, in vivo the phosphorylation event appears to be dependent on cyclic GMP 
being bound to the non-catalytic binding site present on the PDE. This may be 
important in determining which kinase phosphorylates it, as an increase in cyclic 
GMP leads to the occupation of the non-catalytic site, and the PDE is then 
preferentially phosphorylated by PKG (Thomas et al., 1990). Exposure of rat 
vascular smooth muscle to ANF leads to the phosphorylation of cyclic GMP PDE 
within one minute (Wyatt et al., 1994).
This group of PDEs is selectively inhibited by dipyridamole and M&B 
22948, with IC50 values in the region of IpM  (Asano et al., 1977). In a similar 
way to PDE2 activity, competitive inhibitors such as IB MX, dipyridamole or 
papaverine enhance cyclic GMP binding to the PDE (Coquil et al., 1985). An 
important role for this PDE in modulating cyclic GMP effects has been supported 
by the fact that significant levels of this protein is found in many of the tissues 
where it is expressed, relative to PKG (Francis et al., 1980).
I.5.7.7. PD E 6 , photoreceptor PDE.
The mammalian visual pathway is modulated by cyclic GMP specific 
PDE6 isoenzyme family, which hydrolyses cyclic GMP in response to light in 
both rod and cone photoreceptors. PDE6  isoforms are found in the outer 
segments of the rod and cone photoreceptors (Hurwitz et al., 1984; Hurwitz et al..
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1985). Three distinct genes encode this subfamily of PDEs, one cone and two rod 
PDE genes. The structure of this group of PDEs varies enormously when 
compared to other cyclic nucleotide PDEs. The membrane bound molecule is a 
tetramer, that has two larger subunits ( a  (88kDa) and p (84kDa)), and two smaller 
subunits (y) (llk D a) which have an inhibitory function (Baehr eta l., 1979; Miki 
et al., 1975). The soluble rod PDE differs from the membrane bound form as it 
also has a 15kDa 5 subunit associated with it (Gillespie et al., 1989). Upon 
cloning of the a  subunit, it was noted that it contained the conserved region found 
in the major subclass of PDEs (Charbonneau et al., 1986). As mentioned 
previously, this group of PDEs has also been to possess a high affinity non- 
catalytic binding site for cyclic GMP, similar to that seen in cyclic GMP- 
stimulated, PDE2 (Charbonneau eta l., 1989; Gillespie and Beavo, 1989b; 
Gillespie and Beavo, 1989c; Le Trong et a l ,  1990; Li et al., 1990). The 
conservation of this domain implies that the members of this group of enzymes 
evolved from common ancestry, with functions ranging from visual transduction 
to memory.
Retinal cyclic GMP-specific PDEs are effector proteins in photoreceptor 
signal transduction. The interaction of photo-isomerised opsin with molecules of 
the retinal G protein, transducin, allows GTP to bind, leading to the activation of 
transducin. oc-GTP interaction with and activation of an inactive form of PDE6 
causes the hydrolysis of cyclic GMP and a subsequent decrease in intracellular 
cyclic GMP concentrations. The large local change in cyclic GMP concentrations 
is sensed by the cyclic GMP binding site on, or closely associated with the cation 
channel in the plasma membrane (Fesenko et al., 1984). This channel requires 
bound cyclic GMP in order to remain open, therefore the decrease in cyclic GMP 
causes the closure of the cyclic GMP-gated cationic channels of the plasma 
membrane photoreceptor. This results in the hyperpolarisation of a light response 
in photoreceptors (Hurley, 1992).
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Phosphorylation of this isozyme has been reported within the catalytic 
(Udovichenko e ta l ,  1993), and inhibitory subunits (Tsuboi e ta l ,  1994). These 
PDEs can be inhibited by IB MX in a similar way to all other PDE isozymes 
(except PDE7), with a Ki in the region of lOjiM for bovine rod PDE (Baehr et a l ,  
1979; Gillespie and Beavo, 1989a). However, selective inhibitors also exist for 
this subclass of PDEs, dipyridamole (Coquil et a l,  1980), and M&B22,948 
(Weishaar et a l,  1986) inhibiting rod and cone PDEs with Ki values o f 125 and 
400nM respectively (Cerveto e ta l ,  1988).
I.5.7.8. PDE7, cyclic AMP specific PDE.
Ï:::PDE7 is a low K ^  cyclic AMP specific PDE, which is the least
characterised of all the isoforms. PDE7 was originally cloned from a human 
glioblastoma cell line (Michaeli et a l,  1993). The novel gene was discovered by 
complementation strategy based on the rescue of S. cerevisiae mutants as 
described previously (Colicelli et a l,  1989) which was utilised to isolate DPD 
(see section 1.5.7.5.1). The human gene isolated, H C Pl, encoded a PDE with 
significant homology to other cyclic AMP PDEs including the -270  amino acid 
region proposed to contain the catalytic site (Charbonneau et al 1986, Chen et al
1986).
This PDE activity was found to behave like the PDE4 isoenzyme 
regarding its high affinity for cyclic AMP specifically (K ^ 0.2jiM). However,
PDE7 differed, as it is insensitive to inhibition by the classical PDE4 inhibitors 
rolipram and Ro20-1724 and the general phosphodiesterase inhibitor IB MX.
-Northern blot analysis showed that PDE7 was predominantly expressed in skeletal 
muscle.
This activity was previously identified in the soluble fractions of rat 
hepatocytepreparations (Lavan e ta l ,  1989) as an IBMX-insensitive PDE, which
shows an aberrant response to Mg^+. This is in contrast to PDE4 activities which
■
are activated in a dose dependent fashion by Mg^+ and Mn^+ (Lavan et a l ,  1989).
::7I
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covalent modification (ADP-ribosyiation), and activation of Gg subunits with
iThis activity has also been found present in mammalian T cell lines (Bloom, 
1994; Ichimura and Kase, 1993).
1.6. Cyclic nucleotides and the immune system.
The function of cyclic nucleotides in the immune response has been under 
investigation now for many years. Early research suggested that cyclic AMP 
exerted negative modulations on proliferation of lymphocytes, and cyclic GMP
had opposing effects to this. However, it has become increasingly evident that 
this picture is a little oversimplified. Thus, whilst cyclic AMP-mediated negative
'  Imodulation of the proliferative response has been reported (Hammer, 1988), there 
is also a body of research that supports a positive role for cyclic AMP in 
mitogenesis (Rochette-Egly and Kempf, 1981; Wang et a l ,  1978).
1.6.1. PKA inhibition of TCR-mediated signalling pathways.
I
The vast majority of evidence supports the view that cyclic AMP is an 
inhibitory signal to lymphocyte mitogenesis (Hammer, 1988). However, cyclic 
GMP has not been studied a great deal. Intracellular levels o f cyclic AMP have 
been manipulated using forskolin (activator of adenylyl cyclase), cell permeable 
cyclic AMP analogues and cyclic AMP phosphodiesterase inhibitors (Alava et al., 
1992; Lem er et a l ,  1988; O ’Shea e ta l ,  1987), Agonists to receptors which are 
coupled to Gg proteins such as prostaglandins E2 or isoproterenol, or tlurough
cholera toxin have also been utilised to elevate cyclic AMP levels. The results of 
cyclic AMP elevation being an inhibition of proliferation of lymphocytes. 
Sustained elevation of cyclic AMP levels has also been shown to induce 
programmed cell death (apoptosis) in T cell hybridomas and thymocytes (Dowd 
and Miesfeld, 1992; McConkey et a l,  1990a) (see section 1.4.1). In addition, 
evidence has also been collected from disease states, such as leukemic cell lines
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and sarcoidosis patients (Epstein andHachisu, 1984; Nemoz et al., 1993). Taken 
together, the general conclusion is that cyclic AMP has an anti-proliferative role.
Cyclic AMP has been shown to be inhibitory at a number of sites on 
signalling pathways leading to proliferation. Addition of cyclic AMP elevating 
agents have revealed an uncoupling of the TCR/CD3 complex from its 
downstream signalling mediators. These events include the inhibition of tyrosine 
phosphorylation (Anastassiou e ta l ,  1992; Klausner gf a/., 1987; Park era/.,
1992), PIP2 breakdown (Alava et al., 1992; Lerner et al., 1988; O ’Shea et al.,
1987; Park etal., 1992; Takayama e ta l ,  1988; Tam ir and Isakov, 1991), [Ca^+Jj 
elevations and PKC activation (Chouaib et a l ,  1987; Gray et a l ,  1988;
Paliogianni et a l ,  1993; Rothman et a l,  1993), raf-1 activation (Whitehurst e ta l ,
1995) and K+ conductance (Bastin et a l ,  1990; Payet and Dupuis, 1992).
The mechanisms underlying such modulation of T cell signalling are as 
yet poorly understood, but there are some interesting indications of cyclic AMP 
and TCR-coupled m itogenic signalling pathways which provide some insight into 
the role(s) of cyclic AMP pathways in lymphocyte signalling. Cyclic AMP 
appears to exert negative effects on lymphocytes proliferation via PKAI 
(Skalhegg e ta l ,  1992). Follow ing phosphorylation by PKA, PLCyl (Serl248) 
becomes inactivated thus preventing PIP2 hydrolysis and the activation of PKC 
(Alava et a l ,  1992; Park et a l ,  1992; Takayama et a l,  1988; Tam ir and Isakov,
1991). Indeed, recent work (Skalhegg et a l ,  1994) has demonstrated that in 
activated T lymphocytes, the PK A Ia isoform can be isolated with the TCR/CD3 
complex.
Moreover, cyclic AMP elevation suppresses raf-1 activity, enabling cyclic 
AMP to regulate the MAPK signalling cascade. Raf-1 can be activated via p2K^-^ 
(ra.s-dependent mechanism) or via PKC (ras-independent mechanism) (see section
1.2.5). Recent studies have shown that cyclic AMP modulates the ras-
'independent mechanism of raf-1 activation (Whitehurst et a l, 1995). However, in
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fibroblasts, cyclic AMP is able to inhibit raf-1 activation via both routes (Cook 
and McCorm ick, 1993; Lange Carter and Johnson, 1994).
In the later events of proliferation, the main target of T cell inhibition by 
cyclic AMP appears to be at the level of IL-2 production (Anastassiou et ah,
1992; Aussel et a l ,  1988; Averill e ta l ,  1988; Mary e ta l ,  1987; Novogrodsky et 
a l ,  1983; Paliogianni et a l ,  1993). The regulatory region of the IL-2 gene 
consists of compact, clustered binding sites for a range of transcription factors that 
are differentially regulated. It is clear that some factors are more critical than 
others in the regulation of IL-2 gene transcription: AP-1 and NF-AT appear to be 
rate limiting for IL-2 expression. IL-2 promoter activity is found to be reduced by 
elevations in cyclic AMP (Paliogianni et a l,  1993). The mechanism is at present 
poorly understood, but seems to involve the phosphorylation of substrates as the 
addition of PKA inhibitor restores IL-2 production (Anastassiou e ta l ,  1992; 
Averill et a l,  1988). Post-transcriptionally PKA activation reduces the half-life 
of IL-2 mRNA transcripts by >50% (Anastassiou et a l ,  1992), blocks induction of 
c~jun encoding Jun/A Pl transcription factors (Tamir and Isakov, 1991) and 
modulates DNA binding activities of nuclear factor kB (NF-kB) and a TGGGC 
binding factor (Chen and Rothenberg, 1994). This has the effect of leaving no 
stable protein/DNA contacts for entire IL-2 enhancer region. The inhibition by 
cyclic AMP appears to target specific genes, ie. not inhibiting global gene 
transcription, for example IL-2R, c-fos, c-myc and c-myb genes are unaffected 
(Chouaib et a l,  1985; Farrar et a l, 1987; Natumiya et a l ,  1987; Ramarli et a l ,  
1987; Schoiz and Altman, 1989).
Although cyclic AMP exerts inhibitory effects on thymocytes in a similar 
manner to that observed in mature T cells, some interesting studies have been 
carried out to show that different subsets of T cells have differing sensitivities for 
cyclic AMP. The clearest work has been carried out in T helper cells, analysing 
the two subsets T h I and Th2. T helper cells are separated into two groups on 
account of the cytokines which are produced upon proliferation. T y l cells
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produce IL-2, T h2 cells secrete IL-4, IL-5. Increases in cyclic AMP appears to 
inhibit IL-2 production, but does not effect IL-4 production (Alava et al., 1992; 
Galjewski eta l., 1990; Novak and Rothenburg, 1990).
Leukemic T cells have been shown to have an elevated phosphodiesterase 
activity compared with that of normal T cells (Epstein and Hachisu, 1984). 
Interestingly increases in cyclic GMP PDE activities as well as cyclic AMP PDE 
activities have been reported in leukemic T cell lines (Epstein eta l., 1977; Hait 
and Weiss, 1977; Hait and Weiss, 1976). Cyclic GMP has been documented to 
have a regulatory role in the hydrolysis of cyclic AMP in resting lymphocytes, 
inhibiting cyclic AMP PDE by 80% at micromolar concentrations (Takemoto et 
al., 1979; Takemoto eta l., 1978). However this inhibition is diminished in 
transformed human B and T cell lines and patients with lymphocytic leukemia 
(Takemoto et al., 1978). In a further study to analyse this loss of regulation by 
cyclic GMP, Takemoto et al. (1979) activated human peripheral blood 
lymphocytes using mitogens. These were found to lack the cyclic GMP-inhibited 
PDE isoform within four hours of mitogenic stimulation. It would appear that the 
removal of cyclic GMP regulation resulted in the elevation of cyclic AMP PDE 
activity. This led to a loss of growth control, possibly due to the lower cyclic 
AMP levels present in the cells. PDE4 has been shown to be important in 
controlling the levels of cyclic AMP, as the use of rolipram in mitogenically- 
stimulated thymocytes leads to an inhibition of proliferation by 60% (Marcoz et 
al., 1993). Interestingly, in this study, it was found that elevating cyclic GMP via 
the stimulation of guanylyl cyclase synergised with the inhibition of PDE4 
activity. This implies that cyclic GMP has an inhibitory role in rat thymocyte 
proliferation (Marcoz eta l., 1993).
A rather different disease state is illustrated by the study of sarcoidosis. 
Sarcoidosis is a chronic granulomatous disorder which is characterised by 
increased immune response at sites of disease activity. One of the features that 
characterises this disease is the low proliferative response of peripheral blood
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lymphocytes to m itogenic lectins. Interestingly, when these cells were studied, it 
was apparent that cyclic AMP and cyclic GMP PDE activities were decreased by 
26% compared with controls (Nemoz et al., 1993), This could be attributed to a 
sustained elevation in cyclic nucleotide levels which causes anti-proliferative 
effects.
The studies described above have shown how cyclic AMP may exert a 
negative effect on proliferation. However, in all of these cases, the elevation of 
cyclic AMP was achieved either by using pharmacological agents, which mimic 
rather unphysiological levels of cyclic AMP within normal cells, or by the studies 
using leukemic cells and proliferating cell lines. This research nevertheless, 
clearly highlights the importance of a regulated cyclic AMP response and 
illustrates the deleterious effects that a dysfunction in this system can have on the 
immune system.
1.6.2. Positive roles of cyclic nucleotides in lymphocyte proliferation.
It was shown over fifteen years ago that lymphocyte proliferation could 
not proceed without fluctuations in the levels of cyclic nucleotides. Cyclic AMP 
was shown to be transiently elevated upon stimulation of lymphocytes with 
mitogenic lectins. Treatment of the cells with indomethacin reversibly prevented 
the increase in cyclic AMP and the onset of S phase (Wang et al., 1975). This 
study also highlighted that sustained elevation of cyclic AMP levels was 
inhibitory to proliferation. Another study demonstrated that the cyclic nucleotide 
fluctuations and resultant proliferation were dependent on the presence of calcium 
(Rochette-Egly and Kempf, 1981). Thus showing that cyclic AMP and calcium 
work in concert to achieve cellular proliferation. Cyclic GMP has also been 
shown to be important for the proliferation of lymphocytes. Upon stimulation 
with PH A, cyclic GMP becomes elevated in a calcium dependent manner (Coffey 
et al., 1977; Coffey et al., 1981; Rochette-Egly and Kempf, 1981).
76
ïA positive role of low levels of cyclic AMP in lymphocyte proliferation 
was supported by the demonstration that upon inhibition of adenylyl cyclase with 
2 ,3 -dideoxyadenosine, there was a marked inhibition of proliferative responses 
upon stimulation of cells with phorbol ester and ionomycin. Moreover, this 
inhibition could be reversed with the addition of micromolar concentrations of 
dibutyryl cyclic AMP, enhancing phorbol ester/calcium ionophore induced 
lymphocyte proliferation by 25-50% (Koh et aL, 1995). Transient increases in 
cyclic AMP have also been observed following ligation of the TCR/CD3 complex 
(Ledbetter et ah, 1986), resulting in a rapid activation of the PKAI isoform 
(Laxminarayana eta l., 1993).
It was shown that CD3, CD4 and CD8 crosslinking activates a cyclic 
AMP-dependent pathway that regulates the mobility and directional polarisation 
of these molecules (Kammer et al., 1988). This has been shown previously where 
crosslinking of Thy-1 resulted in increases in cyclic AMP and a rise in receptor 
mobility (Butman eta l., 1981). Thy-1 expression appears to be under the control 
of cyclic AMP at CD47CD8" stage of thymocyte development. Indeed cells are 
induced to enter accelerated differentiation in response to prostaglandin E2 or 
cyclic AMP analogs, protecting them from apoptosis (Bach et al., 1975; Goetzl et 
al„ 1995; Scheid et al., 1975; Singh and Owen, 1975). This implies that cyclic 
AMP may have a role in the early differentiation of thymocytes and also 
highlights that altered signalling occurs in at different developmental stages.
Interesting evidence exists for the positive role of cyclic AMP in 
lymphocyte proliferation (Sugiyama et al., 1992). However, there are some 
studies in B and T cells which imply that cyclic AMP may have a dual role in 
regulating the proliferation state of the cell. The first of these involves the effects 
of treating cytotoxic T lymphocytes (CTLs) with antisense mRNA for the 
catalytic subunit of PKA (C a), to identify which processes required PKA activity, 
without increasing the cyclic AMP levels (Sugiyama et al., 1992). It was found 
that TCR-triggered protein-synthesis independent responses were down-regulated.
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such as cytotoxicity and exocytosis, thereby counteracting TCR-triggered 
activation. However, cyclic AMP (or the C a  activity, appears to be required for 
nuclear activity and/or cytoplasmic events in CTL activation, such as cytokine 
synthesis and secretion. This represents a dual regulation model by cyclic AMP 
(Pollock era /., 1991).
1.7. Aims and objectives.
The aim of this research project was to gain an understanding of cyclic 
AMP catabolism in T cells, the cellular arm of the adaptive immune system. The 
research presented will study the isoforms of cyclic AMP PDEs present in T cells 
from different species and distinct developmental stages. The research 
concentrates on immature murine thymocytes, to investigate the differential 
regulation of these enzymes upon ligation of the T cell antigen receptor complex 
with monoclonal antibodies or mitogenic lectins.
aI
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CHAPTER 2.
M ATERIALS AND METHODS.
V
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2.1. M ethods.
2 .1 .1 . Isolation  o f thym ocytes/lym phocytes.
2 .1.1.1. Preparation o f reagents.
In general all reagents were prepared as eptically, as this prolonged their 
shelf-life and was necessary for some experiments.
(i) RPMI-1640 was stored at 4°C and warmed to 37°C for the experiment.
(ii) Percoll was aliquoted in universals (18ml) and stored at 4°C. Freshly 
prepared 100% percoll was obtained by addition of 2 ml of 10 x strength phosphate 
buffered saline, pH7.4 (PBS). Gradient strength percoll was produced by dilution 
of 100% percoll with 1 x PBS, to the desired concentration.
(iii) lOmM Hepes-supplemented RPMI-1640 media: Appropriate volume of 
IM  Hepes was added to RPMI-1640 media to achieve a final concentration of 
lOmM. This was stored at 4°C until required, then it was warmed to 37°C. 10 x 
PBS was prepai’ed to give final concentrations of 1.4M NaCl /  27mM KCl /  15mM 
KH2PO4 /  81mM Na2HP0 4 . This was diluted 1 in 10 in double distilled water 
(ddH2 0 ) to obtain 1 x PBS.
(iv) 2-aminoethyIisthiouronium (AET) (102mg) was dissolved in ddH2 0  
and adjusted to pH9.0 with NaOH and then filter sterilised using Millipore Filters 
(0.22jJ.M). This was fi'eshly prepared for each treatment.
were centrifuged and washed twice in RPMI-1640 medium ( 1 2 0 g a v  for 10 
minutes). AET (4ml) was added to the SRBCs and the suspension was incubated
1 6 4 0  (1 2 0 g a v  for 1 0  minutes) and R P M I - 1 6 4 0  (9ml) was added. AET treated- 
SRBCs were stored at 4°C for up to a week.
(vi) Anti-immunoglobulin (anti-Ig) coated plates were prepared by coating a 
petri dish (90mm uncoated for tissue culture) with 10-50|ig/ml goat anti-Ig antibody 
solution. The antibody, in 130mM NaCl /  0.05M Tris/HCl, pH9.0, was sterile 
filtered using Millipore filters (0.22pM) and incubated on the plates for an hour at
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(v) Sheep eiythrocytes (SRBCs) were coated with AET. SRBCs (5ml)
#
at 37 C for 20 minutes. After this time, the cells were washed 5 times with RPMI-
îî
37°C, then overnight at 4°C. After this time, the antibody solution was poured off 
and the plates were washed with 5% BSA solution containing l|ag/ml anti-Ig 
antibody. The plates were washed five times in PBS and then stored until required 
for use at -20°C.
2.1.1.2. Isolation of m urine thym ocytes/lym phocytes.
The cells were isolated as described previously (Sancho et a l ,  1992). 
Briefly, 4 or 12 week old Balb/c mice were killed by an overdose of Sagatal, and 
the spleens/thymuses were removed and pressed through a steel mesh screen using 
a 5ml syringe plunger to obtain a single cell suspension. The suspension was then 
placed into a 50ml centiifuge tube and the debris was allowed to settle out under
I
i
gravity for 5 minutes. A mononuclear cell suspension was obtained by Ficoll- 
paque density centrifugation, by layering the cells onto a Ficoll-paque cushion
,
(3ml) and spinning in a swing-out rotor at 4 4 0 g a v  for 1 5  minutes. The red blood 
cells pelleted, and the thymocytes/lymphocytes sedimented at the interface. The 
cells were then washed twice with R P M I - 1 6 4 0  media (first 6 3 0 g a v  for 1 0  minutes 
and then 4 4 0 g a v  for 1 0  minutes). At this stage lymphocyte populations were B cell 
depleted (see section 2.1.1.3). In v/va-aciivated and resting populations were 
separated by differential percoll density gradient ( 8 5 % - 6 5 % - 5 0 % )  centrifugation.
Alternatively, ‘mixed’ populations of cells were obtained by separating the cells on 
85%-50% gradients, thus removing red blood cells and dead cells. Cells were 
loaded per gradient (allowing approx. 3 spleens/thymuses per gradient) and the 
cells were spun at 950gav for 15 minutes in the swing-out rotor at The cells 
were harvested from the gradients (resting cells from the 85%-65% interface, in 
viva-activated cells from the 65%-50% interface and mixed cells at the 85%-50% 
interface) and washed twice more, as described previously in lOmM Hepes- 
supplemented RPMI-1640. Cell number and viability was determined by a
i
haemocytometer during the final wash, using Trypan Blue exclusion (see section
2.1.1.5), The cells were resuspended to the desired concentration..
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2.1.1.3. B cell depletion o f murine lym phocytes.
B lymphocytes were removed from lymphocyte preparations by panning the 
cells on anti-Ig coated plates. The cells from approx. 3 spleens were panned per 
plate. The cell suspension was poured on to the plate and left for half an hour at 
room temperature, during which time the B cells bound to the anti-Ig. The cells 
were then carefully removed and poured on to a fresh anti-Ig coated plate for a 
further 30 minutes. After this time, these cells were separated on Percoll gradients 
as described previously (see section 2 .1.1.2 ).
2.1.1.4. Preparation of human tonsillar T lym phocytes.
Tonsillar T cells were prepared by a modification of a method described 
previously (Cheung etal., 1982). Tonsils were rinsed twice in pre-warmed 
R P M I - 1 6 4 0  media, and then diced in a petri dish containing 15ml media. The 
resulting lumps of tissue were then pressed through a steel mesh screen using a 
syringe plunger to obtain a single cell suspension. The spill was transferred to a 
50ml centrifuge tube (one tube per tonsil) and the debris was allowed to settle under 
gravity for 5 minutes. Ficoll-paque density centrifugation of the ‘supernatant’ was 
carried out ( 4 4 0 g a v  for 15mins at room temperature) to obtain a mononuclear cell 
suspension. The lymphocytes were removed from the interface and pooled. The 
suspension was then washed twice in R P M I - 1 6 4 0  media (first 6 3 0 g a v  for 1 0 I 
.
m inutes and then 4 4 0 g a v  for 10 minutes) before the cells were resuspended in 
media (9ml) and AET-SRBCs (1ml). The suspension was pelleted at 120gav for 15 
minutes, then foetal bovine serum (FBS) (1ml) was layered just above the 
‘interface’ of the pellet, and the tube was incubated on ice for 30mins. The pellet 
was resuspended by gently rocking the tube and the entire suspension was 
transferred to a cushion of Ficoll-paque (10ml). This was spun at 4 4 0 g a v  for 20 
m inutes at room temperature in a swing-out rotor. T lymphocytes, which separated 
with the AET-SRBCs, were obtained by lysing the erythrocytes with 0 . 1 4 4 M  
N H 4C I (5ml), allowing to stand for 2 minutes at room temperature, and then adding
.
'Il
R P M I - 1 6 4 0  media and centiifuging at 4 4 0 g a v  for 1 0  minutes. The cells were then 
washed twice as described previously. The T lymphocytes were then layered on to 
a three-step percoll gradient ( 8 5 % - 6 5 % - 5 0 % ) ,  and centrifuged at 9 5 0 g a v  for 2 0  
minutes to obtain in viV<?-activated and resting populations of cells (resting cells 
from the 8 5 % - 6 5 %  interface, and in vivo-activated cells from the 65%-50%
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interface). The cells were washed twice in RPMI-1640 media containing lOmM
Hepes and resuspended at the desired concenttation. The cell number and viability 
was determined by Trypan Blue exclusion during the last wash (see section 
2 .1 .1 .5).
2 .I .I .5 . Determ ination of cell num ber and viability.
An aliquot of cells, which had been removed from the suspension of cells 
during the final wash after differential density centrifugation, was mixed with an 
equal volume of Tiypan Blue solution (0.4%) and the number and viability of the 
cells was determined. This was achieved by viewing the cells under a light 
microscope in a heamocytometer. The viability of newly isolated ceUs was 
established as the percentage of cells that excluded the Trypan Blue dye; that is the 
proportion of cells whose membranes remained intact, thus remaining white under 
the microscope (>95%). The cell number was calculated by using the grid on the 
slide, which ensured that the same ai'ea was counted for each detemiination. 100
I
cells in 32 squtues denoted 1 x 10*^  cells per ml, thus the cell number could be 
calculated. Only viable cells were counted, tlius obtaining the number of viable 
cells isolated.
•Î
2.1.2. Cell Culture.
2.1.2.1. Jurkat - Human T cell leukemic cell line.
The human leukemic T cell line - Jurkat, is a proliferating mature T cell line, 
which was isolated from a 14 year old boy suffering from acute lymphoblastic 
leukemia. This cell line grows in suspension, with a doubling time of 24 hours.
%..I
f as-
The cells required the following:
500ml RPMI-1640 media with glutamine
5 % (v/v) foetal bovine serum (heat inactivated)
1% (v/v) penicillin /  streptomycin solution
1% (v/v) glutamine solution
On removing cells from liquid nitrogen, the medium was further 
supplemented with an additional 5% (v/v) FBS, 0.1% (v/v) gentimycin and 0.1% 
(v/v) ciproxin for the first week of culture.
Jurkat cells were maintained m the media detailed above, under a humidified 
atmosphere of 95% air and 5% 00%, at 37°C. Twice weekly, the cells were sp lit, 
diluting cells into fresh, pre-warmed medium in new 260ml tissue culture flasks (1 
in 5 dilution), under sterile conditions.
When freezing cells, they were first pelleted by centrifugation in 50ml 
tubes, spinning at 4 4 0 g a v  for 10 minutes, before being re suspended in the freezing 
medium at a density of 10^ cells/ml. This medium consisted of 90% FBS (v/v) and 
10% (v/v) dimethyl sulphoxide (DMSO). After aliquoting into cryotubes, the cells 
were frozen slowly overnight in a -80°C freezer, before being transferred to liquid 
nitrogen the following day, and stored there until required.
2.1.2.2. T3.2 m urine thymoma cell line.
The murine thymoma cell line - T3.2 is a proliferating immature T cell line 
derived from double positive (CD4V CD8^) thymocytes which were taken from 
transgenic mice expressing the myc under the Thy-1 promoter. The cell line grows 
in suspension with a doubling time of about 24 hours.
The cells required the following:
500ml RPMI-1640 medium with glutamine
8 % (v/v) foetal bovine serum (heat inactivated)
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1% (v/v) penicillin /  streptomycin solution
1% (v/v) glutamine solution
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On removing cells from liquid nitrogen, the medium was further 
supplemented with an additional 2% (v/v) FBS, 0.1% (v/v) gentimycin and 0.1%
(v/v) ciproxin for the first week of culture.
T3.2 cells were maintained in the medium detailed above, under a 
humidified atmosphere of 95% air and 5% CO2, at 37°C. The cells were able to 
grow to a density of 2  x 10  ^cells/ml, so twice weekly the cells were passaged, 
diluting cells into fresh, pre-warmed medium in new 260ml tissue culture flasks (1 
in 10  dilution), under sterile conditions.
When freezing cells, they were first pelleted by centrifugation in 50ml 
tubes, spinning at 440gav for 10  minutes, before being resuspended in the freezing 
medium at a density of 10^ cells/ml. This medium consisted of 90% FBS (v/v) and 
10% (v/v) DMSO. After aliquoting into cryotubes, the cells were frozen slowly 
overnight in a -80°C freezer, before being transfen'ed to liquid nitrogen the 
following day and stored there until required.
„,iî
2,1.3. Preparation o f the m onoclonal antibody, 145-2C11.
145-2C11 is a monoclonal antibody (IgG) in hamster directed against the e 
chain of the murine T cell receptor/CD3 complex (Leo et a l,  1987).
2.1 .3 .1 , 145-2C 11 cell line.
The antibody was produced as a hybridoma culture supernatant. The cells 
required the following:
500ml RPMI-1640 media witli glutamine
5% (v/v) foetal bovine serum (heat inactivated)
1% (v/v) penicillin /  streptomycin solution
1% (v/v) glutamine solution
On removing cells from liquid nitrogen, the medium was further 
supplemented with an additional 5% (v/v) FBS, 0.1% (v/v) gentimycin and 0.1% 
(v/v) ciproxin for the first week of culture. I
145-2C11 cells were maintained in the medium detailed above, under a 
humidified atmosphere of 95% air and 5% CO2, at 37°C. Twice weekly, the cells 
were passaged and the antibody was collected. This was achieved by pellet ing the 
cells by centrifuging them at 4 4 0 g a v  for 10 minutes, and freezing the antibody- 
containing supernatant until it could be further purified (see section 2.I.3.2.). The 
cells were then diluted 1 in 5 with fresh, pre-warmed medium in new 260ml tissue 
culture flasks, under sterile conditions.
When freezing cells, they were first pelleted by centrifugation in 50ml 
tubes, spinning at 1500rpm for 10 minutes, before being resuspended in the 
freezing medium at a density of 10  ^cells/ml. This medium consisted of 90% FBS 
(v/v) and 10% (v/v) DMSO. After aliquoting into cryotubes, the cells were frozen 
slowly overnight in a -80°C freezer, before being transferred to liquid nitrogen the 
following day, and stored there until required.
2.1.3.2. Purification o f 145-2C11 antibody.
The hamster anti-mouse CD3-e mAb was purified as outlined previously 
(Phillips eta l., 1991).
2 .I .3 .2 .I . Ammonium persulphate precipitation of the antibody.
Saturated ammonium solution prepared by dissolving approx. 77g into 
100ml distilled water. Heating was required in order to achieve this. The pH of the 
solution was then adjusted to pH7.0 using lOM NaOH. The solution could then be 
stored at 4°C, and was heated in order to dissolve the needle-like crystals when 
required for use. The supernatant obtained from pellet ing the cells (see section 
2 .1 .3 .1 )  was defrosted and an equal volume of saturated ammonium sulphate 
solution was added slowly to the tissue culture supernatant, sthring at all times. A 
cloudy precipitate formed. The solution was allowed to stand overnight at 4^C in 
order to complete the precipitation. The following day, the precipitate was pelleted 
at 1 5 3 0 0 g a v  for 3 0  minutes at 4°C, and the supernatant was discarded. PBS
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(10ml) was added to resuspend the pellet, and the resulting solution was dialysed 
against PBS as described in section 2.1.3,2.2.
2.1.3 .2 .2 . D ialysis of the antibody precipitate.
The solution was dialysed in order to lower the concentration of ammonium 
sulphate solution in the antibody containing solution. The dialysis membrane was 
washed with distilled water, before being boiled for 30 minutes in 2mM 
EDTA/5mM NaHCOs. The tubing was then rinsed thoroughly with distilled water, 
and stored in 70% ethanol. The tubing was rinsed in distilled water before sealing
the membrane using two clips at one end, and then the antibody containing solution 
was added to the membrane. The residual air was eased out of the tubing, leaving 
an equal amount o f the membrane empty, before clipping the other end. Note, the 
volume of the solution increases about 2 fold upon dialysis. The solution was 
dialysed overnight (frequent changes of buffer) against 1.5-2 1 PBS or for 48 hours 
w ith less frequent buffer changes. After this time, the antibody solution was 
purified further using a protein A - sepharose column.
2 .I.3 .2 .3 . Protein A-sepharose antibody purification.
The column was prepared in a 2ml syringe, by putting a small amount of 
glass wool into the syringe and then adding Protein A-sepharose (1ml) to the
syringe. The sepharose was washed with five volumes of PBS, and then dialysed
■antibody solution was run through the column. The supernatant contained 0.1- 
lOqg/ml of monoclonal antibody and the binding capacity of the column is 6mg/ml, 
so the ‘run-through’ was saved for further purification. The column was then 
washed with PBS, until unbound proteins had been washed off. This was 
determined by reading the absorbance of the fractions at 280nm (Azgo) (see section 
2.1.9.2). The antibody was eluted using five volumes of 0.2M glycine/HCl 
(pH2.8). The eluate was immediately diluted into IM  Tris buffer to prevent 
dénaturation of IgG at pH2.8. An A280 was earned out to determine the antibody
concentration of each fraction, in order to obtain an elution profile, before pooling 
the fractions. If the protein content was less than 500p,g/ml, the solution was 
concentrated using Centricon tubes, adding the solution to the tubes and 
centrifuging at 6 1 3 g a v  for 15 minutes. The solution was then filter-sterilised using 
Millipore filters (0.22|iM) before being aliquoted and stored at -20°C.
2.1.3.3. Sodium  dodecyl sulphate polyacrylam ide gel 
e lectro p h o res is .
The purity of the antibody solution was checked by separating the proteins 
in the mixture by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). Samples of the antibody containing lOOjig protein (see section 
2.1.9.1) were concentrated in a 0.3% (w/v) acrylamide/0.08% (w/v) N,N’- 
methylenebisacrylamide stacking gel followed by resolution in a 10% (w/v) 
acrylamide gel, in the presence or absence of (3-mercaptoethanol (ie. reduced or 
non-reduced) and controls of y-globulin and BSA (in reduced and non-reduced 
conditions) were run alongside these samples. Under non-reducing conditions the 
antibody was observed at ~150kDa. This should run in parallel with purified y- 
globulin. Upon addition of (3-mercaptoethanol, the protein is reduced (ie. the 
disulphide bonds in the antibody molecule are cleaved), the antibody is seen on the 
gel as two lower molecular weight forms (heavy chain 50kDa, light chain 25kDa). 
A similar situation is seen with y-globulin.
2.1.3.3.1. Preparation of buffers for SDS-PAGE,
Resolving gels were prepared by mixing stock acrylamide solution (30% 
(w/v) acrylamide, 0.8% (w/v) N, N' -methylene bisacrylamide), buffer A (1.5M 
Tris/HCl (pH 8 .8), 0.4% (w/v) SDS) and ddH2 0  to give final concentrations of 
10% (w/v) acrylamide, 0.24% (w/v) N, N'-methylene bisacrylamide, 0.375M 
Tris/HCl (pH8 .8), 0.1% (w/v) SDS, 3% (v/v) glycerol. Polymerisation of the gel
was achieved by the addition of 12p,l of TEMED and 80|o.l of freshly prepared 10%
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(w/v) ammonium persulphate.
The upper stacking gel was prepared by mixing stock acrylamide solution
■(30% (w/v) acrylamide, 0.8% (w/v) N, N'-methylene bisacrylamide), buffer B (0.5M 
Tris/HCl (pH 6 .8), 0.4% (w/v) SDS) and ddH2 0  to give final concentrations of 3% 
(w/v) acrylamide, 0.08% (w/v) N, N'- methylene bisacrylamide, 0.125M Tris/HCl 
(pH6 ,8), and 0.1% (w/v) SDS. This was polymerised by adding 15jil of TEMED 
and 45|ul of freshly prepared 10% (w/v) ammonium persulphate.
The sample buffer (2x) was prepared by mixing IM  Tris/HCl (pH6 .8), 
glycerol, 10% (w/v) SDS and 0.007% (w/v) bromophenol blue and ddH2 0  to give 
final concentrations of 0.13M Tris/HCl (pH6 .8), and 4% (w/v) SDS. For the samples 
which required reducing, 0.1ml p-mercaptoethanol was added to 1.9ml sample buffer 
just prior to use.
2.1.3.3.2. Preparation of sam ples.
The samples containing lOOpg protein were added to an equal volume of 2 x 
sample (Laemmli) buffer with or without p-mercaptoethanol. These samples were 
boiled for 5 minutes and then analysed in a discontinuous gel system (Laemmli,
1970).
i
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2.1.3.3.3. Protein m olecular w eight m arkers.
The pre-stained protein molecular weight standards were myosin H-chain 
(200kDa), phosphorylase B (97.4kDa), BSA (6 8kDa), ovalbumin (43kDa), carbonic 
anhydrase (29kDa), p-lactoglobulin (18.4kDa) and lysozyme (14.3kDa). These 
standards were made up as described by the manufacturers. Briefly, 500pl ImM  
dithiothrietol (DTT) was added to the vial of standards. The contents were boiled for 
5 minutes and then vortexed to ensure the solution was homogeneous. The standards 
were then aliquoted into 20|il aliquots and thawed when required. Once thawed an
equal volume of sample buffer was added to the standard and the vial was boiled for 5 
minutes with the rest of the samples, then 2 0 pl was applied to the g e l
2 .I.3 .3 .4 . Preparation and running of slab gels.
The gel plates measured 160mm x 180mm, and the gels cast were 1.5mm 
thick. The gel apparatus was assembled, ensuring that the plates, spacers and comb 
had been cleaned with acetone prior to use. After ensuring that there were no leaks at 
the bottom of the gel plates, the resolving gel was cast. Distilled water was then 
carefully layered over the top to exclude air, and enhance polymerisation. Once set, 
the water was poured off, and the stacking gel solution was layered on. A gel comb 
was immediately inserted so that wells would form in the gel, which was removed 
once the stacking gel had set. The gel was removed from the casting stand, and placed 
into a gel tank containing 4.5 1 running buffer (25mM Tris /  191mM Glycine /  3.5mM 
SDS). The cathode and anode were immersed in the remaining buffer forming a 
reservoir above the gel. Samples were loaded onto the gels using a Hamilton 
microsyringe (Hamilton Co., Reno, Nevada, USA.). Electrophoresis was toward the 
anode at 40V, 25mA per gel until the bromophenol blue dye front was 0.5cm from tlie 
b o tto m .
2 .1 .3 .3 .5 . S ta in in g /d esta in in g /dry in g .
This procedure was carried out as described previously (Sambrook et aL,
1989). Following electrophoresis, gels were soaked, with gentle shaking on a 
rotary shaker, for Ihr in 45% (v/v) methanol, 10% (v/v) acetic acid containing 
0.25% (w/v) Coomassie Blue R-250. Gels were destained by washing with 45% 
(v/v) methanol, 10 % (v/v) acetic acid with frequent changes of the wash solution. 
Gels were dried down onto Whatman 3MM paper under vacuum at 60°C for two 
hours and then scanned (fig. 2.1). From this gel, it is possible to see that no BSA 
is present in the antibody sample. The antibody sample and y-globulin run
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alongside each other in reducing and non-reducing conditions. Thus indicating that 
the antibody is uncontaminated with other proteins.
2 .1 ,4 . F low  cytom etry.
In order to ascertain the lineage/maturation of lymphocytes, defined by cell 
receptors, fluorescence-activated cell scanning (FACS) was carried out. The 
principle being that on addition of fluorescence-labelled monoclonal antibodies to a 
population of cells, they will bind to specific cell surface receptors. On analysis of 
the fluorescence patterns produced, in the FACS, one can gather information about 
the level of development of T cells, and the composition of the heterogeneous cell 
population isolated fiom murine or human sources, as judged by the distribution of 
three cell surface markers. In this case FACS was utilised to gain information 
regarding the murine thymocyte populations.
2.1 .4 .1 . Procedure.
Cells were washed twice with ice cold PBS in plastic FACS scanning tubes, 
spinning each time at 270gav, and resuspended at a concentration of 10  ^
cells/lOOp-1. Biotinylated anti-CD3 antibody (Ipg/ml), PE-labelled anti-CD8 cc
antibody (Ipg/ml) and/or FITC-labelled anti-CD4 antibody (Ipg/ml) were added to
cells (lOOpl). The tubes were covered in foil (to stop bleaching of the fluorescent
,dyes) and incubated on ice for 30 minutes. Blanks were carried out for each 
condition, preparing cells for incubation with PBS alone. After the appropriate 
incubation time, ceils were washed twice with PBS as before, and Quantum Red 
Streptavidin (lOpl) was added to those tubes that contahied biotinylated anti-CD3 
antibody. The tubes were again incubated on ice for 30 minutes as described 
previously. The cells were then washed twice in PBS, suspended in PBS (0.5ml), 
and fluorescence data was acquired in a Becton-Dickenson Facscan. Analysis of 
the data was then earned out.
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2 .1 .4 .2 . A n a ly sis .
The type of analysis carried out on the data was dependent on the number of 
antibodies used in the labelling process. ‘Paint-a-Gate’ was used if three 
fluorescent antibodies were used, as this programme allows the viewing of 3-colour 
stained, triple positive cells. However, if only two antibodies were used, then two 
colour ‘Dot-plots’ were used to analyse the cell populations.
With the use of the ‘Paint-a Gate’ progi'amme on the Becton-Dickenson 
Facscan, it was possible to analyse the proportions of single, double and most 
importantly triple populations present in cells isolated. The fluorescence channels 
were assigned to a given axes, thus green fluorescence (CD4) was plotted along the 
X axis; red fluorescence (CD3) was plotted along the z axis; orange fluorescence 
(CD8 ) was plotted along the y axis. The blanks were read in the FACS, which 
gave an indication of the background fluorescence in the absence of antibody, then 
the samples were read, eliminating the blanks in each case. In this way, the 
percentages of different populations were obtained.
In order to study dot-plots, gates were set up to eliminate the background 
fluorescence. After these gates had been created, the data collected previously 
could be analysed, once again giving an indication of the thymocyte populations 
present in the cell preparation. FACS analysis showed that the resulting cell 
populations were approx. 70% CD4+/CD8+ double positive cells of which 15% 
CD3+/CD4+/CD8+ triple positive, 10% CD3+/CD4+ and 7% CD3+/CD8+ 
positive.
2.1 .5 . Cell Lysis.
The cells were disrupted by the procedure described previously (Harnett et 
ah, 1991). This method of cell disruption was employed rather than either 
homogenisation or sonication procedures, as they not only failed to disrupt all the 
cells as indicated by Trypan Blue exclusion but caused disruption in a highly 
variable fashion.
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2 .1 .5 .1 . Protocol.
Briefly, the cells were pelleted, and disrupted on ice for 5 minutes in 
homogenisation buffer of lOmM Tris/HCl, pH7.4, ImM  EDTA, 0.25 
sucrose, O.lmM DTT and a protease inhibitor cocktail (1.7mM antipain, 0.15mM 
aprotinin, Im M  benzamidine hydrochloride, 230p,M PMSF, l.SmM  pep statin A, 
Ijj-g/ml leupeptin) together with 0.5mg/ml digitonin. The mixture was then 
centrifuged for 5 minutes at 1 2 ,0 0 0 g a v  and the supernatant taken for PDE activity 
analysis (see section 2.1.7).
In order to extract the membrane proteins, the pellet obtained from soluble 
extraction was further extracted. This was carried out on ice for 45 minutes in 
homogenisation buffer and the protease inhibitor cocktail together with 5mg/ml 
digitonin. As before the mixture was centrifuged for 5 minutes at 1 2 ,0 0 0 g a v  and 
the supernatant taken for PDE activity analysis (see section 2 . 1 .7 ) .  These 
concenuations of digitonin did not affect PDE activity (fig. 2 .2 ) .
2,1.6. Separation of cyclic nucleotide phosphodiesterase activities  
using M ono-Q ion-exchange chrom atography.
This was performed using the Pharmacia Fast Peifoimance Liquid 
Chromatography system (FPLC),
2.1.6.1. Preparation of reagents.
Low salt and high salt buffers (A and B respectively) were prepared freshly: 
with buffer A containing; lOmM Tris/HCl, pH7.4, ImM EDTA, O.lmM DTT and 
protease inhibitor cocktail (see section 2.1.5.1). Buffer B contained; lOmM 
Tris/HCl, pH7.4, Im M  EDTA, 0.75M NaCl, O.lmM DTT and protease inhibitor 
cocktail (see section 2,1.5.1).
In order to prepare the sample, tliymocytes were prepared as described in 
section 2.1.1, and were lysed using digitonin as described in section 2 . 1 . 5 . 1. All 
buffers were filtered through a 0.2 pM  filter, and kept at 4°C.
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2.1.6.2. Equilibration and m aintenance.
When the FPLC system was not in use it was stored in 24% ethanol. In 
order prepare the equipment for use, it was rinsed with the buffers. The superloop 
and the injection valve were washed with buffer A, and the pumps were washed 
with the respective buffers (low salt buffer for pump A, and high salt buffer for 
pump B). The column was equilibrated before use by washing with buffer A for 
10 minutes with a flow-rate of 1 ml/minute, then washing with buffer B for the 
same time, and finally again with buffer A, All operations were carried out at 4“C. 
After use the column was washed in buffer A as before, and then stored in 24% 
ethanol. The pumps and superloop were washed with 24% ethanol and stored this 
way until required for fuither use.
2.1 .6 .3 . Separation o f cyclic nucleotide phosphodiesterases.
This was carried out as a modification of the procedure outlined previously 
(Lavan et aL, 1989). The sample (10ml) was loaded on to the Mono Q column at a 
flow rate of 1 ml/minute (3-4mg protein). Fractions were eluted at Iml/m in using a 
120ml, 3-step gradient of NaCl (0-0.75M) in buffer A as described in Table 2.1. 
Fractions of 1ml were collected and 25pi aliquots assayed for PDE activity as 
described in section 2.1.7.3.
2.1.7. Cyclic AM P phosphodiesterase assay.
Cyclic AMP phosphodiesterase activity was assayed by a modification of 
the two-step procedtue of Thompson and Appleman (1971) and Rutten et.al.
(1973) as previously described by Marchmont and Houslay (1980b). The principle 
of the assay is outlined in fig. 2.3. Briefly, [^H]-cyclic nucleotide (8 position of the 
adenine ring) is hydrolysed to fomi labelled nucleotide mono-phosphate. The 
nucleotide mono-phosphate ring is then converted to the corresponding labelled 
nucleoside by incubation with snake venom which has 5 ’-nucleotidase activity.
The conditions are such that complete conversion takes place within the incubation
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time. Unhydrolysed cyclic nucleotide is separated from the nucleoside by batch 
binding of the mixture to Dowex-1-chloride. This binds the charged nucleotides, 
but not the uncharged nucleosides.
2.1.7.1. Stim ulation o f cells for the assay.
Cells (4x10^ cells/ml) were incubated in RPMI-1640 medium, for up to 30 
minutes in the presence of either PHA or anti-CD3 mAb (at concentrations specified 
in the relevant figure legends) at 37°C. In the experiments where kinase inhibitors 
are used, the conditions are specified in the appropriate figure legend. At the 
indicated time points the cells were harvested by a brief centrifugation for 5 seconds 
at 12 OOOgav. The cells were then disrupted by the procedure described above (see 
section 2.1.5.1). The supernatant obtained was ‘snap’ frozen in liquid nitrogen and 
stored in the -80°C freezer until required.
2.1.7.2. Preparation o f reagents.
- 3',5’-cyclic AMP: Prepared at a concentration of ImM  in 20mM 
Tris/HCl, pH7.4 containing 5mM MgCU and frozen as stock. The concentration 
required for the assay was obtained by diluting the stock on the day of each assay. 
Note, Mg2+ ions are required as a cofactor for cyclic AMP phosphodiesterase 
activity.
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- Rolipram, milrinone, 3-isobutyl 1-methylxanthine (IBMX); These 
inhibitors were routinely prepared as stock solutions in DMSO and frozen down.
On the day of the assay, they were subsequently diluted in 20mM Tris/HCl /  5mM ,,,
MgCl2 buffer, pH7.4 to the desired concentration with a maximum concentration of 
0.1% DMSO being employed in assays. Such levels of DMSO did not affect the
'PDE activities (fig. 2.4).
'- Hannah ophiophagus snake venom: A 10 mg/ml stock solution was 
dissolved in distilled water and frozen down in aliquots. This was diluted to 1 
mg/ml in distilled water for use in the assay.
- Dowex îX8-400-chloride: This was prepared as described previously 
(Thompson et aL, 1979b). Briefly, at 4°C, 400g Dowex 1-chloride was washed 
with IM  NaOH (41) for 15 minutes. After this time, the resin was washed 
extensively with distilled water, until the pH of the eluate fell to 7.0. The resin was 
then washed with IM  HCl (41) for 15 minutes, followed by more washing, in 
distilled water until the eluate pH rose to 3.0. The resin was stored at 4^C with 
ddH2 0  (1:1). For use in the assay, the Dowex:water mix was further diluted with 
ethanol, to a final ratio of Dowex: water:ethanol (1:1:1). Etlianol is used in order to 
prevent non-specific binding of adenosine to Dowex and to inhibit adenosine 
deaminase converting adenosine to inosine, which can bind to Dowex.
2.1.7.3. A ssay p ro ced u re .
Enzyme containing sample (lO^cells) (25pi) was added to 20mM Tris/HCl, 
pH 7.4,5m M  MgCl2 (25pi) containing the required phosphodiesterase effectors at 
four times the desired concentration, at 4°C. Blanks were included with every 
experiment done, replacing the enzyme sample with homogenisation buffer (25pi) 
(see section 2.1.5.1). The reaction was started with the addition of 2pM  cAMP 
containing 0.15pC i cAMP (50pl), mixing the tubes by vortexing, and incubating 
for 10 minutes at 30^C. After this time the tubes with placed in a boiling water bath 
for 2 minutes to terminate the phosphodiesterase activity. The samples were then 
allowed to cool on ice. 25pg snake venom was added to the tubes and they were 
incubated for lOmins in a 30°C waterbath. The tubes were then placed on ice, and 
freshly prepared sluiry of Dowex:ethanol: water (1:1:1) (400pl) was added. During 
this addition, the Dowex was stirred gently, in order to allow a homogeneous 
suspension was being added. The tubes were vortexed twice over a 15 minute 
period, and then spun in a benchtop centrifuge (Jouan) at 12 O O O g a v  to sediment out 
the Dowex resin. An aliquot of 150pl supernatant was removed and mixed with 
2ml Ecoscint, before being counted in a liquid scintillation counter for 3 minutes per 
sample.
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The effector concentration used is described in the appropriate figure 
legends. All assays were carried out in triplicate unless otherwise stated.
2.1 ,7 .4 . C alculation o f specific activities.
The corrected cpm per sample was obtained by subtracting the blank value 
in each case. Determining the protein content (see section 2.1.9.1) of each sample 
allowed the results to be expressed in terms of specific activity. The results were 
then calculated as pmols cAMP hydrolysed/min/mg +/- SEM.
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2.1.8. Cyclic AMP binding assay.
The measurement of cyclic AMP concenuations was carried out as outlined 
previously (Kishihara et aL, 1993). The binding protein utilised in the assay is 
cyclic AMP-dependent protein kinase (PKA) which has binding sites for cyclic 
AMP. A crude preparation of adrenal glands was made (Brown et aL, 1972), 
which is a rich source for this enzyme. Upon stimulation o f the cells in the 
presence of the desired effectors for a fixed time, the cells were lysed, thus
releasing the cytosolic cyclic nucleotides. After neutralising, the cells were
-
incubated with [^H]-cyclic AMP (5- and 8» position of the adenine ring) and cyclic 
AMP binding protein, allowing competition of labelled and unlabelled cyclic AMP 
for a limited number of binding sites on the binding protein. A standard curve was 
obtained by incubating known concentrations of unlabelled cyclic AMP with fixed 
amounts of binding protein and radioactive cyclic AMP, an example of which is 
shown in fig. 2.5. Thus the unknown cyclic AMP concentrations can be 
determined in samples by comparison with the standard curve. After the 
incubation, activated charcoal was added to the sample to absorb unbound cyclic 
nucleotide from the solution. The charcoal with the bound cyclic nucleotide was 
removed by a brief centrifuging step, and a proportion of radioactivity in the sample 
was ascertained.
J
2.1.8.1. Preparation of cyclic AMP binding protein.
Bovine adrenal glands (20-30), obtained from the abbatoir were transported 
to the laboratory on ice. At 4°C, the fat was removed from the outside of glands, 
and they were then henoisected revealing the pale coloured inner medulla and the 
darker outer cortex. The medulla was removed and discarded, retaining the cortex. 
One volume of tissue was homogenised in one and a half volumes o f buffer 
(250mM sucrose /  25mM KCl /  5mM MgSO^ /  50mM Tris/HCl, pH7.4) in a 
Waring blender. The homogenate was filtered through muslin and then centrifuged 
at 15 OOOrpm on MSB 18 for 15 minutes at 4°C. The supernatant was decanted 
through filter paper, and the eluate was aliquoted into 1ml fractions and stored at 
-20°C for up to 3 months. Separate samples were tliawed and diluted for each 
assay.
2.1 .8 .2 . Stim ulation of cells.
Cells were prepared as described previously (see section 2.1,1), and 
suspended at 2 x lO^cells/ml. An aliquot of 100|Ol was used for each time point (2 
X 10^ cells/assay), with each time point being carried out in triplicate. The agonist 
was added to the cells and incubated at 37°C. After the desired period an addition 
of lOOpI 4% perchloric acid (PCA) was made to terminate the reaction. The cells 
were incubated on ice for 2-3 minutes to allow the lysing of the membrane, and the 
extraction of the cyclic nucleotides. After this time, the cell debris was removed by 
centrifuging in a bench-top centrifuge for 2  minutes.
2.1.8.3. N eutralising the sam ple.
Universal indicator was added to the samples, on addition the solution 
turned pink. The solution was then neutralised by addition of 2M KOH /  0.5M 
triethanolamine (TEA) drop wise until the solution turned green. Any precipitate 
that formed was pelleted in a microfuge for 3 minutes, and 50pl of the supernatant 
was removed for assay.
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2 .1.8.4. P re p a ra t io n  o f reag en ts  fo r assay.
(i) [5’,8-^H]-cyclic AMP; 130p.l radioactive cyclic AMP was added to 
200ml Tris/EDTA buffer, and stored at 4°C until required for use.
(ii) Binding protein: the binding protein was prepared as described in 
section 2.1.8.1, then diluting the aliquoted sample to the desired concentration.
(iii) Charcoal solution: The desired amount of charcoal solution was made 
up of 2% activated charcoal and 1% bovine serum albumin in buffer. This was 
stirred on ice for at least 45 minutes before it was required.
2.1 .8 .5 . A ssay p ro c e d u re .
As mentioned previously, a standard curve was carried out with each assay, 
for cyclic AMP concentrations between 0.0625 and 16 pmols. This part of the 
assay was carried out in duplicate, whilst the unknown samples were assayed in 
triplicate, and was set up as follows:
Tube Standards Buffer (pi) [^H]-cAMP (pi) Binding Protein (pi)
1-2 -  200 100
3-4 - 100 100 100
99
;..,r5-22 0.0625-16 50 100 100
23-25 unknown x3 50 100 100
Tube 1 an 2 were blanks, calculating the amount of cyclic AMP not bound 
by charcoal, tubes 3 and 4 represented the total binding of cyclic AMP, and tubes 5- 
22 represent the standard curve, giving counts for fixed concentrations of cyclic 
AMP, allowing unknown cyclic AMP values to be calculated.
The tubes were set up as described above on ice, adding binding protein to 
the tubes last, (note, this allows a fair competition for binding sites between the 
labelled and unlabelled cyclic AMP). The tubes were vortexed and incubated at 4°C 
for 2-3 hours. After this time, 250pl charcoal solution was added, and tubes were
immediately vortexed and spun in a microfuge at 12 OOOgav for 5 minutes. (Note, if 
the charcoal solution is not spun out promptly, cyclic nucleotides will be stripped 
from the binding protein). An aliquot of 300pl was removed from the resulting 
supernatant and added to 4ml Ecoscint, and counted using a curve fitting progi’am.
2.1.8.6, Calculation o f cyclic AMP levels.
The results are expressed as an average of the triplicates assayed, and 
expressed as pmols cyclic AMP produced/10^ cells +/-SEM
2.1 .9 . Protein assays.
2 .1 .9 .1 . Bradford m ethod.
This method of protein determination is based on the Bradford method 
(Bradford, 1976). Briefly, a standard curve was constructed using 0-1 Opg BSA as 
the protein standard, carrying out the standards in duplicate. These concentrations 
of protein were dissolved in distilled water (800pl). Bio-Rad reagent (200pl) was 
added and the tubes were vortexed and the absorbance was read against a blank 
cuvette containing no protein, at an absorbance of 595nm. Protein concentrations 
of the samples were deteimined in a similar way, diluting lOpl of the sample into 
SOOpl distilled water, adding Bio-Rad reagent and reading the absorbance in the 
spectrophotometer as before. The unknown protein samples were also assayed in 
duplicate. Protein concentrations were determined by plotting the standard curve (x 
axis = protein concenU'ation (mg/ml), y axis = A595), gaining the equation of the 
line, and using the absorbance readings gained as ‘y% calculating ‘x ’ ie. 10 x 
protein concentration (fig. 2 .6 ).
2.1.9.2. A280  protein determ ination.
A quicker determination of protein concenti'ation when measuring the 
concentration of tmtibodies can be achieved by taking the absorbance of a solution
100
at 280nm, in a quartz cuvette, against the appropriate blank. An A280 of LO is 
equivalent to l,4mg/ml.
2.1.10. Proliferation  assay.
In order to determine the effect of certain stimuli on the proliferation o f the 
cells, [^H]-thymidine incorporation as a measure of DNA synthesis were carried 
out. The principle of this assay is that after incubating the cells with the stimuli for 
a period of time, 0.5qC i [^H]-thymidine is added to the cells. This becomes 
incorporated into the DNA of cells whilst they are dividing, and the amount of 
incorporation can then be measured. The level of DNA synthesis observed is a 
direct indicator of the proliferative response of these cells.
2.1.10.1. Preparation of reagents.
The cells required the following media:
500ml RPMI-1640 media
50ml foetal bovine serum (heat inactivated)
5ml penicillin /  streptomycin solution
5ml glutamine solution
5ml pyruvate solution
5ml non-essential amino acid solution
0.5ml (3-mercaptoethanol
[^m-thymidine: lOOql labelled thymidine was diluted in 2ml RPMI-1640 
media on the day of use. 0.5pC i (lOp-l) of [^H]-thymidine was used/well
2.1 .10.2 . A ssay procedure.
The cells were prepared as described previously (see section 2.1.1) with 2 x 
10  ^cells being used/well (200|il). The cell number was determined before the cells 
were centrifuged for 5 minutes at 2 7 0 g a v ,  and resuspended in the proliferation
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assay buffer (see section 2.1.10.1). The ceils were aliquoted into flat-bottomed 96 
well plates with desired effectors under sterile conditions, and incubated for 48 
hours under a humidified atmosphere of 95% air and 5% CO2, at 37^C. The 
conditions were carried out in triplicate. After the required time, O.SpCi f  H]- 
thymidine was added to each well, and the plates were incubated for a further 4 
hours, then the cells was harvested.
2.1 .10.3 . H arvesting o f cells.
The cells were harvested using a Skatron cell harvester. The filter paper 
was pre-wet with distilled water, before the cells were aspirated on to the paper, 
causing the cells to lyse, and the DNA to stick to the paper. Once the cells in the 
plate were haivested, the filter paper was dried in the oven, and the individual discs 
were dissolved in 2ml Ecoscint and counted in a liquid scintillation counter for 3 
minutes per tube. The results were calculated as the average cpm +/- SEM.
2.1 .12. Statistical A nalysis.
All statistical analysis was carried out by the Students t test, unless 
otherwise stated.
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2.2. M aterials.
2.2.1. Chem icals and reagents.
BD H., p-Mercaptoethanoi
Poole, U.K. Coomassie Blue (Brilliant Blue R250)
DMSO
Triethanolamine 
Universal indicator
Bio-Rad Laboratories Ltd., Bradford reagent
Hertfordshire, U.K. TEMED
Boeringer (U.K.), Ltd., Dithiothreitol
Lewes, U.K.
Calbiochem,
Fisons,
Loughborough, U.K.
Gibco. BRL., 
Paisley, U.K.
Chelerythiine chloride 
H89 dichloride 
Tyrophostin 1 
Tyrophostin 25
Ammonium sulphate 
Glycerol
Protein molecular weight markers 
Hepes
Peptide Research Foundation,Leupeptin 
distributed by Scientific 
Associates Marketing,
London, UK.
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Pfizer Central Research, 
Sandwich, Kent, U.K.
Pharmingen,
Cambridge Bioscience, 
Cambridge, UK.
Cilostimide
Anti-TCR mAb, H57-597 
FITC-labelled anti-CD4 antibody 
PE-labelled anti-CD8a  antibody
I
Packard, 
Groningen, N.L.
Ecoscint, Scintillation fluid
Rhone Merieux, 
France.
Sagatal
Schering Aktiengesellschaft, Rolipram 
Postfach 650311, D-lOOO 
Berlin 65, Geimany.
Sigma Chem ical Co., 
Poole, UK.
AET
Actinomycin
Antipain
Aprotinin
Benzamidine hydrochloride 
Biotinylated anti-CD3 antibody 
BSA
Calmodulin (bovine brain) 
Charcoal (Norit A)
1r
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Cyclic AMP (disdium salt)
Cyclic GMP
Cycloheximide
Digitonin
Dowex 1X8-400 (chloride form, 200-400 mesh)
Ficoll-paque
Genistein
ÏBMX
lonomycin
Pepstatin A
Percoll
Phytohaemagglutinin
PMA/TPA
PMSF
Protein A-agai'ose beads
Quantum Red Streptavidin
Snake venom {Hannah ophiophagus )
Trypan Blue (0.4%)
Sterling Winthrop, Milrinone
Guildford,
Surrey, U.K.
All other chemicals were of AR grade and obtained from BDH (Poole, 
U.K.) and Fisons (Loughborough, U.K.)
2.2.2. Equipm ent.
Medicell Int. Ltd., 
London, U.K.
Dialysis tubing
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Nunc,
InterMed
Cryotubes
260ml tissue culture flasks 
96 well plates
Pharmacia Fine Chemicals, FPLC 
Sweden
Sigma Chem ical Co., 
Poole, UK.
W hatman Ltd., 
M aidstone, U.K.
50 mesh steel screens
Whatman 3MM Paper
Whatman 0.2pM nitrocellulose paper
2.2 .3 . R adiochem icals.
Amersham, [8-^H] - Adenosine-3',5'- cyclic monophosphate
Bucks, UK. [5',8-^H] - Adenosine-3’,5'- cyclic monophosphate
Thymidine
2.2 .4 . A nim als.
Male 4 week and 12 week old Balb/c mice were used as the source of 
primary thymocytes and lymphocytes from Biochemistiy Department, University of 
Glasgow and Immunology Department, University of Strathclyde, Glasgow.
2 .2 .5 . Cell lines.
The Jurkat T cell line was obtained from European Collection of Cell 
Cultures (ECACC), Centre for Applied Microbiology and Research, Salisbury,
UK. The monoclonal antibody cell line (145-2C11) was brought to the Department 
of Biochemistry and Molecular Biology by Dr. M.M. Harnett, from the National 
Institute of Medical Reseai'ch, Mill Hill, London, U.K. The T3.2 thymoma cell
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line was a very kind gift from Dr. R. Zamoyska, National Institute o f Medical 
Research, M ill Hill, London, U.K.
. All materials used for cell culture were purchased from Gibco. BRL, 
Paisley, Scotland, unless otherwise stated.
2.2 .6 . M iscellaneous.
Tonsils were obtained from the Royal Hospital for Sick Children, Glasgow. 
They were stored at 4°C after the operations, and the lymphocytes were prepared as 
soon as possible. Sheep red blood cells and donkey horse radish peroxidase- 
labelled anti-rabbit antibody were obtained from the Scottish Antibody Production 
Unit, Law Hospital, Carluke, Scotland. Bovine adrenal glands were obtained from 
Duke St. abbatoir, Glasgow, immediately after slaughter, transported at 4°C and 
processed without delay.
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Table 2.1. FPLC programme format.
This table represents the parameters that were set to obtain the 
NaCl gradient used for the separation of phosphodiesterase activity from 
murine thymocytes.
Conc^%B represents the percentage of buffer B (see section 2.1.6.1). 
ml/m in represents the speed at which the column is run. 
cm/ml represents the chart speed.
Port set 6.1 and 6.0 are the instructions for turning the fraction 
collector on and off respectively.
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Time (min.) Parameter Setting
0 .0 Conc’^  % B 0 .0
0 .0 ml/m in 1.0
0 .0 cm/ml 0.5
0 .0 Port set 6.1
2 0 .0 Concn % B 2 0 .0
60.0 Cone" % B 40.0
120.0 Cone" % B 100
125.0 C one"% B 100
125.0 Port set 6 .0
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Figure 2.1. Confirm ation of the purity of the m onoclonal 
antibody , 145-2C 11.
The antibody was purified as described previously in section 
2.1.3.2 and the purity o f the antibody was checked using SDS -PAGE 
gel chromatography as described in section 2.1.3.3.1. The protein 
samples which were run on the gel were prepared in the presence and 
absence of p-mercaptoethanol (ie. in reducing and non-reducing 
conditions, respectively). Purified BSA and y-globulin run alongside 
the antibody sample (2C11-145) as indicated.
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Figure 2.2. Effect of digitonin on rat kidney homogenate
PDE activity
Kidney cells were lysed, by homogenisation, in an isotonic 
solution at 4°C. The resulting homogenate was assayed in the presence 
or absence of digitonin (0.5 or 5|ug/ml as indicated). PDE assays 
were performed in the presence of lp,M cyclic AMP as substrate, 
as described in section 2.1.7. The data presented are 
from single experiments representative of three separate experiments. 
Assays were carried out in triplicate (errors are SEM). PDE activity is 
expressed as pmols cyclic AMP hydrolysed/min/mg protein).
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Figure 2.3. The principle of the cyclic AMP PDE assay.
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Figure 2.4. Dose response of thym ocyte PDE activity to 
D M SO .
PDE assays were performed in the presence of IjiM  cyclic AMP 
as substrate, as described in section 2.1.7. The dose 
dependent action on cyclic AMP hydrolysis by DMSO is shown.
The data presented are from single experiments representative of 
three separate experiments. Assays were carried out in triplicate 
(errors are SEM). PDE activity is expressed as pmols cyclic AMP 
hydrolysed/min/mg protein).
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Figure 2.5. Standard curve for a cyclic AMP binding
assay.
The samples for the standard curve were prepared as described 
in section 2.1.8.5. Cyclic AMP concentrations of 0.0625-16 pmols 
were assayed as indicated. The assays were carried out in duplicate. 
This is a representative experiment which has been carried out at least 
six times.
113
Ëa
a\ir>
0.8
0.6
OAA
0.2 A
10 1284 62
[Protein] (|ig /m l)
il
"S
.
:
%
Figure 2.6. Standard curve for a Bradford protein assay.
The samples for the standard curve were prepared as described 
in section 2.1.9.1. BSA concentrations of O-lOjig were used as 
indicated, and the absorbance was read at 595nm. The tube without 
protein added was used to zero the spectrophotometer. The assays were 
carried out in duplicate. This is a representative experiment which has 
been carried out at least fifteen times.
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C H A PT E R  3.
C H A R A C TE R ISA TIO N  O F C Y C LIC  AM P PDE A C TIV ITIES 
IN T L Y M PH O C Y T ES.
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3.1. In trod u ction .
Cyclic nucleotide phosphodiesterases regulate various physiological 
responses in many different cells and tissues. These include, for example, platelet 
aggregation (Hidaka eî a l,  1979; Simpson et a i ,  1988), vascular relaxation 
(Kauffman et aL, 1987; Tanaka et a i ,  1988), cardiac muscle contraction (Farah et 
ah, 1984; Weishaar et ah, 1987b) and inflammation (Plant et ah, 1980; Torphy et 
ah, 1992). The differential distribution of cyclic AMP PDE isoforms in specific 
cells (see section 1.5.7), as well as their regulation of physiological responses, 
have made members of this enzyme family attractive targets for the development of 
selective inhibitors as potential therapeutic agents (Nicholson et ah, 1991; Reeves 
and England, 1990; Weishaar er a/., 1985).
With the detection of PDE activities within cells, came the discovery of a 
group of compounds, methylxanthines, which inhibited this enzyme activity 
(Butcher and Sutherland, 1962). This group includes theophylline, papaverine and 
IB MX. The structure of IB MX is outlined in figure 3.1. Theophylline has been 
used as a bronchodilator for many years in the treatment of asthma (Weiss et ah, 
1974) and has also been shown to exert a positive inotropic response in the heart 
(Korth, 1978). However, it is a weak inhibitor of cyclic AMP hydrolysis, 
reducing PDE activity in pulmonary tissue by only 6 % when administered at 
therapeutic concentrations (Poison et ah, 1978). This lack of sensitivity means that 
a higher concentration of inhibitor must be used in order to get a beneficial effect. 
However, at higher levels these PDE inhibitors are limited by their other 
pharmacological activities, including adenosine receptor antagonism (Fredholm, 
1980), altering intracellular calcium mobilisation (Kolbeck et ah, 1979) and the 
ability to inhibit the guanine nucleotide binding protein, Gi (Parsons et ah, 1988). 
From the IC50 values summarised in table 3 .1 ,it is possible to see that IB MX has 
inhibitory effects on all the types of cyclic AMP PDEs, hence the attribution as a 
non-selective PDE inhibitor.
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Selective PDE inhibitors exhibit at least a twenty fold specificity as
■inhibitors of their target isozyme family, and they lack many side effects produced
Inhibitors can be generated for the PDEl Ca^VCaM-stimulated PDE by
by non-selective inhibition (Alousi et a l,  1978). Confusion has arisen over initial
,reports of selective inhibition, because of investigators studying samples which 
were contaminated with other PDE activities (see section 1.5.7). However these 
problems have largely been overcome now, with improved purification techniques 
and more sensitive detection methods.
taking advantage of three specific facets of this enzyme; (i) the ability to block 
Ca^VCaM interaction; (ii) the ability to inhibit CaM stimulation by blocking CaM
binding to the PDE; (iii) and the ability to inhibit the PDE activity directly. In 
biochemical assays, the most common way to inhibit PDEl activity is use Ca
chelators, thus interfering with the binding o f Ca^^to CaM. The addition of EGTA
2+to cell extracts stops the stimulation of PDE activity by Ca /CaM. Also possible
is the use of CaM antagonists, such as trifluoperazine and mastporan (Malencik and 
Anderson, 1983; Weiss et a i ,  1974). However these two methods have the 
drawback of being non-selective with respect to other CaM-dependent enzymes, 
such as myosin light chain kinase and CaM-dependent protein kinases within the 
cell, and therefore have short comings in the therapeutic arena and for in vivo 
studies (Kanamori eta l., 1981). More selective inhibitors have been developed 
however, by altering the stmcture of the non-selective PDE inhibitor IB MX. This 
has produced the inhibitor 8-methoxymethyl-IBMX, that is 30-50 times more 
selective for CaM-dependent PDE activities compared with other PDE isoforms 
(Lorenz and Wells, 1983). Another inhibitor described is vinpocetine (Hagiwata et 
aL, 1984) which has an IC50 of 21p,M for PD El, whilst the IC50 of this inhibitor 
for other PDEs is in the millimolar range.
Cyclic GMP-stimulated, PDE2 has been shown to be inhibited by a number 
of compounds known to act non-selectively on various PDE species, including 
IBMX, papaverine and dipyridamole (Moit et a i,  1985) as well as unsaturated fatty
117
îacids, such as palmitic acid and arachidonic acid (Pyne et al., 1986). Until 
recently, it was found that most selective inhibitors of the catalytic site of this PDE 
also bound with high affinity to the aUosteric site of this class of enzyme, leading to 
activation at low concentrations (Emeux eta l., 1981; Yamamoto et a l ,  1983b). It 
has been reported, however, that the erythro-9-(2-hydroxy-3-nonyl-)-adenine 
(EHNA; previously known as MEP-1) is an inhibitor of PDE2 activity (Podzuweit 
et a l ,  1992). This compound is a well established inhibitor of adenosine 
deaminase (Bessodes eta l., 1982; Cristalli et al., 1988). However, an 
investigation carried out on frog heart PDE2 suggests an IC50 of approximately ~ 
4|oM EHNA which is considerably lower than the concentrations required for 
EHNA to inhibit adenosine deaminase in cardiac tissues (Mery et al., 1995).
EHNA has been shown to be selective for PDE2 activities present in human and 
porcine cardiac tissue with IC50 values of 0.8 or 2p.M respectively, as opposed to 
>lGG(aM for other soluble PDE isoforms (see table 3.1) (Podzuweit et al., 1995).
PDE3, cyclic GMP-inhibited PDE inhibitors are the largest group of 
selective PDE inhibitors. Amrinone was the first cardiotonic and antithrombotic 
drug which was found to have positive inotropic effects (Alousi et al., 1979;
Silver, 1989) (fig. 3.2). This group now consists of a number of drugs such as 
milrinone, cilostimide and siguazodan. When administered, these drugs have the 
ability to increase the force of contraction of the heart, presumably by elevating 
[Ca^+li, secondary to an increase in the phosphorylation status of a cardiac calcium 
channel (Olson et al., 1987). These effects appear to be mediated through the 
inhibition of membrane-bound, PDE3, cyclic GMP inhibited PDE and the 
subsequent increases in cyclic AMP levels (Ahn et al., 1986; Weishaar et al.,
1985). PDE3 inhibitors have also been shown to be effective as smooth muscle 
relaxants and platelet aggregation inhibitors.
Although there are tissue-dependent differences in the sensitivity of PDE3 
inhibitors, it is clear that this group of inhibitors is selective for cyclic GMP- 
inhibited PDEs above other PDEs (Hoey and Houslay, 1990; Torphy and
118
■...
119
I
f
Cieslinski, 1990; Valette era/., 1990). The IC50 values for milrinone, cilostimide 
and amrinone are summarised in table 3.1. It is possible to see that they are all 
selective for PDE3 activities, however their potencies of inhibition differ 
(cilostimide > milrinone > amrinone).
The evidence for a functional role of PDE4 isoforms in mammalian CNS 
initially came from the development of selective inhibitors of this class of PDEs. 
Rolipram is a neurotropic drug that can induce a profile of behavioural 
modifications in animals (Watchel, 1983b) such as hypothermia, hypoactivity and 
head twitches. It and other similar drugs, such as its structural analogue Ro20- 
1724 (fig. 3.3), have activities involved with regulation of central nervous system 
functions (Horowshi and Stastre, 1985; Watchel, 1983a). As well as the 
established anti-depressant properties of rolipram (Watchel, 1983b), this inhibitor 
also been shown to exert a relaxant effect on bovine trachea (Hall and Hill, 1992) 
and anti-inflammatory actions (Chan and Hanifin, 1993; Torphy et al., 1992).
These drugs have been shown to act as specific cyclic AMP PDE inhibitors 
in mammalian tissues (Davis and Davidson, 1984; Fredholm et a l,  1979; Nemoz et 
al., 1985; Schwabe et al., 1976). More recently with the cloning of mammalian 
homologues of the Drosophila dnc locus, it has been established that the PDE4 
isozymes are selectively inhibited (Henkel-Tigges and Davis, 1989; Swinnen et al., 
1989b; Swinnen et al., 1991b) by rolipram and Ro20-1724. All mammalian PDE4 
isozymes tested exhibit inhibition by rolipram but interestingly, the Drosophila dnc 
PDE is not inhibited by rolipram (Henkel-Tigges and Davis, 1989). This may 
indicate that drug sensitivity has been established by sequence changes of the 
vertebrate progenitor PDE4 gene (Chen et al., 1986; Davis et al., 1989) after the 
separation of vertebrates from invertebrates. When contrasting the sensitivity of 
rolipram between PDE4 and other PDEs, the sensitivity of this inhibitor for PDE4 
activities is striking, IC50 values for rolipram and its structural analogue Ro20- 
1724 are summarised in table 3.1. It is seen from these values, that rolipram is a 
more potent PDE4 inhibitor than Ro20-1724.
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3.1. A im s an d  O bjectives.
The purpose of this study was to identify the cyclic AMP PDE activities
expressed in T lymphocytes and to detect possible differences in cyclic AMP
.catabolism during T cell maturation. The main part of my research was earned out
using murine thymocytes isolated from four week old Balb/c mice. Comparisons 
were made between these thymocytes and mature murine lymphocytes, a murine 
thymoma cell line (CD4+/CD8+), mature human T lymphocytes derived from 
tonsillar tissue and a human leukemic cell line, Jurkat.
PDE activities are known to be modulated by effectors such as cyclic GMP 
and Ca^VCaM (see section 1.5.7). These agents, as well as the isoform selective 
PDE inhibitors rolipram, milrinone and EHNA were used to identify the PDE 
activities present in T lymphocytes. Confnmation of the specificity of these 
effectors was carried out by assessing the PDE activities upon separation of cell 
extracts using an ion-exchange chromatography system.
•i;
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3.2. R esults.
3.2.1. Cyclic AMP PDE activities in murine thym ocytes.
The availability of selective inhibitors and activators of PDE activity
■(Houslay and Kilgour, 1990; Manganiello eta l., 1990a; Nicholson eta l., 1991; 
Reeves and England, 1990) and the separation of PDE activities by FPLC using ion 
exchange chromatography (Mono-Q) provided a means of determining the relative 
activities of PDE isoform groups in a murine thymocyte extract.
3.2.1.1. Dose response analysis o f thym ocyte extracts.
The cells were prepared from four week old Balb/c mice, lysed and assayed 
for cyclic AMP PDE activity as described in section 2.1.1.1. The extracts were 
assayed in the presence of highly selective PDE inhibitors in order to ascertain the 
proportion of PDE activity that existed in un stimulated thymocytes. As discussed 
previously (see section 3.1 and table 3.1), rolipram is a highly selective inhibitor 
for PDE4 enzymes with IC50 values observed in the O .lpM -ljiM  cyclic AMP range 
(Bolger, 1994; Henkel-Tigges and Davis, 1989; Lobban etal., 1994; McLaughlin 
et al., 1993; Nicholson et al., 1991; Sullivan et al., 1994). In contrast, other PDE 
forms are either insensitive to rolipram, or show IC50 values at least 50-100 fold 
higher ((Nicholson et al., 1991) and table 3.1). Thus the inhibition of total PDE 
activity caused by 10(iM rolipram can be taken to represent the magnitude of PDE4 
activity, as it can be expected to result in maximal inhibition of this isoform group, 
with no effect on the other isoform groups present. Indeed, when rolipram 
inhibition was analysed in thymocyte extracts, there was a dose-dependent decrease 
in PDE activity (fig. 3.4a), with an IC50 of 65 +/- 9nM (n-3; errors are SEM). At 
lOjiM rolipram, the reduction of PDE activity in the extract was 75 +/- 6 % (n=3; 
errors are SEM). A reduction in PDE activity was also apparent when rolipram was 
added to thymocyte extracts together with lOjuM cyclic GMP. The amount of 
activity inhibited by rolipram was consistent with the proportion of PDE4 present 
in the sample (fig. 3.4b), as determined from fig. 3.4a.
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In the presence of low cyclic GMP concentrations, there was a profound 
increase in the hydrolysis of cyclic AMP, which occurred in a dose-dependent 
fashion (fig. 3.5), with an EC50 of 1.3 +/- 0.3p,M cyclic GMP (n=4; errors are 
SEM). However, at cyclic GMP concentrations above lOjiM, an inhibition of PDE 
activity can be expected to occur as a result of competitive inhibition o f the 
conversion of cyclic AMP to 5 '-AMP (Pyne et a l ,  1986), and as result of cyclic 
GMP competing with cyclic AMP for the active site (Hidaka and Asano, 1976). 
This cyclic GMP-stimulated PDE activity was inhibited by EHNA in a dose- 
dependent manner (fig. 3.6) (Podzuweit et a l ,  1992). This yielded an IC50 of 3.5 
•+•/- 0.6jaM (n=3; errors are SEM).
Upon addition of cyclic GMP, one would expect to inhibit PDE3, cyclic 
GMP-inhibited PDE activity (Manganiello et al., 1990a; Pyne e ta l ,  1987a; Pyne et 
a l ,  1987b), leading to a reduction in cyclic AMP hydrolysis. However with the 
use of the selective PDE3 inhibitor milrinone (Nicholson et a i,  1991; Pyne et al., 
1987a; Torphy et al., 1992) no inhibitory effect on cyclic AMP hydrolysis (< 5%) 
was noted at low milrinone concentrations, suggesting this activity was absent from 
murine thymocytes (fig. 3.7). However at higher concentrations (> lOjiM) it 
appeared to inhibit PDE activity, suggesting that the inhibitor is becoming non- 
selective.
PDEl, Ca2+/CaM-stimulated PDE activity was assessed by deteimining the 
ability of Ca^+ZCaM (50|i.M/20ng/ml) to activate cyclic AMP hydrolysis. This was 
done in the presence or absence of the calcium chelator EGTA (ImM ) in the buffer, 
to prevent Ca^+ arising from cell extracts eliciting full activation of any PDEl 
activity present, in the absence of exogenous Ca^+. However no stimulation of 
PDE activity was observed under any conditions (table 3.2) indicating the absence 
of this isoform.
The non-selective PDE inhibitor IBMX is considered to inhibit all PDE 
forms, with IC50 values in the range of l-30|aM (Beavo, 1990; Hoey and Houslay, 
1990; Torphy and Cieslinski, 1990), except for cyclic AMP specific type-VII
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isoform (Lavan et a l ,  1989; Michaeli et al., 1993). In murine thymocytes in the 
presence of lOOpM IBMX, the PDE activity was totally abrogated in the absence 
(IC50 of 4.6 +/- O.SfiM; errors are SEM; n=3) (fig. 3.8a.) or presence (IC50 is 10 
+/- 2|iM; errors are SEM; n=3)(fig.3.8b.) of stimulating concentrations of cyclic 
GMP. This indicates that PDE7 is not present in these cells.
The basal PDE activities in murine thymocytes were the same in buoyant 
density centrifugation-separated ‘m v/vo-activated’ and ‘resting’ populations of 
cells (table 3.3). The activities in activated and resting, and thus in ‘mixed’ 
population were found to be similar in the case of each isoform. The PDE activities 
are given in the presence (table 3.3b.) and absence (table 3.3a.) of cyclic GMP.
In order to ascertain whether there was any PDE activity associated with the 
membrane fraction of murine thymocytes, further extraction of the pellet present 
after the cell lysis was carried out as outlined in section 2.1.5.1. No further PDE 
activity was found to be present in murine thymocytes membranes.
.3 .2 .I.2 . S ep ara tio n  of thym ocyte PDE activ ities by F P L C .
The presence of PDE2 and PDE4 activities in murine thymocytes was 
supported by studies carried out using ion exchange chromatography to resolve 
thymocyte PDEs, as described in section 2.1.6.3. These studies identified two 
peaks of cyclic AMP PDE activity (fig. 3.9a). The activity of the fii'st peak (Peak 
‘1’) was stimulated in the presence of lOjaM cyclic GMP (310 +/- 34% stimulation; 
n=3; errors are SEM) and was therefore identified as PDE2. The second peak of 
activity (peak ‘2’) was unaffected by cyclic GMP (95 +/- 8%; n=3; errors are SEM) 
or Ca^VCaM (96 +/- 14%; n=3; errors are SEM) (fig. 3.9a and fig. 3.9b) and was 
susceptible to inhibition by rolipram (92 +/- 2% inhibition; n=3; errors ai’e SEM)
(fig. 3.10). Upon closer analysis of the PDE profile obtained by this separation, 
studying fractions 31-80, there was no evidence for a peak of cyclic AMP PDE 
activity which could be inhibited by either cyclic GMP (fig. 3.9a and fig. 3.11a) or 
milrinone (fig. 3.11b) (95 +/- 8%; n=3; errors are SEM). Similarly, both peaks of
I
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cyclic AMP PDE activity were completely (>95%) inhibited by ImM IBMX, 
indicating the absence of a PDE7 activity (fig. 3.12).
3.2.1.3. Dose response curves of isolated PDE activities.
Dose response curves were carried out on pooled fractions of each peak of 
PDE activity, in order to demonstrate the specificity of the selective PDE inhibitors 
used in this study. Cyclic GMP-stimulated PDE activity was inhibited in a dose 
dependent manner by EHNA only in the presence of cyclic GMP (74-80%; range; 
n=3) compared with 11-17% (range; n=3) in the absence of cyclic GMP (fig.
3.13). No inhibition of PDE activity was observed upon addition of milrinone up 
to 50pM (fig. 3.14a). There was no inhibition by rolipram at lower concentrations, 
although appeared to cause a slight inhibition (15%) of PDE activity at 50pM, 
indicating that this inhibitor may be non-selective at this high concentration (fig. 
3.11b).
In the same way as described for peak ‘1’, peak ‘2’ fractions were pooled 
and dose response analysis of PDE inhibitors was earned out. PDE activity of peak 
‘2’ was shown to be selectively inhibited by rolipram (fig. 3.15), causing a 95% 
inhibition of activity at lOjiM with an IC50 of 50 +/- 1 InM (error is SEM; n=3). 
However, PDE activity in these fcactions was unaffected by milrinone (fig.3.16a), 
EHNA (fig. 3.16b).
3,2.2. Cyclic AMP PDE activities in lymphocytes from 4 week old 
m ice .
Lymphocytes were isolated from spleens of four week old Balb/c mice and 
separated into resting and in vivo activated cell populations, or T lymphocytes were 
purified by B cell depletion, as described in section 2.1.1. On studying the 
activities of cyclic AMP PDEs in these cells, it was noted that activated lymphocyte 
populations had a higher basal cyclic AMP PDE activity (assayed in the presence of 
IjiM  cyclic AMP) than the resting population (table 3.4). This may suggest a
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difference in the regulation of cyclic AMP degradation in activated cells, which may 
be of importance to the proliferation status of the cell (Epstein and Hachisu, 1984; 
Rochette-Egly and Kempf, 1981; Smith et aL, 1971). However, upon studying a 
B cell depleted ‘mixed" T  lymphocyte population, it was interesting to note that the 
PDE activity was not elevated. This indicated that the elevation of cyclic AMP PDE 
activity in in v/vo-activated lymphocytes may be due to the presence of in vivo- 
activated B lymphocytes.
Upon addition of a stimulatory concentration of cyclic GMP (lOjiM) there 
was a profound increase in cyclic AMP PDE activity which was similar to that
observed in thymocytes. However it was noted that the activation of PDE activity 
by cyclic GMP was at least 6  fold in lymphocytes, compared with about 3.5 fold in 
thymocytes (table 3.3). As outlined in table 3.4, no PDEl activity was found to be 
present on addition of Ca2+/CaM. This was similar to that seen in thymocytes 
(table 3.2 and fig. 3.12).
3.2.3. Cyclic AMP PDE activities in lymphoid cells from  12 week 
old mice.
Thymocytes and lymphocytes were isolated and PDE activities were 
determined in the presence and absence of cyclic GMP. Basal cyclic AMP PDE 
activity in murine thymocytes was found to be lower than that of lymphocytes (table 
3.5). However, the specific activities of in v/vo-activated and resting populations of 
thymocytes isolated from immunologically immature and mature mice did not differ 
(table 3.3 and table 3.5). However, in vzvo-activated lymphocytes isolated from 12 
week old mice did not have an elevated basal cyclic AMP PDE activity (table 3.5), 
which was noted in the in v/vo-activated population of lymphocytes isolated from 
immature mice (table 3.4).
Upon addition of cyclic GMP to cell extracts from mature mice, there was a 
pronounced stimulation of PDE activity in all of these cell populations (approx. 10 
fold). This was of interest, as it indicates that the capacity of cyclic GMP to
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stimulate cyclic AMP hydrolysis is greater in lymphoid cells isolated from mature 
mice than in immature mice. This increase in cyclic AMP PDE sensitivity to cyclic 
GMP is particularly pronounced in thymocytes. PDEl activity could not be 
detected in thymocytes isolated from twelve week old mice.
3.2.4. Cyclic AMP PDE activities in T3.2 thymoma cell line.
The T3.2 cell line was studied, as it was derived from a murine thymoma 
which undergoes apoptosis following ligation of its TCR. This cell line allowed 
comparisons to be made between primary thymocytes and proliferating cell lines. 
Also this cell line represented a homogeneous population of cells as it was derived 
from a defined population of thymocytes (expressing both CD4 and CD8 co­
receptors). Table 3.6a and table 3.6b outlines the cyclic AMP hydrolysing activities 
which were found to be present with the use of selective PDE isoform inhibitors.
Of particular interest in these cells was the lack of stimulation of total PDE activity 
in the presence of cyclic GMP (table 3.6a.). Indeed, addition of cyclic GMP lead to 
a reduction in PDE activity by about 20%. This does not necessarily indicate the 
absence of the cyclic GMP stimulated, PDE2 activity, but it does indicate that any 
cyclic GMP-stimulated activity that may be present was dominated by the presence 
of a PDE3, cyclic GMP-inhibited PDE activity.
The use of selective inhibitors revealed the presence of PDE2, PDE3 and 
PDE4 activities (table 3.6b.). The predominant activity present was the rolipram- 
sensitive PDE4 activity. This constituted over 50% of the activity in the absence in 
cyclic GMP. However, in direct contrast to primary thymocytes, the percentage of 
PDE4 activity increased on addition of cyclic GMP. The presence of a PDE3 
isoform was surprising, when one considers that this activity appears to be absent 
from primary thymocytes (fig. 3.11 and fig.3.14a). However, this may suggest 
that PDE2 and PDE3 activities are developmentally regulated within the thymus.
3.2.5. Cyclic AM P PDE activities in human T lym phocytes.
Upon analysis of the Jurkat leukemic T cell line, it was revealed that these 
ceils possessed a similar cyclic AMP PDE profile to the T3.2 thymoma cell line. 
Jurkat cells appeared to express PD El, PDE2, PDE3 and PDE4 activities (table 
3.6a. and table 3.6b.). In a similar manner to thymoma cells, following addition of 
cyclic GMP the total PDE activity was reduced by about 30%. The predominant 
activity in the Jurkat cell line was found to be a cyclic GMP-inhibited PDE activity. 
Rolipram inhibition of the Jurkat cell extract was small (approx. 6 %) indicating little 
or no PDE4 activity in unstimulated cells. IB MX (lOOjiM) inhibited about 80% of 
the total PDE activity, implying that the IBMX-insensitive PDE7 activity may be 
present. However, due to the competitive nature of IB MX as an inhibitor, the 
presence of PDE7 activity cannot be confirmed without further analysis. However, 
this isoform has been reported to be expressed in proliferating T cell lines (Bloom, 
1994; Ichimura and Kase, 1993). A Ca^VCaM-stimulated PDE activity was found 
to be present in the Jurkat cell line when PDE activity was assayed in the presence 
of stimulatory concentrations of Ca^VCaM (50jiM/20ng/ml) elevating PDE activity 
1.37 fold (Table 3.6a).
Additional studies in human tonsillar T cells were carried out to establish the 
effect of cyclic GMP on PDE activities in human cells. In a similar fashion to 
Jurkat cells, the addition of cyclic GMP caused a reduction in PDE activity of 
approximately 35% (Table 3.7). This was apparent in resting and in v/m-activated 
T cells. The absence of stimulated activity upon addition of cyclic GMP does not 
necessarily indicate the absence of a PDE2 isozyme, but it does strongly suggest 
the presence of a PDE3. This may indicate a species specific difference between 
murine and human primary cells. Similarities were apparent between human 
tonsillar T lymphocytes and the human T cell line, Jurkat (table 3.6 and table 3.7).
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3.3. D iscussion
It is clear from these studies that the major enzymes which provide cyclic 
AMP PDE activity in murine thymocytes are a rolipram-sensitive, PDE4 activity 
and an EHNA-inhibited, cyclic GMP-stimulated, PDE2 activity. The magnitude of 
the cyclic GMP-stimulated, PDE2 activity increased the cyclic AMP hydrolysis 
capabilities of the cell, by approximately 3.5 fold, in the presence of stimulatory 
cyclic GMP concentrations. Thus PDE2 forms the major portion of PDE activity 
within thymocytes. This stimulation of PDE activity by cyclic GMP was also 
evident in murine splenic lymphocytes. However the stimulation of PDE activity 
was nearer 8 fold in these cells, indicating an enormous potential for cyclic GMP to 
regulate the levels of cyclic AMP within murine lymphoid tissues. The expression 
of PDE2 activity in lymphocytes may confer maturity on these murine cells. A 
cyclic GMP-stimulated PDE activity has previously been identified in rat thymic
lymphocytes (Franks and MacManus, 1971; Valette et a l, 1990). A compaiison of 
the PDE activities present in the cell types studies here is summarised in table 3.8. 
These studies revealed that in v/vo-activted murine lymphocytes have an
elevated basal PDE activity in comparison to resting populations of cells. In the 
past, studies canied out in leukemic cells have established that these proliferating 
cells have elevated PDE activities (Epstein e ta l ,  1980; Epstein et a l,  1977; Hait 
and Weiss, 1979; Hait and Weiss, 1976). One possible reason for the proliferation 
of these cells may be a lesion in cyclic AMP metabolism. Sustained increases in 
cyclic AMP levels within lymphocytes have been shown to be inhibitory to the 
induction of proliferation at a number of stages in T cell proliferation (see section 
1.6.1). Therefore it may be that upon receiving a proliferative signal, lymphocytes
elevate their PDE activities, and once in the proliferative state, the regulation of PDE
■
activities may be uncoupled, thus maintaining a lower level of cyclic AMP.
In murine thymocytes, Ca^VCaM-stimulated, PDEl activity, cyclic GMP- 
inhibited, PDE3 activity and IBMX-insensitive, PDE7 activity did not provide any 
significant basal activity. This was suiprising, as both rat thymocytes and primary
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human lymphocytes have been shown to express a PDE3 activity, implying species 
specific differences in the distribution of PDE activities in lymphoid tissue (Franks 
and MacManus, 1971; Marcoz et a l,  1993; Meskini et a l, 1992; Robicsek et a l,
1991; Valette et a l,  1990) (table 3.8). Moreover, studies earned out in the 
leukemic T cell line Jurkat, identified a cyclic GMP-inhibited PDE3 activity, which 
constituted the majority of basal PDE activity in these cells. This PDE3 activity 
also appears to be present in human primary T cells isolated from tonsils. Jurkat 
cells were also shown to contain a cyclic GMP-stimulated PDE2 activity and a 
rolipram-sensitive PDE4 activity. Therefore, it appears that cyclic GMP plays an 
opposing role in the regulation of cyclic AMP hydrolysis in lymphoid cells from 
the two species. This may lead to very divergent biological responses as a 
consequence of cyclic GMP elevations.
The study of murine T3.2 thymoma cells was therefore interesting, as it
,was found that upon addition of cyclic GMP there was a decrease in PDE activity, 
similar to that seen in human T cell models studied. This suggested the presence of 
PDE3 activity in T3.2 cells. This cell line is a thymoma derived firom the 
CD4+/CD8‘^  stage of thymocyte development. It is possible that alterations in PDE 
isoform expression reflect changes due to cell transformation or differences in 
thymocyte maturation state. Indeed, it has been shown that PDE expression 
changes upon alteration of the proliferation status of lymphoid cells (Takemoto et 
a l,  1979; Takemoto et a l ,  1978). However the situation presented here indicates 
that PDE3 activity is gained not lost (Takemoto et a l, 1979), upon proliferation.
However the resulting aberrant regulation of cyclic AMP may be partially 
responsible for the uncontrolled proliferation of the cells.
Consistent with our finding that Ca^VCaM-stimulated, PDEl activity was 
absent in murine thymocytes and lymphocytes, and human tonsillar T cells, this 
activity has also been reported to be absent in rat splenic lymphocytes (Hait and 
Weiss, 1977), rat thymocytes (Valette e ta l ,  1990), human and bovine peripheral 
blood lymphocytes (Hurwitz et a l,  1990; Thompson et a l,  1976) and human
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monocytes (Thompson eta l., 1980). Intriguingly, however, PDEl activity has 
been shown to be induced by the mitogenic lectin, PHA after 14 hours of 
stimulation o f these peripheral blood lymphocytes (Hurwitz eta l., 1990). Hurwitz 
et al. showed that PDEl activity remained elevated for at least 100 hours following 
stimulation. Rapid induction of PDEl has also been reported in Chinese hamster 
ovary (CHO) cells in response to the PKC activator, PMA (Spence et al., 1995).
In the light of this, it is interesting to note that PDEl activity was found to be 
present in the proliferating T cell line Jurkat and has been found to be present in a 
B-lymphoblastoid cell line derived from a patient with acute lymphocytic leukaemia 
(Epstein et al., 1987). However the inability to detect PDEl activity in primary 
lymphoid cells might be due either to the loss of Ca^+ZCaM-dependent activity 
through proteolysis or to the binding of endogenous CaM by the PDE, thus 
preventing detection of a stimulation of PDE activity upon addition of exogenous 
Ca^VCaM (Epstein et al., 1980). Indeed, steps were taken to ensure that 
proteolysis was limited by using a ‘protease inhibitor cocktail’ upon lysing the cells 
(see section 2.1.5.1). Experiments were also carried out in the presence of EGTA, 
a Ca^”^ chelator, to remove endogenous calcium, ensuring that any Ca^VCaM 
stimulated activity could be activated with the addition of exogenous Ca^frCaM. 
However, no stimulation of PDE was detected in the presence of EGTA, 
suggesting that PDEl activity was absent from these cells.
Cyclic GMP increases cyclic AMP PDE activity in a dose-dependent 
manner in murine thymocytes extracts, indicative of a cyclic GMP-stimulated 
activity. The pattern of cyclic AMP hydrolysis in the presence of increasing 
concentrations of cyclic GMP was similar to that seen in calf liver (Wada et al., 
1987) and rat liver (Pyne et al., 1986). Cyclic GMP-stimulated PDE activity has 
also been observed in rat thymocytes. However, this activity was only observed at 
higher concentrations of cyclic AMP (lOqM), with a maximal stimulation of PDE 
activity seen at approximately lOp-M cyclic GMP (Franks and MacManus, 1971). 
At l|iM  cyclic AMP, rat thymocyte PDE activity was inhibited by increasing
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i
. .amounts of cyclic GMP due to the presence of a PDE3 activity. This implies that Imurine thymocytes lend themselves to the study of cyclic GMP-stimulated PDE 
activity, as they do not have the ‘interference’ of a PDE3 activity complicating the 
interpretation o f the results. Inhibition of cyclic AMP hydrolysis at higher levels of 
cyclic GMP (20|iM) was probably due to cyclic GMP competing with cyclic AMP
S'
at the catalytic site (Wada et a l,  1987), but may also be due to competitive 
inhibition of the conversion of cyclic AMP to 5 ’-AMP (Pyne et al., 1986).
EHNA inhibited PDE activity in thymocyte extracts and the cyclic GMP- 
stimulated PDE activity fractions in a dose-dependent manner, in the presence and
I
absence of cyclic GMP. The inhibition was however greater in the presence of 
cyclic GMP. This suggested that at maximally effective concentrations of EHNA 
the stimulation of PDE activity induced by cyclic GMP could be entirely ablated. 
Thus indicating that EHNA may serve to prevent the stimulatory action of cyclic 
GMP, perhaps by competing with cyclic GMP for binding of the allosteric site.
This is consistent with our observations that EHNA produced a small inhibition of 
PDE2 activity in the presence of cyclic AMP alone. At concentrations up to 50|iM, 
rolipram did not inhibit the PDE2 fraction of activity, indicating that at 10|iM 
rolipram the only PDE activity being inhibited is the PDE4 poition of activity. 
Milrinone did not inhibit PDE2 activity. Milrinone and EHNA did not effect the 
cyclic AMP PDE activity in the PDE4 peak of activity in murine thymocytes, 
indicating that the PDE inhibitors were selective.
Rolipram elicited a dose-dependent inhibition on cyclic AMP hydrolysis in 
murine thymocytes indicating the presence of a rolipram-sensitive PDE activity in 
these cells. The I C 5 0  of this enzyme is comparable with PDE4 activities from other 
sources (Shakur era/., 1993; Sullivan era/., 1994). The particular isoform of 
PDE4 present in thymocytes is currently unknown. However, mRNA of PDE4B 
has been isolated in a human lymphocytic B cell line (Obemolte et a l,  1993). This 
transcript was absent from unstimulated Jurkat cells, where only PDE4A mRNA 
was identified when tested for the four isoforms (Engels et al., 1994). This may
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illustrate another example of lineage specific PDE expression in lymphoid cells (see 
above and (Ichimura and Kase, 1993)).
Upon addition of IBMX to Jurkat cell extracts, about 20% of the total PDE 
activity remained. This observation, coupled with previous reports (Bloom, 1994; 
Ichimura and Kase, 1993) indicated the presence of the IBMX- and rolipram- 
insensitive PDE7 activity in Jurkat cells. Due to the competitive nature of this 
inhibitor, one would not expect to observe a complete inhibition of PDE activity, so 
whilst PDE7 activity may be present in Jurkat cells, it does not constitute a fifth of
absent from human B cell lines and in human promyelocytic cell line HL-60
i
the PDE activity in these cells. Interestingly, a rolipram-insensitive PDE activity 
has also been reported in other human T cell lines. However it was found to be
(Ichimura and Kase, 1993). This finding contrasted with murine thymocytes 
where IBMX fully inhibited cyclic AMP PDE activity. This indicates a lineage- 
specific difference in the expression of cyclic AMP PDE activities.
The findings presented here identify the predominance of PDE4 and PDE2 
isoforms in murine thymocytes and lymphocytes. This may suggest the existence 
of a molecular ‘switch’, which is responsive to intracellular cyclic GMP levels and 
could be expected to have a profound effect on the control of cyclic AMP 
metabolism within these cells. At concentrations of cyclic GMP which are too low 
to stimulate PDE2 activity, the predominant PDE species involved in the hydrolysis 
of cyclic AMP in thymocytes/lymphocytes would be the PDE4 activity. However, 
under conditions where cyclic GMP levels become elevated, such as through the 
stimulation of soluble guanylyl cyclase via NO (Moncada et al., 1991), then a 
dramatic increase in PDE2 activity may become apparent. This may be relevant to 
the control of apoptosis within thymocytes, and is discussed further in section
4 .3 .4 .
These studies indicate that cyclic AMP PDE activities in primary murine
.lymphocytes and thymocytes appear to be highly sensitised to changes in .,'j|
intracellular cyclic GMP levels. These studies also highlight the differences that
.1
   -  .    . ...  .
exist in different populations of T cells with respect to cyclic AMP hydrolysis and 
may have a direct effect on the role which cyclic GMP and calcium has in the 
regulation of cyclic AMP hydrolysis.
1 3 3
Table 3.1. Summary of IC50 values o f cyclic AM P PDE 
inhibitors for cyclic AMP PDE activities.
This table summarises information about cyclic AMP PDE 
inhibitors, concerning their selectivity for particular isoforms of activity. 
The values given represent I C 5 0  values (|iM) (the concentration at which 
50% inhibition of PDE activity has ensued). The values have been 
gathered from different tissue and species sources. The references cited 
are as follows:
^ Hoey and Houslay, 1990,  ^Weishaar et al,, 1986,
Harrison et al., 1986, ^ Kithas et al., 1988,
® Valette et al., 1990,  ^Mery et al., 1995, 
s Lavan et al., 1989,  ^H idaka and Endo, 1984,
 ^Yamamoto et al., 1983b, J Weishaar et al., 1987,
^ Manganiello et a i ,  1992,  ^Schwabe et al., 1976,
^  Torphy and Cieslinski, 1990, “ Henkel-Tigges and Davis, 1989,
° W ilson et al., 1994a, p Shakur et al., 1993,
9 Livi et al., 1990,  ^M ichaeli et al., 1993, 
s Spence et al., 1995,  ^Mery et al., 1995,
 ^Podzuweit et al., 1995,  ^Pyne et al., 1986,
Decourcelles et al., 1992,  ^Conti et al., 1995a, 
y McLaughlin et al., 1993,  ^Bolger et al., 1993.
NI=not inhibited;
ND=not determined.
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Table 3.2. Assessment of PD El activity in thymocytes.
PDE assays were performed in the presence of IpM  cyclic AMP 
as substrate, as described in ‘Materials and Methods’. Stimulatory 
concentrations of Ca^VCaM was added to the thymocyte extract, and 
fold stimulation of PDE activity was assessed. This was carried out in 
the presence and absence of EGTA (ImM). The data presented are from 
single experiments representative of three separate experiments. Assays 
were carried out in triplicate (errors are SEM). PDE activity is 
expressed as pmols cyclic AMP hydxoiysed/min/mg protein.
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Table 3.3. Basal PDE activities o f thym ocytes isolated  
from  4 week old Balb/c mice.
The cells were prepared, and the PDE assays were carried out as 
described in ‘Materials and Methods’. PDE assays were performed 
with l|iM  cyclic AMP as substrate. Table A shows the PDE activities in 
the absence of stimulatory concentrations (lOpM) of cyclic GMP.
PD E l activity was expressed as the fold stimulation on addition of Ca^+ 
/CaM  to thymocyte extract. PDE2 activity was assessed as a percentage 
o f inhibited PDE activity on addition of 10p.M EHNA. PDE3 activity 
was assessed as the percentage inhibition of PDE activity on addition of 
5jiM milrinone. PDE4 activity was assessed as a percentage inhibition 
of PDE activity on addition of lOpM rolipram. PDE7 activity was 
expressed as the percentage activity remaining after the addition of 
lOOp-M IBMX.
In the presence of lOjiM cyclic GMP, table B shows the fold 
stimulation of PDE activity upon addition of cyclic GMP. The selective 
inhibitors were used in the same way as described above to calculate the 
relative PDE activities in miuine thymocytes. The data is the average of 
at least four separate experiments. Assays were carried out in triplicate 
(errors are SEM). Specific activity is expressed as pmols cyclic AMP 
hydrolysed/min/mg protein). Percentages are calculated as the average 
of percentage inhibition/stimulation from each separate experiment.
ND“  not determined.
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Table 3.4. Basal PDE activities of lym phocytes and T cells 
isolated from 4 week old Balb/c mice.
The cells were prepared, and the PDE assays were carried out as 
described in ‘Materials and Methods’. PDE assays were performed 
with l|aM  cyclic AMP as substrate. Specific activities were assessed in 
the presence or absence of stimulatory concentrations (lOpM) of cyclic 
GMP. The fold stimulation of PDE activity upon addition of cyclic 
GMP or Ca^+/CaM was assessed. The data is the average of at least 
three separate experiments. Assays were carried out in triplicate (errors 
are SEM). Specific activity is expressed as pmols cyclic AMP 
hydrolysed/min/mg protein). Percentages are calculated as the average 
of percentage stimulation from each separate experiment.
137
•J3
oo
l i
COCO CN
oo
(N
ooo\
4Itiî bo
Table 3.5. Basal PDE activities of thym ocytes and  
lym phocytes isolated from  12 week old Balb/c m ice.
The cells were prepared, and the PDE assays were carried out as 
described in ‘Materials and Methods’. PDE assays were performed 
with IfiM cyclic AMP as substrate. Specific activities were assessed in 
the presence or absence of stimulatory concentrations (lOjJ-M) of cyclic 
GMP. The fold stimulation of PDE activity upon addition of cyclic 
GMP or Ca2+/CaM was assessed. The data is the average of at least 
three separate experiments. Assays were carried out in triplicate (errors 
are SEM). Specific activity is expressed as pmols cyclic AMP 
hydrolysed/min/mg protein). Percentages are calculated as the average 
of percentage stimulation from each separate experiment.
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Table 3.6. Basal PDE activities of Jurkat T cell lym phom a  
and T3.2 thymoma cell lines.
The cell lines were maintained and the PDE assays were carried 
out as described in ‘Materials and M ethods’. PDE assays were 
performed with l}xM cyclic AMP as substrate. In table A, specific 
activities were assessed in the presence or absence lOjiM cyclic GMP. 
The percentage inhibition of PDE activity upon addition of cyclic GMP 
was assessed. PDEl activity was expressed as the fold stimulation on 
addition of Ca^+/CaM to thymocyte extract. In table B, PDE2 was 
expressed as the difference between the activity ‘inhibited’ by cyclic 
GMP and the activity inhibited by 5|iM  milrinone. PDE3 activity was 
assessed as the activity which was inhibited by 5|iM  milrinone. PDE4 
activity was assessed as the activity inhibited on addition of 10|iM 
rolipram. PDE7 activity was the remaining after the addition of lOOjxM 
IBMX. The data is the average of four separate experiments. Assays 
were carried out in triplicate (errors are SEM). Specific activity is 
expressed as pmols cyclic AMP hydrolysed/min/mg protein). 
Percentages are calculated as the average of percentage inhibition from 
each separate experiment.
ND= not determined.
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Table 3.7. Basal PDE activities of human tonsillar T 
lym p h o cy tes .
The cells were isolated and the PDE assays were carried out as 
described in ‘Materials and Methods’. PDE assays were performed 
with IfiM cyclic AMP as substrate. Specific activities were assessed in 
the presence or absence of lOpM cyclic GMP. The percentage 
inhibition of PDE activity upon addition o f cyclic GMP was assessed. 
PD El activity was expressed as the fold stimulation on addition of 
Ca^+/CaM to the T lymphocyte extract. The data is the average of 
three separate experiments. Assays were carried out in triplicate (errors 
are SEM). Specific activity is expressed as pmols cyclic AMP 
hydrolysed/min/mg protein). Percentages are calculated as the average 
of percentage inhibition from each separate experiment.
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Table 3.8. Summary o f cyclic AMP PDE isoforms present 
in the lym phoid cells studied.
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Figure 3.1. Structure of cyclic AMP and non-
selective PDE inhibitor, IBMX.
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Figure 3.2. Structure of PDE3 selective inhibitors.
Shown are the structures of amrinone [5-amino-(3’,4’- 
bipyridin)-6(lH0-one], milrinone [l,6-Dihydro-2-methyi-6-oxo- 
(3,4’-bipyridine)-5-carbonitrile] and cilostamide [4,5-dihydro-6 
[4-( IH-imadazol- 1 -yl)phenyl] -5-methyl-3(2H)-pyrazone].
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Figure 3.3. Structure of PDE4 selective inhibitors.
Shown are the structure of rolipram [4-{3-(cyclopentoxyl)- 
4-methoxyphenyl}-2-pyrrolidone] andRo20-1724 [4-(Butoxy-4- 
methoxybenzyl)-2 -imidazolidinone].
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Figure 3.4. Identification of PDE4 activity in thym ocytes: 
Inhibition by rolipram.
PDE assays were performed in the presence of cyclic AMP 
as substrate, as described in ‘Materials and M ethods’. The dose 
dependent inhibition of cyclic AMP hydrolysis by rolipram is shown; a) 
in the absence of lOfiM cyclic GMP and b) in the presence o f lOjiM 
cyclic GMP. The data presented are from single experiments 
representative of three separate experiments. Assays were carried out 
in triplicate (errors are SEM). PDE activity is expressed as pmols 
cyclic AMP hydrolysed/min/mg protein).
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Figure 3.5. Identification o f PDE2 activity in thymocytes: 
A ctivation by low concentrations o f cyclic GMP.
PDE assays were performed in the presence of l|iM  cyclic AMP 
as substrate, as described in ‘Materials and Methods’. The dose 
dependent action of cyclic GMP is shown. The data presented are from 
single experiments representative of three separate experiments. Assays 
were carried out in triplicate (errors are SEM). PDE activity is 
expressed as pmols cyclic AMP hydrolysed/min/mg protein).
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Figure 3.6. Identification of PDE2 activity in thymocytes: 
Inhibition by EHNA.
PDE assays were performed in the presence of l|iM  cyclic AMP 
as substrate, as described in ‘Materials and M ethods’. The dose 
dependent inhibition of PDE activity by EHNA is shown for assays 
done in the presence of stimulatory concentrations (lOjiM ) of cyclic 
GMP. The data presented are from single experiments representative of 
three separate experiments. Assays were carried out in triplicate (errors 
are SEM). PDE activity is expressed as pmols cyclic AMP 
hydrolysed/min/mg protein).
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Figure 3,7. Dose response o f thym ocyte PDE activity by 
m ilr in on e.
PDE assays were performed in the presence of lp,M cyclic AMP 
as substrate, as described in ‘Materials and Methods’. The dose- 
dependent action of milrinone on cyclic AMP hydrolysis is shown, a) in 
the absence of 10p.M cyclic GMP and b) in the presence of 10|iM cyclic 
GMP. The data presented are from single experiments representative of 
three separate experiments. Assays were carried out in triplicate (errors 
are SEM). PDE activity is expressed as pmols cyclic AMP 
hydrolysed/min/mg protein).
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Figure 3.8. Dose-dependent inhibition of thym ocyte PDE  
activity by IBM X.
PDE assays were performed in the presence of l|iM  cyclic AMP 
as substrate, as described in ‘Materials and Methods’. The dose 
dependent inhibition of cyclic AMP hydrolysis by IBMX is shown, a) 
in the absence of 10|xM cyclic GMP and b) in the presence of lOpM 
cyclic GMP. The data presented are from single experiments 
representative of three separate experiments. Assays were carried out in 
triplicate (errors are SEM). PDE activity is expressed as pmols cyclic 
AMP hydrolysed/min/mg protein).
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Figure 3.9. FPLC analysis of a soluble thym ocyte extract 
using ion exchange chrom atography (M onoQ).
This was carried out as described in ‘Materials and Methods’, 
1ml fractions were collected over a 120ml gradient, alternate fractions 
were assayed. PDE activity was assessed using l|iM  cyclic AMP as 
substrate; a) in the absence (circles) and presence (diamonds) of 
stimulatory concentrations of cyclic GMP and b) in the absence (circles) 
and presence (triangles) of Ca^^/CaM (50|aM/20ng/ml). Peak 1 activity 
is stimulated in the presence of stimulating concentrations (lOpM) of 
cyclic GMP. Peak 2 is activated in the presence or absence of cyclic 
GMP or Ca^+/CaM. PDE activity is expressed as cpm. The data 
presented are from single experiments representative of results obtained 
three times.
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Figure 3.10. FPLC analysis of a soluble thym ocyte extract 
using ion exchange chrom atography (MonoQ): The 
assessm ent of PDE4 or PDE7 activity.
This was carried out as described in ‘Materials and Methods’. 
1ml fractions were collected over a 120ml gradient, alternate fractions 
were assayed. PDE activity was assessed using IpM  cyclic AMP as 
substrate in the absence (circles) of presence (squares) of inhibitory 
concentrations of PDE4 selective inhibitor rolipram. PDE activity is 
expressed as cpm. The data presented are from single experiments 
representative of results obtained tliree times.
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Figure 3.11. FPLC analysis of a soluble thym ocyte extract 
using ion exchange chromatography (MonoQ): The 
assessm ent of PDE3 activity.
This was carried out as described in ‘Materials and Methods’. 
1ml fractions were collected over a 120ml gradient, and fractions 31-80 
were assayed, PDE activity was assessed using IjiM  cyclic AMP as 
substrate a) in the absence (circles) and presence (diamonds) of 
stimulatory concentrations of cyclic GMP. Peak 1 activity is stimulated 
in the presence of stimulating concentrations (10 |0,M) of cyclic GMP. 
Peak 2 is activated in the presence or absence of cyclic GMP. b) PDE 
activity was assessed in the absence (circles) or presence (triangles) of 
5pM milrinone, the PDE3 selective inhibitor. PDE activity is 
expressed as cpm. The data presented are from single experiments 
representative of results obtained three times.
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Figure 3.12. FPLC analysis o f a soluble thym ocyte extract 
using ion exchange chrom atography (MonoQ): The 
assessm ent of PDE7 activity
This was carried out as described in ‘Materials and Methods’. 
1ml fractions were collected over a 120ml gradient, and fractions 31-80 
were assayed. PDE activity was assessed using l|iM  cyclic AMP as 
substrate in the absence (circles) of presence (crosses) of inhibitory 
concentrations of non-selective inhibitor IBMX. PDE activity is 
expressed as cpm. The data presented are from single experiments 
representative of results obtained tliree times.
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Figure 3.13. Dose-dependent inhibition o f peak 1 PDE 
activity  with EHNA.
Samples eluted in fractions 55-60 were pooled. PDE assays 
were performed in the presence of IjiM  cyclic AMP as substrate, as 
described in ‘Materials and Methods’. The dose dependent inhibition of 
PDE activity by EHNA is shown for assays carried out a) in the 
presence and b) the absence of stimulatory concentrations of cyclic 
GMP. The data presented are from single experiments representative of 
tliree separate experiments. Assays were carried out in triplicate (errors 
are SEM). PDE activity is expressed as percentage of control ie. in the 
absence of cyclic GMP (100%).
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Figure 3.14. Dose-dependent action of milrinone or
rolipram on peak 1 PDE activity.
Samples eluted in fractions 55-60 were pooled. PDE assays 
were performed in the presence of l(iM  cyclic AMP as substrate, as 
described in ‘Materials and Methods’. The dose dependent action of a) 
milrinone on PDE activity in peak 1 and of b) rolipram on PDE activity 
in peak I was assessed. The data presented are from single 
experiments representative of three separate experiments. Assays were 
carried out in triplicate (errors are SEM). PDE activity is expressed as 
percentage of control ie. without inhibitors (10 0%).
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Figure 3.15. D ose-dependent inhibition o f rolipram  on 
peak 2 PDE activity.
Samples eluted in fractions 71-73 were pooled. PDE assays 
were performed in the presence of l|iM  cyclic AMP as substrate, as 
described in ‘Materials and Methods’. The dose dependent inhibition of 
PDE activity by rolipram on peak 2 is shown. The data presented are 
from single experiments representative of three separate experiments. 
Assays were carried out in triplicate (errors are SEM). PDE activity is 
expressed as percentage of the control ie. without rolipram (10 0%).
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Figure 3.16, Dose-dependent action o f m ilrinone or EHNA  
on peak 2 PDE activity.
Samples eluted in fractions 71-73 were pooled. PDE assays 
were performed in the presence of l|iM  cyclic AMP as substrate, as 
described in ‘Materials and Methods’. The dose dependent action of a) 
milrinone on PDE activity in peak 2 and of b) EHNA on PDE activity in 
peak 2 was assessed. The data presented are from single experiments 
representative of three separate experiments. Assays were carried out in 
triplicate (errors are SEM). PDE activity is expressed as percentage of 
control ie. without inhibitors (100%).
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CHAPTER 4.
REGULATION OF CYCLIC AMP PDEs FOLLOW ING  
LIGATION OF THE TCR/CD3 COMPLEX.
Î
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4.1. Introduction.
It is well established that following ligation of the TCR/CD3 complex,.the 
activation of PTKs such as and results in the rapid tyrosine
phosphorylation, recruitment and activation of key signal transducers such as the 
inositol phospholipid-specific PLCy-1 (June et al., 1990a; Secrist et al., 1991;
Weiss and Littman, 1994). Hydrolysis of PIP2 generates the second messengers,
IP3 and DAG leading to a release of calcium from intracellular stores and the 
activation of PKC. Other signalling events, downstream of PTK activation include 
the recruitment of the PI-3-K (Rudd et al., 1994), p2P^^ (Downward et al., 1992) 
and MAPK (Nel e ta i ,  1991; Siegel e ta l ,  1990) signalling cascades (see section
-1.2.4).
As mentioned previously (see section 1.4), a central problem yet to be 
resolved in T cell signalling is how the TCR transduces differential signals in a 
maturation state-dependent manner (Hueber et al., 1994). Proliferation and 
differentiation into effector cells occurs upon ligation of the TCR in mature cells.
However, within the thymus, TCR-derived signals in developing thymocytes can 
result in proliferation (selection) or programmed cell death (apoptosis) depending 
on the antigen specificity of the TCR (Hueber et a l, 1994; Kaye and Ellenberger,
1992). The molecular mechanisms underlying these biological responses are, as
:yet, poorly understood. However, it has been proposed that the TCR may be 
partially uncoupled from PTK activation, tyrosine phosphorylation of PLCy-1 and
;calcium mobilisation in immature thymocytes upon ligation (Finkel et al., 1991;
Sancho et al., 1992). This ultimately leads to immunological unresponsiveness due 
to a lack of IL-2 receptor expression, IL-2 secretion and proliferation (Finkel et al.,
1991; Ramarli et al., 1987). In addition, elevation of cyclic AMP levels has been 
implicated in both the differentiation of early thymocytes (Bach et al., 1975; Scheid 
et al., 1975) and the stimulation of thymic apoptosis (Kaye and Ellenberger, 1992;
McConkey et al., 1990a). It is possible, therefore, that cyclic AMP may play a
. ;
pivotal role in thymocyte maturation and/or cell death. As such, the regulation of
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cyclic AMP hydrolysis by cyclic AMP PDEs may provide a route for achieving 
such a process. There is very little evidence concerning the early changes in cyclic 
AMP PDE activity occurring upon ligation of the TCR/CD3 complex. However, 
there is some evidence which suggests that these enzymes may play a central role in 
regulating cyclic AMP levels during lymphocyte activation and cell cycle 
progression (Epstein et al., 1980; Hurwitz et al., 1990; Marcoz et al., 1993;
Meskini et al., 1992). There is a growing interest in the roletl^atspecific PDE 
isoforms may play in the maturation, proliferation and cell death of lymphocytes.
Anti-CD3 monoclonal antibodies and mitogenic lectins have been shown to 
be extremely useful in deciphering signalling pathways which lead to T cell
- ;•proliferation. In vivo, T lymphocytes are activated by antigen presented in the 
context of processed peptide in self MHC molecules on the surface of antigen 
presenting cells. Such an interaction involves the recognition of the antigen by a 
TCR/CD3 complex. In vitro, T cells can be activated not only by antigen on 
appropriate antigen-presenting cells, but also by ligands that interact with the 
TCR/CD3 complex. These interactions can be provided by monoclonal antibodies 
that are raised against specific epitopes on TCR/CD3 complex or by mitogenic 
lectins.
Mitogens are a class of molecule which can activate T or B cells in a non- 
antigen-specific polyclonal manner. The majority of human and mouse T cells can 
be stimulated by phytohaemagglutinin (PHA), extracted from red kidney beans 
(Phaseolus vulgaris), and concanavalin A (Con A), extracted from castor beans.
Since PHA was first discovered to induce blast transformation in normal leukocytes 
(Nowell, 1960), mitogenic stimulation has been studied extensively as a model for 
antigenic activation and growth control. It has been shown that lectins bind specific 
glycoproteins on the cell surface of the cells leading to polyclonal stimulation of 
lymphoid cells. Initial events in lectin-induced activation include; tyrosine 
phosphorylation (Hirata et al., 1984), calcium influx (Coffey et al., 1981; Parker et 
al., 1979) and inositol phosphate production (Taylor et a i ,  1984). Early studies
I
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Ialso indicated fluctuations in cyclic nucleotide levels (Hadden et a l,  1972;
Krishwaraj and Talwar, 1973; Wedner et al., 1975). Analysis of the mechanisms 
underlying PHA-stimulation of proliferation in both peripheral T cells and Jurkat 
cells, has shown that two signals were required in order to obtain IL-2 
production from these cells (Weiss et al., 1984b). The first involved ligation of the 
TCR/CD3 and the second was provided by accessory cells, CD28 ligation, or could 
be in the form of the phorbol ester, phorbol-12- myristate, 13-acetate (PMA)
(Imboden et al., 1985; Sperling et al., 1993; Weiss et al., 1984b; Weiss et al.,
1986b). Thus, Jurkat cells produce IL-2 upon addition of PMA in combination 
with the ligation of the TCR/CD3 complex. IL-2 production also occurred in the 
presence of PHA and PMA (Weiss et al., 1984b). In contrast, mutants of Jurkat 
cells that did not express the TCR/CD3 complex were unable to produce IL-2 in 
response to PHA and PMA (Weiss et al., 1984b; Weiss and Stobo, 1984). This 
indicates that the TCR/CD3 complex is necessary for T cell activation via PHA.
Such a notion was confirmed when the TCR/CD3 complex was reconstituted back 
into the mutant Jurkat cell line, thus restoring its ability to respond to PHA and 
PMA . These data strongly support the contention that the mitogenic action of PHA 
requires its direct or indirect interaction with the T cell antigen receptor. Evidence 
now suggests that PHA binds with the afT C R  region of the receptor 
(Kanellopoulos et al., 1985). CD2 (sheep red blood cell receptor) has also been 
described to be a receptor for PHA (O'Flynn et al., 1985). This is of relevance to 
this study, as CD2 is expressed during the early stages of thymic development (Fox
'et al., 1985), present on 85-95% of all developing T cells (Lanier et al., 1986;
Sewell et al., 1986) and has been suggested to play an essential role in the 
signalling pathways of TCR/CD3” immature thymocytes (Fox etal., 1985; O’Flynn 
et al., 1985).
Monoclonal antibodies raised against discrete epitopes of lymphocyte 
surface receptors have been shown to be useful tools that can be used to delineate 
signalling pathways during the activation of T cells (Oettgen and Terhorst, 1987;
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Weiss and Winchurch, 1978). These have an advantage over mitogenic lectins, as 
they recognise a single cell surface receptor, as opposed to the lack of specific 
interaction seen with lectins. Antibodies directed against either the apTCR 
heterodimer or CD3 complex cause a diverse range of responses. These include, 
increased tyrosine phosphorylation, increased PIP2 hydrolysis, PKC activation, the 
release of intracellular calcium release, calcium influx, a transient increase in cyclic 
AMP concentrations and IL-2 receptor induction and display. Studies by Ledbetter
..i
et a l  (1986) demonstrated that the use of monoclonal antibodies raised against CD5 
and CD28 can mimic the actions of accessory cells. This is because they induce IL-
i2  production and subsequent proliferation when used in concert with anti-CD3 
antibodies. This suggests that the study of T cell signalling and activation with 
monoclonal antibodies may result in a response which can be compared to a 
physiological response.
I
4.1.1. Aims and objectives.
With the use of monoclonal antibodies (mAbs) directed against specific 
components of the TCR and the mitogenic lectin PHA, the regulation of cyclic AMP 
PDE activities were studied, focusing mainly on murine thymocytes. However 
comparisons have been drawn between these cells and the proliferating Jurkat T cell 
line. Data are discussed in relation to cyclic AMP metabolism and the development 
of T cells.
4.2, R esults.
4.2.1. Cyclic AMP PDE activities following stim ulation of murine 
thym ocytes with PHA.
Stimulation of murine thymocytes isolated from four week old Balb/c mice 
with mitogenic concentrations of PHA (50p,g/ml) induced a rapid and dramatic 
decrease in PDE activity assayed at IpM  cyclic AMP (fig. 4.1a and 4.1b). A 
reduction of approximately 80% in total cellular cyclic AMP PDE activity was 
observed within 5 minutes of addition of PHA. Analysis of the rolipram inhibited 
component of this activity (fig. 4.1a and 4.1b) revealed that the decrease was due 
primarily to a reduction in the PDE4 activity. However, this decline in activity was 
only transient as, 7 minutes after PHA addition, PDE activity began to slowly rise. 
PDE activity had reached 60-70% of basal activity after 20 minutes of challenge 
with PHA.
Analysis of thymocyte PDE activity in the presence of stimulatory 
concentrations of cyclic GMP identified an immediate, but again transient, decrease 
in PDE activity (fig. 4.2). This transient decrease was also evident in analysis of 
PDE2 activity assessed as the cyclic GMP-stimulated component (fig. 4.2). Within 
5 minutes of challenge with PHA, PDE2 activity fell to around 61% of its basal 
activity. However, unlike the PDE4 activity, the PDE2 component had regained its 
starting level after about 7 minutes. This level of activity was maintained for at least 
20 m inutes (fig. 4.2). Essentially similar results were obtained on analysis of 
activated (figs. 4.1a and 4.2a) and resting (figs. 4.1b and 4.2b) populations of 
cells, when thymocytes were stimulated with PHA.
PHA was shown therefore, to induce rapid inhibitory effects on both PDE2 
and PDE4 activities. The PDE2 activity reduction was extremely transient on 
addition of PHA (fig. 4.2), whereas the reduction in PDE4 activity was slower to 
recover, not re-gaining basal levels until 20 minutes after PHA challenge (fig. 4.1). 
Over this 20 minute period of challenge with PHA, PD El, PDE3 and PDE7 
activities were not evident (table 4.1).
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4.3a, 4.4a, 4.5a and 4.6a) and resting cells (figs. 4.3b, 4.4b, 4.5b and 4.6b).
4.2.3. Cyclic AMP levels in PHA stim ulated thymocytes.
i
4.2.2. Cyclic AMP PDE activities following stim ulation of m urine 
thym ocytes with anti-CD3 and anti-TCR antibodies.
Stimulation of thymocytes with anti-CD3 and anti-TCR mAbs appeared to 
cause a small transient decrease in PDE activity, assayed with IqM  cyclic AMP 
(figs. 4.3 and 4.5). This was rapidly followed by a substantial and sustained 
increase in PDE activity. Such changes could be attributed predominantly to the 
PDE4 activity because the activity was almost entirely abrogated (approx. 80%) by 
rolipram treatment. In striking contrast to the pattern of PDE responses observed 
with PHA, the initial small, transient inhibition of PDE activity caused by anti-CD3 
and anti-TCR antibodies was followed by a profound increase in the PDE4 activity. 
This PDE activity was elevated 2-2.5 fold over the basal activity 20 minutes after 
challenge with anti-CD3 or anti-TCR mAbs (P<0.05; n=3) (Figs 4.3 and 4.5). 
Similar results were obtained using both soluble and crosslinked anti-CD3 
antibodies (fig. 4.7). This implies that the differences observed between these 
responses and those seen with PHA cannot be attributed to differential levels of 
crosslinking of the TCR by these reagents.
In contrast to the response elicited by PHA, addition of anti-CD3 or anti- 
TCR mAbs had no significant effect on PDE2 activity. Whilst there were 
observable changes in the total cyclic AMP PDE activity in the presence of cyclic 
GMP (lOjLiM), these effects could be accounted for by the increases in PDE4 
activity (figs. 4.4 and 4.6). As found using PHA to stimulate thymocytes, no 
PD El, PDE3 or PDE7 activities were identified following the ligation of the 
TCR/CD3 complex with anti-CD3 or anti-TCR antibodies (tables 4.2 and 4.3), 
respectively. Similar profiles of PDE activities were obtained with activated (figs.
In order to determine the effects of such PHA-mediated modulation of PDE 
activity on cyclic AMP homeostasis, cyclic AMP levels were measured in PHA-
.■;'s
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stimulated thymocytes. A 2-fold elevation of cyclic AMP levels was obtained 
within 5 minutes of PHA treatment, which was consistent with the observed 
decrease in total cyclic AMP PDE activity (P<0.02; n=3) (fig. 4.8). In addition, the 
transient nature of this rise in cyclic AMP levels paralleled the kinetics o f PDE4 
modulation, reaching basal levels within 30 minutes of challenge with PHA. Assay 
of cyclic AMP levels in the presence of PDE inhibitors, such as IB MX and 
rolipram, caused an elevation in cyclic AMP above that seen in the absence these 
PDE inhibitors (table 4.4). This indicates that in addition to modulating PDE 
activities, PHA stimulated substantial adenylyl cyclase activity. The PDE3 
selective inhibitor milrinone did not potentiate cyclic AMP levels in thymocytes, 
with no difference observed in cyclic AMP concentrations in the presence or 
absence of milrinone (table 4.4). Since only a small, transient increase in cyclic 
AMP was observed in the absence of PDE inhibitors, these results suggested that 
PHA modulated both cyclic AMP synthesis and degradation.
The use of the PDE4 selective inhibitor rolipram suggested that PDE4 
activity was mainly responsible the regulation of cyclic AMP degradation (table
4.4). The finding that milrinone did not effect cyclic AMP levels within thymocytes 
supported the contention that PDE3 activities were not present in these cells. The 
potentiation of cyclic AMP levels, when assayed in the presence of rolipram or 
IB MX, indicated that adenylyl cyclase activity was increased upon challenge of 
thymocytes with PHA. Again, similar results were obtained with resting (fig. 4.8b 
and table 4.4) and activated populations of thymocytes (fig 4.8a and table 4.4).
I
4.2.4. Cyclic AMP levels in anti-CD3 antibody stim ulated  
th y m o cy tes .
In contrast to the transient PHA-mediated increase in cyclic AMP levels, 
stimulation of thymocytes with anti-CD3 mAbs induced a slow, but sustained, rise 
in cyclic AMP levels following a lag of 3 minutes (fig. 4.9). This was despite (i) a 
rise in PDE4 activity and (ii) maintenance of PDE2 activity over the same period of
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time. Such data suggest that ligation of the CD3 by anti-CD3 also induced a 
substantial activation of adenylyl cyclase activity in thymocytes. This was 
confirmed by the enhanced cyclic AMP signals observed in the presence of the PDE 
inhibitors IB MX and rolipram (table 4.5). However, once again milrinone did not 
potentiate any increase in cyclic AMP levels (table 4.5) above those seen in the 
presence of anti-CD3 mAb alone. Once again, similar results were obtained with 
activated (fig. 4.9a and table 4.5) and resting populations of thymocytes (fig. 4.9b 
and table 4.5).
4.2.5. Cyclic AMP PDE activities in Jurkat cells on stimulation with  
P H A .
Upon challenge of the human T cell line Jurkat with PHA, there was little 
change in cyclic AMP PDE activity throughout the 30 minute stimulation (fig.
4.10). However, addition of cyclic GMP (lOpM) to PDE assays of the Jurkat cell 
extract (fig. 4.10a) identified a decrease in this form of PDE activity. This indicated 
the presence of cyclic GMP-inhibited PDE activity. A small decline in this cyclic 
GMP-inhibited proportion of PDE activity was observed when the cells were 
treated with PHA. Jurkat cell extracts treated with Ca^VCaM (50}iM/20ng/ml) 
showed an increase in PDE activity (fig. 4.10b) indicating the presence of PDEl.
This level of stimulation declined slightly when cells were challenged with PHA 
however it was not statistically significant, indicating that this ligand had little effect 
on PD El activity.
PDE2, PDE3, PDE4 and PDE7 activities all appeared to be present in the 
Jurkat cell extract (table 4.6) as indicated in section 3.2.5. Interestingly, an 
increase in rolipram sensitive, PDE4 activity was observed upon stimulation with 
PHA (-15%  stimulation; P< 0.02; n-4), and a decrease in cyclic GMP-inhibited 
PDE3 activity (-15%  inhibition; P< 0.05; n=4). Therefore, there appears to be 
differential regulation of specific PDE isoforms in the Jurkat cell line upon 
stimulation with PHA.
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4.2.6. Proliferation studies on m urine thymocytes and lym phocytes.
DNA synthesis experiments (thymidine incorporation) were carried out in 
order to ascertain the long-term effects of PHA and anti-CD3 stimulations on 
murine thymocytes. These studies were carried out with a view to investigating the 
effects of cyclic AMP level alterations on proliferation. However it was found that 
in v/vo-activated and resting populations of thymocytes did not proliferate in 
response to PHA or anti-CD3 antibodies (table 4.7 and fig. 4.11) after stimulation 
for 48 hours. Instead, a low incorporation of [^H]-thymidine was observed, 
suggesting that the cells were anergic ie. non-responsive rather than dying. 
Although a dose-dependent increase in [^Hj-thymidine uptake were observed, it 
was in the range of hundreds of cpms, whereas one would have expected tens of 
thousands of cpms to constitute a proliferative response (Haiding et al., 1992). 
Research carried out in thymic cultures suggests that communication between 
stromal cells and maturing T cells is essential for the maintenance of both 
populations of cells (Ritter and Boyd, 1993). Indeed, thymocytes have been 
shown to proliferate in the presence of IL-1, but this is inhibited in purified 
thymocytes (Rock and Benacerraf, 1984) indicating the lack of proliferation seen in 
thymocytes is due to the lack of stromal cells.
Murine lymphocytes responded slightly better, increasing their [% ]- 
thymidine uptake in response to PHA (table 4.7) and anti-CD3 antibodies (fig. 
4.12). However there was not a substantial incorporation of [^H]-thymidine, 
indicating the requirement of accessory cells.
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4.3. D iscussion.
In this study, the regulation of PDE activities within murine thymocytes has 
been investigated upon challenge of the cells with the mitogenic lectin PHA or anti- 
CD3/anti-TCR antibodies. It was shown that these two classes of TCR ligands 
appeared to regulate differentially the PDE2, PDE4 activities and cyclic AMP levels 
within these cells. The cyclic AMP PDE activities were also studied in Jurkat cells 
in response to PHA.
4.3.1. PDE activities upon ligation o f the TCR/CD3 com plex.
There were two key differences in the PDE activities stimulated in 
thymocytes following ligation of the TCR by anti-CD3/TCR mAbs or the mitogenic 
lectin PHA: (i) PHA mediated a rapid decrease in PDE4 activity followed by a slow 
recovery towards basal levels, whereas anti-CD3/TCR mAbs mediated an initial 
small and transient decrease in PDE4 activity followed by a slow, but sustained, 
increase in this activity, approximately 2 fold above basal, (ii) The kinetics of
'
PDE2 modulation differed in PHA- and anti-CD3 stimulated thymocytes. PHA 
caused a dramatic, but transient loss in PDE2 activity. In contrast, there was no 
change in PDE2 activity upon ligation of TCR/CD3 complex. This might imply that 
signalling pathways emanating from the TCR/CD3 complex are not coupled to the 
regulation of PDE2 activity.
In contrast to murine thymocytes, the proliferating Jurkat T-cell line did not 
show altered total cyclic AMP PDE activity upon stimulation with PHA. However, 
upon analysis of specific PDE isoforms it was apparent that there was an increase in 
the cyclic AMP-specific PDE4 activity, together with a concomitant decrease in 
cyclic GMP-inhibited, PDE3 activity. This loss of cyclic GMP-inhibited PDE 
activity has been reported in peripheral blood lymphocytes within four hours of 
mitogenic stimulation (Takemoto etal., 1979). In Jurkat cells the stimulation of 
PDE4 activity and the loss of PDE3 activity occurred within 30 minutes. This may 
indicate some influence of the cell cycle-mediated regulation of PDE3 activity.
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Engels et al. (1994) have identified PDE4A at the mRNA level in Jurkat 
cells. However, it has been shown here (see section 3.2.5) that little, if any PDE4 
activity was observed in unstimulated Jurkat cells. It is therefore interesting to note 
an increase in this activity, as it suggests that this PDE activity is rapidly induced in 
response to PHA. Rapid induction of a Ca^VCaM-stimulated, PDEl activity has 
recently been shown in CHO cells in response to either challenge with the phorbol 
ester, PMA, or the selective overexpression o f PKC isoforms (Spence et al.,
1995). This PDE activity, which was found to be absent from untreated cells, 
could be detected within 25 minutes of their exposure to PMA. Thus it appears 
possible that rapid induction of PDE activities can occur in response to mitogenic 
agents.
Upon stimulation of murine thymocytes with anti-CD3/TCR antibodies, a 
PDE4 activity increases 2-2.5 fold within 20 minutes. An increase in PDE4 activity 
has been shown previously upon stimulation of rat thymocytes with Con A (Valette 
et al., 1990). This was found to due to an increase in the V^ax of the PDE. In 
contrast, it has been found that PDE3 activity was selectively elevated within 10 
minutes of stimulation of human peripheral blood lymphocytes (HPBLs) with Con 
A (Meskini er <3/., 1992). Interestingly, challenge of HPBLs with anti-CD3 
antibodies also caused an elevation in PDE3 activity, although the rise in PDE 
activity was less strong (Meskini et al., 1992). Chapter 5 will address the 
mechanism which underlies the elevation in PDE4 activity in murine thymocytes.
Upon long-term stimulation of murine thymocytes, there was no evidence 
of proliferation in response to anti-CD3 antibodies or mitogenic lectins. Indeed 
anti-CD3 monoclonal antibodies have been shown to induce apoptosis in 
thymocytes in organ culture experiments (Smith et al., 1989) and in vivo (Shi et al., 
1991). However, it has been reported that the addition of rolipram to purified rat 
thymic cells which were induced to proliferate with Con A, led to a reduction in 
proliferation, of 60% (Marcoz et al., 1993). Their report highlighted the 
importance of PDE4 activity in the control of proliferation in thymocytes, so it is
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interesting that PDE4 activity has also been shown to be regulated and elevated in 
murine thymocytes and Jurkat cells upon ligation of the TCR/CD3 complex.
4.3.2. Cyclic AM P levels upon ligation o f the TCR/CD3 complex.
Differences in cyclic AMP levels were also observed upon ligation of 
thymocytes with PHA or anti-CD3 antibodies. PHA stimulation of thymocytes led 
to a transient elevation of cyclic AMP levels, whereas anti-CD3 mAb treatment led 
to a slow, sustained increase in cyclic AMP. IB MX was used to inhibit PDE 
activity in the cells, allowing changes in cyclic AMP level to be regarded as an 
index of adenylyl cyclase activity. Thus the increase in cyclic AMP levels observed 
upon anti"CD3 mAb or PHA treatment of thymocytes in the presence of IB MX, 
implied an activation of adenylyl cyclase. Rolipram was used to inhibit PDE4 
activity, therefore indicating the relevance of this PDE activity in the regulation of 
cyclic AMP degradation. An increase in cyclic AMP levels was seen in response to 
anti-CD3 mAbs and PHA in the presence of rolipram in thymocytes. This elevation 
in cyclic AMP was similar to that seen in the presence of IBMX, indicating that the 
PDE4 may be the main PDE isoform responsible for degrading cyclic AMP in 
thymocytes following stimulation with PHA or anti-CD3 mAbs. The addition of 
milrinone did not potentiate cyclic AMP concentrations, implying that the PDE3 
isoform was not involved in the regulation of cyclic AMP levels in murine 
thymocytes. This supported the previous finding that PDE3 activity is not present 
in these cells. Consistent with PDE regulation studies, investigation of cyclic AMP 
concentrations revealed that PHA stimulated a transient 2-fold elevation of cyclic 
AMP levels, which correlated with the modulation of PDE activities within the 
cells. However, anti-CD3 ligation induced a slow sustained increase in cyclic 
AMP. This indicated that a complex balance of adenylyl cyclase and PDE activities 
occurred following TCR activation. These results implied that fundamental 
differences exist in the PHA- and anti-CD3-stimulated cyclic AMP signalling 
pathways in thymocytes.
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The differential cyclic AMP signalling responses resulting from stimulation 
of thymocytes with PHA and anti-CD3 may be due, at least in part, to the 
complement of cell surface receptors recruited by these agents. Whereas anti-CD3 
acts solely through the TCR/CD3 complex, PHA is known to crosslink multiple cell 
surface receptors, including the TCR/CD3 complex and CD2 accessory molecule 
(O’Flynn et a l ,  1985). CD2 is expressed during the early stages of thymic 
development (Fox et a l,  1985) and it has been suggested that CD2 may trigger 
differentiation and IL-2-dependent proliferation signals in immature thymocytes via 
interaction with its complementary molecule, LFA-3, on thymic epithelial cells 
(Denning e ta l ,  1987; Fox e ta l ,  1985; Reem e ta l ,  1987). Therefore, a different 
array of signals is likely to be generated following stimulation of thymocytes with 
PHA or anti-CD3/TCR. McConkey et a l  (1990a) have shown that a sustained 
elevation of cyclic AMP in thymocytes leads to apoptosis. Thus, the above finding 
that anti-CD3 induced sustained cyclic AMP generation, whilst PHA only elicited a 
transient cyclic AMP signal, might explain why thymocytes undergo apoptosis, 
rather than proliferation in response to anti-CD3 (fondai et a l,  1993; Shi et a l, 
1991; Smith e ta l ,  1989). Anti-CD3 antibody stimulated thymocytes also apoptose 
in the presence of PMA or IL-2 (Sancho et a l,  1992), whereas thymocytes can 
respond mitogenically to co-stimulation with lectins and PMA (Taylor et a l,  1984). 
This suggests that PHA might rescue thymocytes from programmed cell death by 
co-ligating CD3 and CD2. CD3 and CD2 ligation has been shown to cause a 
significant, but not sustained, increase in cyclic AMP levels in mature T cells 
(Carrera et a l, 1988; Hahn et a l ,  1991; Kammer et a l,  1988; Ledbetter et a l,  
1986). Indeed, increased cyclic AMP concentrations subsequent to CD2 receptor 
ligation have been found to be dependent on the expression of TCR/CD3 complex 
(Kvanta et a l,  1991). Furthermore the kinetics of anti-CD3-mediated cyclic AMP 
rises in thymocytes and in mature T cells may suggest that CD3 is coupled to 
differential cyclic AMP signalling pathways during T cell maturation. Thymocytes 
have been shown to have lower concentrations of cyclic AMP than lymphocytes
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(Niaudet et a l,  1976). However, they are more sensitive to stimulation via 
isoproterenol, leading to a substantial cyclic AMP response, indicating that the 
cyclic AMP generating pathways are more readily activated in the thymocyte (Bach, 
1975; Niaudet e ta l ,  1976).
The cyclic AMP generated in response to ligation of CD2 has been linked to 
the potential avidity that exists between cells (Hahn e ta l ,  1993). This indicates 
that cyclic AMP may be important in modulating the interaction between mature 
cells, and possibly aiding the TCR/CD3 contact with APCs. Adhesion processes 
are essential in producing viable cell responses, as inhibition of these actions stops 
proliferation (Rabin et a l ,  1993). This would be of particular importance in 
thymocytes, where antigen is presented to the cells and apoptosis or proliferation of 
a clone of cells occurs in response to the interaction.
4.3.3. Signalling im plications for T cell developm ent.
A hypothesis has been proposed to explain how differential biological 
responses occur during T cell development (Finkel et a l,  1991). It is thought that 
differential TCR signalling may be due to distinct signals being transmitted through 
different regions of the antigen receptor, leading to proliferation or deletion of 
particular thymocyte clones (Finkel et a l,  1989). However, the studies presented 
here propose that PDE activities may be modulated in a similar fashion when 
murine thymocytes are stimulated with either anti-CD3 antibodies or anti-TCR 
antibodies. This suggests that thymocyte apoptosis may be the result of partial 
uncoupling of the TCR to the “activation” pathways of the mature T cells acting in 
concert with the coupling of the TCR to thymocyte of cell death-specific “negative” 
signalling pathways.
It is interesting to note that PHA did not lead to any comparable increase in 
PDE4 activity, despite the fact that this mitogen is known to interact with the 
TCR/CD3 complex (OFlynn e ta l ,  1985; Weiss e ta l ,  1984a). This suggests that 
an additional signalling action of PHA may negate such regulation on thymocyte
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PDE4 activity. It is possible that co-ligation of CD2 (and/or other surface 
receptors) by PHA can actively prevent an elevation in PDE4 activity by exerting a 
powerful inhibitory effect on the process triggered upon TCR/CD3 ligation. It is 
interesting to note however, that PDE4 activity appears to increase in Jurkat cells 
upon stimulation with PHA. This may support the idea, mentioned previously (see 
section 4.3.2) that CD2 can signal independently of the TCR in immature T cells 
but upon expression of the antigen receptor in mature T lymphocytes, CD2 signals 
are directed through the TCR/CD3 complex (Alcover etal., 1988; Blue et al., 1987; 
Fox et al., 1985). However, considering the complexity of T cell activation this 
may be a very simplistic view. The Jurkat cell line has been utilised in signalling 
studies relating to T cell activation pathways assessing the biochemical activation 
pathways coupled to the TCR/CD3 complex as these cells were reputed to mimic 
the responses of normal mature human T cells (Nel et a l,  1991; Weiss et a l,  
1984a). However the original characterisation of the Jurkat T cell line suggests that 
these cells may have been derived from a thymic origin (Schneider, 1977). 
Interestingly, PHA has been shown to cause apoptosis in the Jurkat T cell line (D. 
Williams and M. M. Harnett, personal communication). Therefore there may be a 
link between the elevation of PDE4 activity and apoptosis, as it is known that anti- 
CD3 simulation of thymocytes also induces programmed cell death (Shi et a l,
1991; Smith e ta l ,  1989).
4.3.4. Cyclic GMP and im plications for NO signalling.
Clearly, cyclic GMP could have an enormous effect on cyclic AMP 
hydrolysis in murine cells, with the possibility of a ‘molecular switch’ existing for 
the control of cyclic AMP hydrolysis in these cells as outlined previously (see 
section 3.3). Cyclic GMP has been documented to increase following stimulation
of thymocytes and lymphocytes in the absence of adherent cells with PHA, Con A, 
PMA and calcium ionophore, A23187 (Coffey et a l,  1977; Hadden and Coffey, 
1982; Hadden et a l ,  1972). In the case of PHA, this may be due to its ability to
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iactivate membrane and soluble forms of lymphocyte guanylyl cyclase (Coffey et 
a i ,  1981; Rochette-Egly and Kempf, 1981).
Cyclic GMP may be elevated through the stimulation of soluble guanylyl 
cyclase by NO (Furchgott and Zawadski, 1980). NO is a freely diffusable 
molecule synthesised from the amino acid /-arginine by NO synthase, and can 
function as an intercellular as well as an intracellular messenger (Lee et a l,  1988; 
Moncada et a l,  1991; Southam and Garthwaite, 1993). It appears to have a role in 
mediating cytotoxicity in the immune system, being responsible for stimulating the 
phagocytosis of pathogens by cytokine-activated macrophages (Nathan and Hibbs, 
1991). However recently, NO has been shown to inhibit apoptosis in B 
lymphocytes (Genaro et a l,  1995), indicating that nitric oxide may also have a role 
as a ‘survival’ signal in the immune system.
It has been established that sustained elevations of cyclic AMP by agents 
such as cyclic AMP analogues or E series prostaglandins, as well as glucocorticoid 
treatment, leads to apoptosis in thymocytes (Cohen and Duke, 1984; Dowd and 
Miesfeld, 1992; Kaye and Ellenberger, 1992; McConkey e ta l ,  1989a; McConkey 
et a l ,  1990a; Wyllie, 1980). However, these cell death pathways can be linked, as 
cyclic AMP can potentiate apoptosis caused by glucocorticoids (McConkey et a l,
1993). Interestingly, glucorticoids have been shown to inhibit the induction, but 
not the activity, of calcium independent NO synthase in response to LPS alone or in 
combination with IFN-y in vitro (Radomski et a l ,  1990; Rees et a l,  1990; Di 
Rosa et a l,  1990) and in vivo (Knowles et a l,  1990). It is tempting to suggest 
that one of the actions of glucocorticoids may be to stimulate apoptosis by raising 
cyclic AMP levels by removing cyclic GMP regulation of cyclic AMP hydrolysis.
The connection between cyclic nucleotides and NO signalling pathways is 
exciting, especially in the context of the murine thymus, where it is apparent from 
these studies that cyclic AMP hydrolysis may be greatly influenced by the 
intracellular levels of cyclic GMP.
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Table 4.1. P D E l, PDE3 and PDE7 activities in murine 
thym ocytes upon challenge with PHA.
Thymocytes were stimulated with PHA (50|ig/ml) for 20 
minutes. PDE activity was observed in the presence of l|iM  cyclic 
AMP as substrate. Shown is the percentage inhibition of activity in the 
presence of 5{iM milrinone (PDE3 activity) or lOOp-M IBMX (PDE7 
activity), and the stimulation of PDEl activity in the presence of 
Ca^VCaM (50p.M/20ng/ml). This is shown for a) zero minutes 
(basal) and b) 20 minutes of stimulation with PHA. These data 
show an average of at least four experiments, with assays done in 
triplicate (errors are SEM). Percentages are calculated as the average 
of percentage stimulation from each separate experiment with basal 
PDE activity representing 100%, assayed with IpM  cyclic AMP.
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Table 4.2. P D E l, PDE3 and PDE7 activities in murine 
thym ocytes upon challenge with anti-CD3 monoclonal 
an tib od ies.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5jig/ml) for 20 minutes. The antibody used was directed 
against the £ chain of the CDS complex (Philips et al. 1991). PDE 
activity was observed in the presence of IpM  cyclic AMP as substrate. 
Shown is the percentage inhibition of activity in the presence of 5p.M 
milrinone (PDE3 activity) or lOOpM IB MX (PDE7 activity), and the 
stimulation of PDEl activity in the presence of Ca^’*' /CaM 
(50|iM/20ng/ml). This is shown for a) zero minutes (basal) and b) 20 
minutes of stimulation with anti-CD3 monoclonal antibodies. These data 
show an average of at least four experiments, with assays done in 
triplicate (errors are SEM). Percentages are calculated as the average 
of percentage stimulation from each separate experiment with basal 
PDE activity representing 100%, assayed with l|iM  cyclic AMP.
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Table 4.3. P D E l, PDE3 and PDE7 activities in murine 
thym ocytes upon challenge with anti-TCR monoclonal
an tib o d ies .%
Thymocytes were stimulated with anti-TCR monoclonal 
antibodies (lp,g/ml) for 30 minutes. The antibody used was directed 
against the p chain of the TCR complex. PDE activity was observed in 
the presence of IjiM cyclic AMP as substrate. Shown is the percentage 
inhibition of activity in the presence of 5jiM milrinone (PDE3 activity) or 
lOOfiM IB MX (PDE7 activity), and the stimulation of PDEl activity in 
the presence of Ca^VCaM (50pM/20ng/ml). This is shown for a) zero 
minutes (basal) and b) 30 minutes of stimulation with anti-TCR 
monoclonal antibodies. These data show an average of at least 
three experiments, with assays done in triplicate (errors are SEM). 
Percentages are calculated as the average of percentage stimulation 
from each separate experiment with basal PDE activity representing 
100%, assayed with IpM  cyclic AMP.
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Table 4.4. Effect of PDE inhibitors on cyclic AMP 
concentrations upon stim ulation with PHA.
Thymocytes were stimulated with PHA (50|ig/ml) for 30 
minutes. The table shows the cyclic AMP levels in ‘activated 
thymocytes’ and ‘resting thymocytes’ i.e. the in vivc-activated 
population of cells which were isolated on the basis of their buoyant 
density. The cells were stimulated in the presence of ImM  IB MX, 
lOpM rolipram or 5}iM milrinone. Cyclic AMP concentrations were 
assayed in triplicate (errors are SEM). These data are representative 
values of three experiments. The results are expressed as pmols/cyclic 
AMP/10^ cells against time with PHA (minutes).
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Table 4.5. Effect o f PDE inhibitors on cyclic AMP 
concentrations upon stim ulation with anti-CD3 antibodies.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5|ig/ml) for 30 minutes. The antibody used was directed 
against the E chain of the CD3 complex (Philips et al. 1991). The table 
shows the cyclic AMP levels in ‘activated thymocytes’ and ‘resting 
thymocytes’ i.e. the in vivo-activated population of cells which were 
isolated on the basis of their buoyant density. The cells were stimulated 
in the presence of ImM  IBMX, lOpM rolipram or 5pM milrinone. 
Cyclic AMP concentrations were assayed in triplicate (errors are SEM). 
These data are representative values of three experiments. The results 
are expressed as pmols/cyclic AMP/10^ cells against time with anti-CD3 
antibodies (minutes).
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Table 4.6. PDE2, PDE3, PDE4 and PDE7 activities in the 
Jurkat cell line upon stimulation with PHA.
Jurkat cells were stimulated with PHA (50|ig/ml) for 30 minutes. 
PDE activity was observed in the presence of IfiM cyclic AMP as 
substrate. Shown is the percentage inhibition of activity in the presence 
of lOjiM EHNA plus cyclic GMP (PDE2 activity), 5p.M milrinone (PDE3 
activity), lOpM rolipram (PDE4 activity) or lOOjiM IBMX (PDE7 activity). 
This is shown for a) zero minutes (basal) and b) 30 minutes of stimulation 
with PHA. These data show an average of at least four experiments, with 
assays done in triplicate (errors are SEM). Percentages are calculated as 
the average of percentage stimulation from each separate experiment 
with basal PDE activity representing 100%, assayed with IpM  cyclic AMP.
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Table 4.7. pH ]-thym idine incorporation o f m urine thym ocytes 
and lymphocytes upon stim ulation with PHA.
Cells isolated from 4 week old Balb/c mice were stimulated for 
48 hours in the presence of PHA (50jig/ml), [^H]-thymidine was added 
to the cells for the last 4 hours of the incubation, as outlined in 
‘Materials and Methods.’ 2 x 10  ^cells were used per well (200p,l). These 
data show results typical of experiments carried out three times, with 
assays done in triplicate (errors are SEM). The thymidine incorporation 
(a direct indication of proliferation state of the cells) is presented as 
cpm/well of cells.
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[3H] “Thymidine
incorporation
48hours
-PH A
cpm
+ PHA 
cpm
Resting 134 +/- 16 235 +/- 17
thymocytes
Activated 152 +/- 22 264 +/- 29
thymocytes
Resting 47 +/- 4 2500 +/- 144 .lymphocytes
Activated 242 +/- 50 4160 +/- 260 .i
lymphocytes
Figure 4.1. PDE4 activity in murine thymocytes upon
challenge with PHA.
Thymocytes were stimulated with PHA (50jag/ml) for up to 20 
minutes as indicated. The total PDE activity observed in the presence of 
IjiM  cyclic AMP as substrate (circles) is shown. Also given is that 
fraction of activity (squares) which is inhibited by lOpM rolipram. This 
is not the residual rolipram-insensitive fraction, but the fraction of PDE 
activity which was inhibited by rolipram and, as such, can be taken as 
an index of PDE4 activity. The graphs show the PDE activities in;
a) ‘activated thymocytes’ i.e. the in vzvo-activated population of cells 
which were isolated on the basis of their buoyant density, and b) ‘resting 
thymocytes’ i.e. the in vivo-resting population of cells which 
were isolated on the basis of their buoyant density. These data show 
results typical of experiments carried out at least five times. PDE 
assays were carried out in triplicate (errors are SEM). PDE activity is 
expressed as pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 4.2. PDE2 activity in murine thymocytes upon
challenge with PHA.
Thymocytes were stimulated with PHA (50|ig/ml) for up to 20 
minutes as indicated. Shown is the total PDE activity (diamonds) 
observed in the presence of stimulatory concentrations of cyclic GMP 
(lOjiM) and lp.M cyclic AMP as substrate. Also given is the magnitude 
of the increase in PDE activity elicited by cyclic GMP (triangles); this is 
taken to serve as an index of PDE2 activity. In this regard it must be taken 
as an underestimate as it does not take into account the basal activity of the 
enzyme. However, given the magnitude of the stimulation by cyclic GMP, 
then such a basal component is likely to be small. This approach has the 
advantage in that it solely represents PDE2 activity. The graphs show the 
PDE activities in; a) ‘activated thymocytes’ i.e. the in Wvo-activated 
population of cells which were isolated on the basis of their buoyant 
density, and b) ‘resting thymocytes’ i.e. the in v/vo-resting population 
of cells which were isolated on the basis of their buoyant density. These 
data show results typical of experiments carried out at least five times.
PDE assays were carried out in triplicate (errors are SEM). PDE activity 
is expressed as pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 4.3. PDE4 activity in murine thymocytes upon
challenge with anti-CD3 monoclonal antibodies.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5|ig/ml) for up to 20 minutes as indicated. The antibody 
used was directed against the e chain of the CDS complex (Philips et a l  
1991). The total PDE activity observed in the presence of IfiM cyclic 
AMP as substrate (circles) is shown. Also given is that fraction of 
activity (squares) which is inhibited by 10[xM rolipram. This is not the 
residual rolipram-insensitive fraction, but the fraction of PDE activity 
which was inhibited by rolipram and, as such, can be taken as an index 
of PDE4 activity. The graphs show the PDE activities in; a) ‘activated 
thymocytes’ i.e. the in vivo-activated population of cells which were 
isolated on the basis of their buoyant density, and b) ‘resting thymocytes’ 
i.e. the in vivo-resting population of cells which were isolated on the 
basis of their buoyant density. These data show results typical of 
experiments carried out at least four times. PDE assays were carried 
out in triplicate (errors are SEM). PDE activity is expressed as pmols 
cyclic AMP hydrolysed/min/mg protein.
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Figure 4.4. PDE2 activity in murine thymocytes upon challenge
with anti-CD3 monoclonal antibodies.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5|ig/ml) for up to 20 minutes as indicated. The antibody 
used was directed against the e chain of the CD3 complex (Philips et al.
1991). Shown is the total PDE activity (diamonds) observed in the 
presence of stimulatory concentrations of cyclic GMP (lOp-M) and Ip-M 
cyclic AMP as substrate. Also given is the magnitude of the increase in 
PDE activity elicited by cyclic GMP (triangles); this is taken to serve as 
an index of PDE2 activity. In this regard it must be taken as an 
underestimate as it does not take into account the basal activity of the 
enzyme. However, given the magnitude of the stimulation by cyclic 
GMP, then such a basal component is likely to be small. This approach 
has the advantage in that it solely represents PDE2 activity. The graphs 
show the PDE activities in; a) ‘activated thymocytes’ i.e. the in vivo- 
activated population of cells which were isolated on the basis of their 
buoyant density, and b) ‘resting thymocytes’ i.e. the resting population 
of cells which were isolated on the basis of their buoyant density.
These data show results typical of experiments carried out at least four 
times. PDÈ assays were carried out in triplicate (errors are SEM).
PDE activity is expressed as pmols cyclic AMP hydrolysed/min/mg 
protein.
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Figure 4.5. PDE4 activity in murine thymocytes upon
challenge with anti-TCR monoclonal antibodies.
Thymocytes were stimulated with anti-TCR monoclonal 
antibodies (Ipg/ml) for up to 30 minutes as indicated. The antibody 
used was directed against the p chain of the TCR. The total PDE 
activity observed in the presence of IpM  cyclic AMP as substrate 
(circles) is shown. Also given is that fraction of activity (squares) 
which is inhibited by lOjiM rolipram. This is not the residual rolipram- 
insensitive fraction, but the fraction of PDE activity which was inhibited 
by rolipram and, as such, can be taken as an index of PDE4 activity.
The graphs show the PDE activities in; a) ‘activated thymocytes’ i.e. the 
n viv<?-activated population of cells which were isolated on the basis of 
their buoyant density, and b) ‘resting thymocytes’ i.e. the resting 
population of cells which were isolated on the basis of their buoyant 
density. These data show results typical of experiments carried out at 
least three times. PDE assays were carried out in triplicate (errors are 
SEM). PDE activity is expressed as pmols cyclic AMP hydrolysed/min/mg 
protein.
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Figure 4.6. PDE2 activity in murine thymocytes upon
challenge with anti-TCR monoclonal antibodies.
Thymocytes were stimulated with anti-TCR monoclonal 
antibodies (l|ig/m l) for up to 30 minutes as indicated. The antibody 
used was directed against the P chain of the CD3 complex. Shown is 
the total PDE activity (diamonds) observed in the presence of 
stimulatory concentrations o f cyclic GMP (lOjiM) and l|iM  cyclic AMP 
as substrate. Also given is the magnitude of the increase in PDE activity 
elicited by cyclic GMP (triangles); this is taken to serve as an index of 
PDE2 activity. In this regard it must be taken as an underestimate as it 
does not take into account the basal activity of the enzyme. However, 
given the magnitude of the stimulation by cyclic GMP, then such a basal 
component is likely to be small. This approach has the advantage in that 
it solely represents PDE2 activity. The graphs show the PDE activities in;
a) ‘activated thymocytes’ i.e. the in vzvo-activated population of cells 
which were isolated on the basis of their buoyant density, and b) Testing 
thymocytes’ i.e. the in vivo-resting population of cells which were isolated 
on the basis of their buoyant density. These data show results typical of 
experiments carried out at least three times. PDE assays were carried out 
in triplicate (errors are SEM). PDE activity is expressed as pmols cyclic 
AMP hydrolysed/min/mg protein.
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Figure 4,7. PDF activities in murine thymocytes upon 
challenge with anti-CD3 monoclonal antibodies, and 
crosslinking with anti-ham ster IgG antibodies.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5|ig/ml) for up to 30 minutes as indicated in the presence of 
antibodies directed against hamster IgG antibodies (lOpg/ml). The first antibody 
(anti“CD3 antibody) used was directed against the e chain of the CD3 
complex (Philips et al. 1991). Shown is a) the total PDE activity 
observed in the presence of IfiM cyclic AMP as substrate, in the 
absence (circles) and that fraction of activity (squares) which is inhibited 
by lOpM rolipram. This is not the residual rolipram-in sensitive 
fraction, but the fraction of PDE activity which was inhibited by 
rolipram and, as such, can be taken as an index of PDE4 activity. Graph 
b) shows the total PDE activity observed in the presence of stimulatory 
concentrations of cyclic GMP (lOpM) (diamonds) and the magnitude of 
the increase in PDE activity elicited by cyclic GMP (triangles); this is 
taken to serve as an index of PDE2 activity. In this regard it must be 
taken as an underestimate as it does not take into account the basal activity 
of the enzyme. However, given the magnitude of the stimulation by 
cyclic GMP, then such a basal component is likely to be small. This 
approach has the advantage in that it solely represents PDE2 activity.
These data show results typical of experiments carried out two times 
on ‘mixed’ populations of thymocytes PDE assays are carried out in 
triplicate (errors are SEM). PDE activity is expressed as pmols cyclic 
AMP hydrolysed/min/mg protein.
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Figure 4.8. Cyclic AMP concentration in murine 
thym ocytes upon stim ulation with PHA.
Thymocytes were incubated with PHA (50|ig/ml) for up to 30 
minutes as indicated. The graphs show the cyclic AMP levels in; a) 
‘activated thymocytes’ i.e. the in viv<?-activated population of cells 
which were isolated on the basis of their buoyant density, and b) 
‘resting thymocytes’ i.e. the in v/vo-resting population of cells which 
were isolated on the basis of their buoyant density. These data show 
results typical of experiments carried out three times. Assays were 
carried out in triplicate (errors are SEM). The results are expressed as 
pmols/cyclic AMP/10  ^cells against time with PHA (minutes).
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Figure 4.9. Cyclic AMP concentration in murine 
thym ocytes upon stimulation with anti-CD3 m onoclonal 
a n tib od ies .
Thymocytes were incubated with anti-CD3 monoclonal 
antibodies (5fig/ml) for up to 30 minutes as indicated. The antibody 
used was directed against the e chain of the CD3 complex (Philips et al. 
1991). The graphs show the cyclic AMP levels in; a) ‘activated 
thymocytes’ i.e. the in vivo-activated population of cells which were 
isolated on the basis of their buoyant density, and b) ‘resting 
thymocytes’ i.e. the in vivo-resting population of cells which were 
isolated on the basis of their buoyant density. These data show results 
typical of experiments carried out three times. Assays were carried out 
in triplicate (errors are SEM). The results are expressed as pmols/cyclic 
AMP/10  ^cells against time with anti-CD3 antibodies (minutes).
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Figure 4.10. PDE activities in the human leukem ic T cell 
line, Jurkat, upon stim ulation with PHA.
Jurkat cells were stimulated with PHA (50fig/ml) for up to 30 
minutes as indicated. The total PDE activity observed in the presence of 
IfiM cyclic AMP as substrate (circles) is shown. Also given is a) the 
fraction of activity (squares) remaining after addition of 10[xM cyclic 
GMP and b) the total activity upon addition of Ca^VCaM 
(50|iM/20ng/ml) (triangles). These data show results typical of 
experiments carried out at least five times, with assays done in triplicate 
(errors are SEM). PDE activity is expressed as pmols cyclic AMP 
hydrolysed/min/mg protein.
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Figure 4.11. pH ]-thym idine incorporation o f m urine 
thym ocytes upon stim ulation with anti-CD3 m onoclonal 
a n tib od ies .
Thymocytes isolated from 4 week old Balb/c mice were 
stimulated for 48 hours in the presence of increasing doses of anti-CD3 
monoclonal antibodies, as indicated. The antibody used was directed 
against the e chain of the CD3 complex (Philips et al. 1991). [^H]- 
thymidine was added to the cells for the last 4 hours of the incubation, 
as outlined in ‘Materials and Methods.’ The graphs show [^H]- 
thymidine incorporation in; a) ‘activated thymocytes’ i.e. the in vivo- 
activated population of cells which were isolated on the basis of their 
buoyant density, and b) ‘resting thymocytes’ i.e. the in vivo-resting 
population of cells which were isolated on the basis of their buoyant 
density. 2x10^  cells were used per well (200|il). These data show results 
typical of experiments carried out three times. Assays were carried out 
in triplicate (errors are SEM). The [^H]-thymidine incorporation (a 
direct indication of proliferation state of the cells) is presented as 
cpm/well of cells.
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Figure 4.12. pH ]-thym idine incorporation o f m urine  
lym phocytes upon stim ulation with anti-CD3 monoclonal 
a n tib od ies.
Lymphocytes isolated from 4 week old Balb/c mice were 
stimulated for 72 hours in the presence of increasing doses of anti-CD3 
monoclonal antilxxfres. The antibody used was directed against the e 
chain of the CD3 complex (Philips et al. 1991), [^H]-thymidine was 
added to the cells for the last 4 hours of the incubation, as outlined in 
‘Materials and Methods.’ The graphs show [^H]-thymidine 
incorporation in; a) ‘activated thymocytes’ i.e. the in vivo- 
activated population of cells which were isolated on the basis of their 
buoyant density, and b) ‘resting thymocytes’ i.e. the in vivo-resting 
population of cells which were isolated on the basis of their buoyant 
density. 2 x 1 0 ^  cells were used per well (200p.l). These data show results 
typical of experiments carried out three times. Assays were carried out 
in triplicate (errors are SEM). The [^H]-thymidine incorporation (a 
direct indication of proliferation state of the cells) is presented as 
cpm/well of cells.
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5.1. Introduction.
The regulation of a number of processes including, metabolism, DNA 
transcription and replication, protein synthesis, proliferation and differentiation in 
response to hormones and growth factors, is largely achieved by coordinated 
changes in protein phosphorylation of enzymes and structural components. It is 
well established that phosphorylation-déphosphorylation processes play an 
important role in signal transduction, altering enzyme activities upon receptor 
ligation. Processes controlled by reversible phosphorylation require not only a 
protein kinase, but also a protein phosphatase (PPT). It is now realised that these 
processes are regulated by a large group of enzymes, with mammals having as 
many as 2000 protein kinase genes (Hanks and Hunter, 1995) and, possibly, as 
many as 1000 PPT genes (Wilson et a l ,  1994b). In general these enzymes are 
divided into serine/threonine or tyrosine kinases or phosphatases, although some 
activities have the ability to phosphorylate or dephosphorylate all residues (Hanks et 
al., 1988; Hunter, 1987). Activities of protein kinases and PPTs may be regulated 
by protein phosphorylation, allosteric effectors and second messengers, therefore 
being sensitive to extracellular and intracellular signals. The first example 
illustrating the role of protein phosphorylation in signal transduction was that 
involving cyclic AMP and cyclic AMP-dependent protein kinase (see section 1.5.4) 
which was elucidated as a result of work on the mechanism of action of epinephrine 
on skeletal muscle (Krebs, 1973). This also constituted the first example of a 
protein kinase cascade, in which a kinase activated another by phosphorylation.
It is apparent that PPTs are not simply a reversal of a phosphorylation 
reaction, but also represent another level at which regulation can occur, leading to 
the control of cellular processes (Shenolikar, 1994). Transient production of 
second messengers upon receptor stimulation can result in proliferation and 
differentiation, which are long lasting effects and sometimes irreversible. Protein
,....
phosphorylation can regulate gene expression by modulating sequence specific 
transcription factors, whose activity is altered by phosphorylation. This form of
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control has been established for CREB/ATF (see section 1.5.6), AP-1 (jun/fos) and 
NF-kB proteins. Signal-induced post-translational activation o f these factors 
results in induction of downstream genes, some of which encode other transcription 
factors, which in turn effect the expression of target genes. Such signalling 
cascades result in long lasting nuclear signals.
5.1.1. Protein kinase C.
PKC is a serine/threonine kinase which was first discovered by Nishizuka 
et al. as a protein kinase activity which was only active after limited proteolysis 
(Inoue et al., 1977). Later, it was found to be activated by calcium and 
phospholipids (especially phosphatidylserine (PS)) (Takai et al., 1979) or phorbol 
esters and phospholipids (Castagna et al., 1982). Phorbol esters are a group of 
compounds which activate PKC in a similar manner to DAG, representing non- 
metabolisable analogs of DAG (Bell and Burns, 1991). With the use of phorbol 
esters as a pharmacological tool it has become recognised that PKC is involved in a 
variety of diverse processes within the cell. Initially, PKC was recognised to exist 
as three isoenzymes (a, (3, y), but now it is realised that there are at least twelve 
members of the PKC multigene family which can be divided into sub-species, 
possibly explaining why PKC has been implicated in so many cellular processes 
(Hug and Sarre, 1993; Nishizuka, 1992). These sub-species display subtly 
different enzymological properties, differential tissue expression and limited 
intracellular localisation, and structural properties (Nishizuka, 1988). Thus, three 
main groups are recognised, one containing a , pl, p il and y which is the calcium 
dependent or ‘conventional’ PKC family (cPKCs), one group consisting of the 
novel or calcium-independent isoenzymes, 5, e, 0, T] (nPKCs) (Ohno et al., 1991), 
and the last group are the atypical PKCs, Ç, p., t ,  X (aPKCs), which although 
structurally related to the PKC family, differ as their activities are not regulated by 
DAG or phorbol esters (Niskizuka, 1988; Ohno et al., 1994).
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Marked differences are found with regard to tissue disnibution of the 
various isoforms of PKC, with a , pVH, 5, e and Ç isoforms being widely 
expressed, found in the brain, thymus, spleen and lung (Niskizuka, 1988; Ohno et 
a l ,  1991; Wetsel etaL , 1992; Yoshida et al., 1988). However, y, T] and 9 have 
restricted distribution, with each isoform being found mainly in the brain 
(Niskizuka, 1988; Ohno et a l ,  1991; Wetsel et al., 1992), skin and lung (Bacher et 
al., 1991; Osada et al., 1990) and skeletal muscle (Osada et al., 1990),
respectively. Indeed, human peripheral blood-derived T cells have been shown to 
be express PKC-a, pi, 5, e, and ri subtypes (Lucas et al., 1990; Mischak et al.,
1991a; Mischak et al., 1991b) which appear to be differentially translocated to
.intracellular membranes among T cell subsets (Gupta and Harris, 1994). These 
tissue specific variations in the pattern of expression may underline divergence in 
function occurring between isotopes.
Compartmentalisation of PKC isoforms appears to be dependent on the 
activation state of the cell. It has been generally thought in the past that stimulation 
of cells leads to the translocation of PKC from the cytosol to the Plasma membrane 
as this was seen upon stimulation with phorbol ester (Bell, 1986; Borner et al., 
1992; Hocevar and Fields, 1991; Strulovici et al., 1991). However this picture is a 
little over simplified, as it has been noticed that isoforms tend to behave differently 
depending on the cell in which they are studied and the form of activation used.
PKC isoforms have also been reported to be rapidly translocated from the cytosol to 
the nucleus (Cambier et a l ,  1987; Leach et al., 1989), cytoskeletal elements 
(Mochly-Rosen et a l,  1990), golgi apparatus (Saito et a l,  1989) as well as being 
down regulated (Kiley et a l,  1991) or being non-responsive (Ha and Exton, 1993; 
Kiley e ta l ,  1991; Olivier and Parker, 1994). Hence, it appears that there is no 
clear cut pattern of cellular distribution and behaviour of any one PKC isoform 
upon stimulation of cells with particular stimuli. In a similar fashion to that seen for 
PKAn (see section 1.5.5) intracellular PKC receptors have been described that act
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as receptors for activated PKCs (RACKs) possibly contributing to the localisation 
o f PKCs within the cell (Mochly-Rosen eta l., 1991).
PKC isoforms show differing co-factor requirements and responsiveness to 
phospholipid metabolites in vitro (Bell and Bums, 1991; Nishizuka, 1992). The 
differences in calcium dependence is well established (see above), however there 
are some interesting differences in regulation between isoforms. PKC-J^ is not 
activated by phorbol ester or DAG, but has a low constitutive kinase activity 
(Liyanage et at., 1992), which can be enhanced markedly by PS or arachidonic acid 
(Nakanishi and Ezton, 1992). There is evidence for some PKCs being stimulated 
by PIP3 (Nakanishi et a l,  1993). This is of particular interest as it opens up the 
possibility of cross-talk between PKCs and PÏ-3-K, as well as breaking the 
restriction of PKC activation only in the presence of DAG generation. Activation of 
cPKCs is thought to require DAG as an activator and PS as a cofactor. The 
presence of both lowers the concentration of calcium required for activation. 
However in addition to this, PKC isotypes can be activated by fatty acids and 
lysophosphatidic acids in synergy with DAG, in vitro (Asaoka et al., 1992; 
Nakamura et a l,  1993). It is evident that the array of PKC isotypes offer a 
multitude of prospects for interactions with signalling cascades upon stimulation.
5.1 .2., C on tro l of gene expression .
Protein phosphorylation is known to regulate gene expression within cells 
upon stimulation, A growing list of nuclear effector proteins includes proto­
oncogene products which function as transcription factors as well as tumour 
suppressor proteins, which may be involved in regulating the onset of DNA 
replication. Control of activities can occur through phosphorylation and 
dephosphorylation of transcription factors, which can respond to extracellular 
signals transduced via signalling pathways to the nucleus. Among the proteins 
controlled are CREB/ATF family that mediates the stimulation of gene expression in
.
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response to factors which elevate intracellular levels of cyclic AMP (see section
1.5,6), and activator protein 1 (AP-1).
AP-1 is a collection of homodimeric and heterodimeric complexes 
composed of jun m d fo s  gene products. These products interact with a common 
DNA binding site (TGAC/GTCA) (Angel and Karin, 1991), termed the PM A 
responsive element (TRE), since this motif was first identified in the promoters of 
genes induced by phorbol esters such as PMA (Lee et al., 1987). Thus, activation 
of gene transcription occurs in response to activators of PKC, growth factors and 
transforming oncogenes (Angel et al., 1987). The jun o.nd fos  genes are immediate- 
early genes whose transcription is rapidly induced by the same signals which 
induce AP-1 activity (Angel and Karin, 1991). In several cell types the basal level 
o f fo s  and Jun is very low, but expression can be induced rapidly and transiently 
(Morgan and Curran, 1991). Indeed c-Fos accumulation has been reported within 
an hour of the initial stimulus (Greenberg and Ziff, 1984; Kruijer et al., 1984). The 
induction of c-jun is longer lasting and can elevated for days depending on the 
manner of the cell type and stimulus provided (Karin, 1990).
Functional AP-1 consists of dimers of proteins of the Fos and Jun families 
(Bohmann et al., 1987; Chiu et al., 1988; Franza et al., 1988). The Jun family 
proteins c-Jun, JunB and JunD have the ability to homo- or hetero-dimerise with 
other AP-1 proteins (Nakabeppu et al., 1988). In contrast, Fos family proteins c- 
Fos, Fra-1, Fra-2 and FosB need one of the Jun family proteins for dimérisation.
The hetero-dimers formed are more stable than Jun homodimers, and are 
consequently more efficient in binding to DNA (Chiu et al., 1988; Smeal et al.,
1989).
Increases in AP-1 activity can occur in the absence of de novo protein 
synthesis by a process involving modulation of pre-existing AP-1. PMA directly 
activates most PKC isotypes, leading to phosphorylation of target proteins which 
results in the up-regulation of AP-1 activity. Resting cells contain a latent form of 
phosphorylated c-Jun, which is unable to effectively bind to TRE (Boyle et al..
«1991). Upon stimulation with PMA, there is a rapid site specific 
dephosphorylation of c-Jun close to the DNA binding domain, and an activation of 
DNA binding (Boyle et a l ,  1991). Two N-terminal serines are phosphorylated 
upon phorbol ester treatment of cells, and this phosphorylation event appears to be 
important for the activation of c-Jun activity (Pulverer et a l ,  1991). As c-Jun is 
positively regulated, these phosphorylations result in the production of c-Jun 
protein. PKC activation also stimulates the phosphorylation of c-Fos (Barber and #
■ fVerma, 1987). In addition to its role in transcriptional activation, it also has a 
repressor activity (Sassone-Corsi et a l,  1988). The phosphorylation sites are 
present in the C-terminal end of the protein, in the same region as its activation and 
repression domains. Substitution of these phosphorylatable residues for alanines f
abolishes the repressor activity, without effecting the activation of transcription 
(Offir et a l ,  1990). The biological consequence is that c-Fos is likely to contribute 
to its own transient synthesis, whereas in the case of c-Jun it prolongs its 
production and therefore generates a longer lasting signal.
Clearly, the regulation of transcription factor AP-1 by different mitogenic 
signals can occur through the phosphorylation of c-Jun and c-Fos protein families.
Although other signalling pathways are involved in the regulation of these proteins,
PKC appears to play an important role the control of gene transcription through 
TRE- regulated genes.
5.1.3, Protein phosphatase and protein kinase inhibitors.
A number of selective protein kinase inhibitors are available, but it has 
become apparent with the generation of more sensitive techniques, that some 
inhibitors are not as selective for a particular type of kinase as was first thought.
'I
W ith this in mind, it is essential when administering kinase inhibitors to treat results 
obtained with extreme caution.
■ f
Intense efforts have been made to find protein kinase inhibitors which target
I:PKC or PTKs, as the action of many oncogenes involves the aberrant activation of t
I
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these protein kinases. The specificity of each a selection of the protein kinase
inhibitors is summarised in table 5.1. It can be seen that chelerythrine, which was
,used in this study displays a high selectivity for PKC, with an IC50 approximately
.100 fold lower than that of any other protein kinase tested. This inhibitor targets 
the substrate binding site of the kinase (Herbert et al., 1990), being a competitive 
inhibitor with respect to the phosphate acceptor, and a non-competitive inhibitor 
with respect to ATP. Staurosporine, which binds to the ATP binding site was also 
used in this study, although, this kinase cannot be considered to be a selective PKC 
inhibitor, as it is obvious from table 5.1 that this inhibitor shows little selectivity for 
PKC over any other serine/threonine or tyrosine kinase (Kiss and Deli, 1992; 
W ilkinson and Hallum, 1994). H-89 was utilised as a selective PKA inhibitor, as it 
shows an IC50 of 40nM against PKA activity (Chijiwa et al., 1990; Hidaka et al.,
1991). The structures of chelerythrine, staurosporine and H89 are outlined in 
figure 5.1.
Tyrophostins are a large group of inhibitors that have different potencies 
towards different PTKs (Lyall et a l, 1989; Margolis et a l,  1989). They are 
synthetic derivatives of the naturally occurring aromatic compound erbstatin, 
produced by strains of Streptomyces. Two such inhibitors were used in this study, 
tyrophostin A l and tyrophostin A25. The former does not have an inhibitory action 
against PTKs and was therefore utilised as a negative control. Genistein has been 
shown to inhibit PTKs that regulate T cell proliferation (Akiyama and Ogawara,
1991). However, genistein has also been shown to inhibit PKC at higher 
concentrations (Akiyama and Ogawara, 1991). The structures of these PTK 
inhibitors are represented in figure 5.2.
The tumour promoter okadaic acid is a polyether fatty acid produced by 
marine dinoflagellates, which potently and specifically inhibits protein phosphatases 
1 and 2A (Bialojan and Takai, 1988) (IC50 of 0.01 and IjitM respectively), two of 
the four major protein serine/threonine phosphatases in mammalian cells (Cohen 
and Cohen, 1989). Ca^VCaM dependent PP2B (calcineurin) is far less sensitive to
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#this inhibitor (IC50 of lOmM), whilst dependent PP2C is unaffected (Bialojan
'
and Takai, 1988). The structure of this PPT inhibitor is outlined in figure 5.3. 
Okadaic acid was used in this study to ascertain whether of not dephosphorylation 
via PP1/PP2A played any role in the regulation of PDE activities in murine 
thymocytes.
5.1.4. Aims and objectives.
It is evident from chapter 4 that, upon stimulation of activated and resting 
population of murine thymocytes with anti-CD3 monoclonal antibodies, there was a 
significant increase in PDE4 activity. It was therefore of interest to study the 
mechanism behind this elevation. The studies were carried out on ‘mixed’ 
populations of thymocytes, as it was apparent that both in v/vo-activated and resting 
cells behave similarly with respect to the modulation of their PDE activities upon 
stimulation with anti-CD3/TCR antibodies or with PHA. As changes in PDE 
activity differed upon PHA stimulation or anti-CD3 stimulation, it was decided to 
concentrate on the regulation of the anti-CD3-antibody induced stimulation of PDE4 
activity. This is because the mechanism could be directly attributed to the CD3 
component of the TCR/CD3 complex. PHA is known to cross-link a number of 
cell surface receptors, including CD2 and the TCR/CD3 complex (O’Flynn et al., 
1985), therefore making interpretation of the results, and assigning an effect to a 
single cell surface receptor more difficult.
I
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5.2. R esults.
With the use of selective inhibitors towards particular serine/threonine or 
tyrosine kinases, the underlying mechanism of TCR-mediated elevation of PDE4 
activity was studied in murine thymocytes. As mentioned previously, ‘mixed’ 
populations of thymocytes were used in this part of the study as opposed to ‘m 
vivo-activated’ and ‘resting’ populations of cells (see chapters 3 and 4). Figure 5.4 
shows murine thymocytes stimulated with anti-CD3 antibodies (5p.g/ml) for up to 
30 minutes. In a similar fashion as described before (see section 4.2 and fig. 4.3), 
there was an elevation in total PDE activity, which upon analysis with rolipram, the 
PDE4 selective inhibitor, was shown to be due to the PDE4 component of the 
thymocyte extract (fig 5.4). Upon addition of stimulatory concentrations of cyclic 
GMP (lOpM), total PDE activity was elevated about 4 fold, in keeping with the 
presence of cyclic GMP-stimulated, PDE2 activity (fig. 5.5). This activity 
remained unchanged upon stimulation with anti-CD3 antibodies, although a slight 
increase in total PDE activity is observed, due to the elevation of PDE4 activity (tig.
5.5). This result was similar to that shown previously (tig. 4.4).
5.2.1. M odulation of PKC activities.
Selective inhibitors and activators of PKC were employed to ascertain 
whether or not these serine/threonine kinases had a role in the activation of this 
PDE4 activity elevation. Stimulating murine thymocytes with anti-CD3 antibodies 
in the presence of chelerythrine (lOpM), which shows selectivity for inhibition of 
PKC at low concentrations (Herbert e ta l ,  1990), abrogated the elevation in PDE4 
activity (tig. 5.6b). With the use of rolipram, it was seen that chelerythrine was 
responsible for blocking the rise in PDE4 activity specifically (fig. 5.6a). 
Intriguingly, abrogation of PKC activity caused a decrease in PDE activity (tig. 
5.6b). Staurosporine also abrogated the elevation in PDE4 activity (table 5.2).
Upon addition of PMA (lOOnM) alone, there was an elevation in PDE4 
activity (fig. 5.7a), which was similar to that seen upon stimulation of anti-CD3
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antibodies alone (fig. 5.7b). This implies that the rise in PDE4 activity was a PKC- 
mediated response. Interestingly, addition of PMA alone appeared to block the 
initial decrease in PDE activity observed upon stimulation of the cells with anti-CD3 
mAbs. This may indicate that a pathway which is inhibitory to PDE4 is initially 
activated prior to PKC activation following ligation of the TCR and can be 
bypassed by the direct activation of PKC. An elevation of PDE4 activity was 
observed upon addition of PMA and anti-CD3 antibodies together (fig 5.8). The 
increase in PDE4 activity was of the same magnitude as that seen in the presence of 
PMA or anti-CD3 mAbs alone suggesting they are using the same pathway (rig. 
5.7b). PDE2 activities remained unchanged following PMA treatment of 
thymocytes (table 5.3).
Basal PDE4 activities were generally unaffected by incubation with the 
inhibitors alone (table 5.4) and PDE2 activities were unchanged by protein kinase 
inhibitors in the absence (table 5.5) and presence (table 5.3) of anti-CD3 mAbs.
5.2.2. M odulation o f PKA activities.
In order to determine whether PKA played a role in controlling the activity 
of PDE activities, the selective PKA inhibitor H89 was employed in the assays 
(Chijiwa et al., 1990). It was found to have no effect on the elevation of PDE4 
activity when incubated in the presence of anti-CD3 antibodies (rig 5.9). This was 
also true of PDE2 activity which remained unchanged in the presence of H89 (table 
5.3).
5.2.3. Effect of protein phosphatase inhibitor, okadaic acid.
Okadaic acid is a PPT inhibitor which is selective for the serine/threonine 
phosphatases-1 and -2A (Bialojan and Takai, 1988). Murine thymocytes stimulated 
with anti-CD3 mAbs showed an increase in PDE4 activity (rig. 5.10a) in the 
presence of okadaic acid (lOOnM). This was similar to that seen in the absence of 
the PPT inhibitor (fig. 5.10b). Thus implying that a serine/threonine
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déphosphorylation event, involving PPl and PP2A, is not necessary for the 
activation of PDE4 activity upon ligation of the TCR/CD3 complex. Once again, 
PDE2 activity was unaffected by the addition of okadaic acid to anti-CD3 antibody 
stimulated thymocytes (table 5.3). Okadaic acid alone was found to be without 
effect on PDE activity throughout the incubation time (table 5.4 and 5.5).
5.2.4. Effect o f tyrosine kinase inhibitors on PDE activities.
The elevation in PDE4 activity resulting from anti-CDS ligation was 
inhibited by addition of genistein (10|iM) (table 5.6). This result indicated that 
tyrosine phosphorylation was also probably involved in the process of PDE4 
activation. Similar results were observed on addition of lOOpM genistein (table
5.6). Indeed, at the higher concentration the inhibition by genistein was greater, 
which may imply that this tyrosine kinase inhibitor is non-specifically inhibiting 
serine/threonine kinases (Akiyama and Ogawara, 1991). However this may also 
indicate that a higher concentration of genistein is required to inhibit PTK activities 
in murine thymocytes. Tyrophostins A l and A25 were also used to determine 
whether tyrosine phosphorylation played a role in the elevation of PDE activity. 
Tyrophostin A l was chosen as it is a non-inhibitory tyrophostin and should 
therefore be without effect when incubated with anti-CD3 stimulated thymocytes. 
However, tyrophostin A l and A25 revealed similar results to those results obtained 
with IOjllM genistein (table 5.6). The inhibition seen with tyrophostin A l indicated 
that these tyrophostins may be acting in a non-specific manner in murine 
thymocytes.
However, the inhibition of PDE4 activity was evident on addition of 
genistein. This indicated that tyrosine phosphorylation was involved with the 
elevation of PDE4 activity in murine thymocytes. Neither type of PTK inhibitor 
affected basal PDE activities of murine thymocytes (table 5.4 and 5.6).
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5.2.4. Effect of RNA and protein synthesis inhibition.
Both actinomycin D and cyclohexamide abolished the elevation of PDE4 
activity, seen in response to either anti-CD3 antibodies (fig 5.11 and 5.14a), PMA 
(fig. 5.12 and 5.14b) or anti-CD3 antibodies plus PMA (fig. 5.13 and 5.14c). This 
is exciting, as it implies that the increase in PDE4 activity is derived by rapid 
induction of a PDE4 gene generating de novo enzyme upon ligation of the 
TCR/CD3 complex.
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5.3. D iscussion
It has previously been established that upon ligation of the TCR in murine 
thymocytes there is an increase in PDE4 activity (see chapter 4). The results 
presented above suggest that the PDE4 activity is elevated in a PKC-dependent 
manner. This is indicated by three lines of evidence: (i) Upon addition of PKC 
selective inhibitor, chelerythrine, the rise in PDE activity was abolished, (ii) Upon 
addition of the phorbol ester, PMA, which activates most isoforms of PKC (Ohno 
et al., 1994), there was an immediate increase in PDE4 activity in the absence of 
stimulation with anti-CD3 antibodies. This elevation of activity was of a similar 
magnitude to that seen with anti-CD3 antibodies alone, (iii) The addition of TP A ■ 
and anti-CD3 antibodies was not additive regarding PDE4 activation.
Staurosporine and the PTK inhibitor, genistein also led to an abrogation of 
PDE4 increase in activity, in the presence of anti-CD3 antibodies. This result 
implied that a tyrosyl phosphorylation event may be involved in the activation of 
PDE4 activity. Tyrophostin A25 also inhibited the elevation of PDE4 activity, 
however, this activity was also affected by the negative control tyrophostin A 1 
indicating that tyrophostins may have non-specific effects in these cells. The 
selective PKA inhibitor, H-89 did not effect PDE4 elevation, suggesting that PKA 
is not involved in the elevation of PDE4 activity. Serine/threonine residue 
dephosphorylation is also not thought to be implicated in the increase of PDE4 
activity, as the PPl and PP2A inhibitor, okadaic acid had no effect.
In order to test whether enzyme induction might have been responsible for
the increase in PDE activity, stimulations were carried out in the presence of either 
.actinomycin D or cyclohexamide. It was exciting to note that the incubation of 
murine thymocytes with either of these agents inhibited the PMA/anti-CD3- 
mediated elevation in PDE4 activity. This result was also somewhat surprising 
when one considers that the elevation in PDE activity, above basal, occuiTcd within 
ten minutes of anti-CD3 stimulation. However this is not to say that the activity is 
being induced this quickly. There is clearly PDE activity present in the extracts of
•I
unstimulated thymocytes, which may be further activated by post-translational 
modification such as phosphorylation, as has been described previously for PDE4D 
activity (Sette et a l ,  1994a). However in this case, the rise in PDE activity did 
appear to be inhibited by incubation with actinomycin D or cyclohexamide. This 
suggests a rapid induction of a PDE4 gene. This rapid induction bears a similarity 
to the ability of phorbol esters to activate immediate early genes (Greenberg and 
Ziff, 1984; Hata et al., 1993). It may be that a PDE4 gene is under the same 
transcriptional control as c-jun (Angel et al., 1988) and c-fos, as well as other 
proteins (Angel e ta i ,  1987; Imbra and Karin, 1988). Therefore, PDE4 gene 
expression may be regulated by a cw-acting PMA responsive element which is 
bound by AP-1 transcription factors (see section 5.1.2). In several cell types the 
basal level of Fos and Jun is very low, but expression can be induced rapidly and 
transiently, with transcriptional activation (Greenberg e ta i ,  1985; Greenberg and 
Ziff, 1984). PMA has been shown to induce Fos in CHO cells in a transient 
fashion within 30 minutes of exposure (Stumpo et a l, 1988). Indeed, a recent 
paper has established the induction of PDE 1 activity within 25 minutes of 
stimulation with PMA in CHO cells (Spence et a l ,  1995). This was transient in 
nature, similar to that of o-fos induction (Greenberg et a l,  1985). This cell line 
was found to be devoid of type-I PDE activity in the resting state, unlike the 
situation presented here. This study was of particular interest, as it identified PKC- 
a  and -e to be essential in mediating the induction of the PDE activity, whilst PKC- 
p l and -y were ineffectual (Spence e ta i ,  1995). Interestingly, PKC-e has been 
shown to be expressed at high concentrations in murine thymocytes (Strulovici et 
a l,  1991). Therefore, it may be the case that an early event in stimulation of 
murine thymocytes is the activation of a PDE4 activity mediated by a specific PKC 
isoform, possibly, PKC-e, which is known to be activated early in T cell 
stimulation.
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5.3.1. The role o f PKC in T cell activation
It is well established that PKC plays an important role in downstream 
signalling pathways of T cell activation (Farrar and Ruscetti, 1986; Gupta etai.,
1991; Weiss et a l,  1986a). It has been reported that early in T cell activation,
PK C -a was activated, whilst PKC-p activation was prolonged after a lag phase.
PK C -a activation was sufficient in induce the expression of IL-2Ra, whereas the 
sustained activation of PKC-p was required for the expression o f IL-2 and 
subsequent proliferation (Berry et a l ,  1990; Szamel and Resch, 1992). Signalling 
through the TCR/CD3 complex initiates a complex series of events resulting in the 
activation of immediate early genes that are involved in the proliferation of T cells,
the development of immune function and a variety of cellulai* interactions that
.contribute to immune responses (Crabtree, 1989). In addition, signalling through 
the antigen receptor is essential for several transitions in thymic development. f
Upon TCR/CD3 ligation, e~fos, but not-c-Jwn gene product is induced. Both genes 
exhibit binding sites for transcription factor NF-kB which is bound to I-kB in the 
inactive state. This inhibitoiy factor can be removed by a phosphorylation event, 
therefore PKC may act in a dual way to aid in the activation of T cells. PMA 
stimulation of T cells has been shown to up-regulate c-jun and c-fos (Kontny et a l,
1992). However, PMA incubation with an elevation in cyclic AMP only up- 
regulated c-fos, and decreased c-jun, thus elevating AP-1 activity (Kontny et a l,
1992). This is interesting when one considers that upon ligation of the TCR/CD3 
complex in murine thymocytes an elevation in cyclic AMP levels was observed (see 
section 4.3).
It is believed that there are two signalling pathways which are activated from 
the TCR: one mediated by PLC-yl and the other mediated by p2F'“ ((Izquierdo et 
a l,  1992) and see section 1.2.4). PKC activation via phorbol ester or DAG has
1c'also been demonstrated to activate raf-1 (Sozeri et a l ,  1992). The expression of
■AP-1 driven promoters and genes is thought to require raf-1 kinase activity (Binder
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et al., 1992) and may indicate the existence of a protein kinase cascade consisting of 
PKC isoenzymes and the Raf-1 kinase during T cell activation.
It is interesting to note that the PTK inhibitor genistein abrogated PDE4 
activation, as it is thought that a PTK-mediated event is responsible for activating 
PLC-yl, resulting in the activation of PKC via DAG (Secrist et a l,  1991; Weiss et 
ah, 1991). However recent studies indicate that this is not the only pathway 
responsible for activating PKC upon stimulation of thymocytes with anti-CD3 
antibodies. Indeed, there appears to be a stimulation of phospholipase D activity 
which may cause the activation of PKC via phosphatidic acid or DAG derived from 
phosphatidic acid (P. Reid and M. M. Harnett, personal communication). Anti- 
CD3 antibodies have also been shown to activate PLA2 activity which is 
responsible for the generation of arachidonic acid (J. J. Gilbert and M. M, Harnett, 
personal communication). Arachidonic acid is known to stimulate PKC-Ç 
(Nakanishi and Ezton, 1992). In light of this, it was interesting to note that the 
PKC inhibitor chelerythrine was more effective at inhibiting the elevation of PDE4 
activity than genistein, indicating that PDE4 may be activated by a mechanism 
which involves PKC which has been stimulated via different pathways.
I
5.3.2. R egulation  o f cyclic A M P PD Es.
PDE4D activities have been shown to be activated on stimulation with 
thyioid-stimulating hormone (Sette et al., 1994a) via an increase in cyclic AMP 
levels in thyroid cells. This investigation was interesting, as it demonstrated that 
splice variants from the same locus could be differentially regulated on stimulation 
of the cell by a particular hormone (Sette et at., 1994b). Differential regulation led 
to short-term activation of PDE4D3.3, via changes in phosphorylation status, and 
longterm regulation by stimulating de novo protein synthesis of two other splice 
variants PDE4D3.1 and PDE4D3.2. An elevation of cyclic AMP has also been 
shown to cause an increase in ratPDE3 (PDE4D) expression in immature Sertoli 
cells on stimulation with follicle stimulating hormone (FSH) (Monaco etai., 1994;
2 1 0
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Sette e ta i ,  1994b; Swinnen e ta i ,  1991b) and in cardiac myoblasts (Kovala et a l,  
1994). In these cases, cyclic AMP has also been shown to play a role in the 
regulation of its own degradative enzyme, via PKA. PDE4D has also been induced 
in Jurkat cells upon incubation of these cells with a cyclic AMP analog (Engels et 
a l ,  1994). An interesting point to note about that study was the strong mRNA 
signal that was observed in unstimulated Jurkat cells for PDE4A. In chapter 4 it 
was demonstrated that the activity of PDE4 was extremely low in unstimulated 
cells, but that the proportion of activity increased within 2 0  minutes of stimulation 
with cyclic AMP. It may be the case that murine thymocytes have a high 
concentration of PDE4 mRNA. This could at least partially explain the rapid onset 
of PDE4 induction in these cells. However actinomycin D blocked the induction of 
PDE4 activity, therefore indicating that RNA synthesis is also necessaiy for the rise 
in PDE activity. It is not known which PDE4 is induced in murine thymocytes, 
although studies are currently underway in the laboratory to investigate this further 
with the use of PCR amplification and Western blotting techniques. These 
investigations will, hopefully, identify which PDE4(s) are present in murine 
thymocytes, as well as shedding light on the PDE4 species being rapidly induced 
upon stimulation with anti-CD3 antibodies and PMA.
The situation presented above represents a connection between lipid and
i
cyclic AMP signalling within murine thymocytes. The complex family of PDEs
lends itself to the ability to partake in the interactions between signalling pathways, 
due to its ability to be regulated by a number of different effectors (see section
1.5.7) and (Beavo, 1990; Bolger, 1994; Conti e ta i ,  1995b; Houslay and Kilgour, 
1990; Manganiello et a l,  1990a)). This, coupled with the enormous capacity for 
differential regulation of adenylyl cyclase (Chen and Iyengar, 1993; Krupinski et 
a l,  1992), demonstrates the immense opportunity for dynamic control of a vast 
network of intracellular signals. The action of PKC has been shown to regulate a 
number of elements of the cyclic AMP signalling pathway (Houslay, 1991), leading 
to an inhibition (Beckner and Farrar, 1986; Kelleher et a l ,  1984) or an
Overexpression of this PKC isoform, and PKC-e, have been shown to induce 
PD El activity previously (Spence etai., 1995). In this regard, it is interesting to 
note that PKC-e has been found to play an active role during thymocyte activation 
by PMA (Strulovici et a l ,  1991).
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enhancement (Cronin e ta i ,  1986; Yoshimasa et a l,  1987) of agonist induced 
increases in cyclic AMP, depending on the cell type. The regulation of cyclic AMP 
signalling by PKC can occur at various different stages of the signalling pathway, 
such as the modification of stimulatory and inhibitory receptors coupled to adenylyl 
cyclase such as the p2-adrenoceptor (Bouvier et a l,  1987), the 02 -adrenoceptor 
(Convents et a l,  1989), and the inhibitory G; protein (Bell and Brunton, 1986;
Morris et a l,  1994; O’Brien et a l,  1987). Adenylyl cyclase has been shown to be 
modulated by PKC phosphorylation recently in intact cells (Jacobowitz and 
Iyengar, 1994; Kawabe et a l,  1994; Williams et a l ,  1987), as well as in purified 
cell membranes (Nagshineh et a l,  1986; Pyne e ta i ,  1994). Moreover, differing 
sensitivities of the cells may occur due to the different complement of PKC and 
adenylyl cyclase/PDE isoforms which aie expressed within the cell types. It has 
recently been established that PKC-y and PKC-a selectively activated type-V 
adenylyl cyclase (Kawabe et a l,  1994). Cyclic AMP PDE activities have been 
shown to be influenced dramatically by treatment with phorbol esters in 
hepatocytes. For example, glucagon-treated cells become sensitised to cyclic AMP 
elevation upon addition of PMA, resulting from an inhibition of PDE activity 
(Irvine et a l ,  1986).
Therefore, it is apparent that upon ligation of the TCR/CD3 complex in
%
murine thymocytes, there is a rapid induction of a PDE4 activity. The activation of 
this PDE activity appears to be mediated by a PKC-dependent process, as PMA 
activates the activity in a fashion similar to that of anti-CD3 stimulation.
Furthermore, PTK activity(s) also appears to play a role in the activation of PDE4.
An early event in T cell activation is the stimulation of PKC-a, and it may be this
isoform that is responsible for the induction of PDE activity within these cells.
Table 5.1. Summary of ÏC 5 0  values of protein kinase  
in h ib ito rs.
The potency and selectivity of protein kinase inhibitors is 
compared. The values are expressed as IC50S, i.e. the concentration of 
the inhibitor at which there is half maximal inhibition.
 ^Herbert et al., 1990, ^ Kiss and Deli, 1992,
Schachtele et a l,  1988, ^ Tischler et al., 1990,
® Tamaoki et al., 1986,  ^Yanagihara et al., 1991, 
g Girault, 1994,  ^C h ijiw aeta i., 1990,
 ^Akiyama et al., 1987, J Gazit et al., 1989,
^ Lyall et al., 1989,  ^Margolis et al., 1989,
^  Bilder, 1991.
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Table 5.2. PDE4 activity upon stim ulation of murine 
thym ocytes with anti-CD3 monoclonal antibodies, in the 
presence o f protein kinase inhibitor, staurosporine.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5fig/ml) for 30 minutes, in the presence of lOOnM 
staurosporine. The antibody used was directed against the e chain of the 
CD3 complex (Philips eta i. 1991). PDE activities were assessed with 
IpM  cyclic AMP substrate. The tables show a) total PDE activity as a 
percentage of the basal, and b) the fraction of activity inhibited by lOjiM 
rolipram, expressed as a percentage of the PDE4 basal activity. These 
experiments were carried out on a ‘mixed’ population of cells as 
described in ‘Materials and Methods.’ The data shown is an average 
of three separate experiments. Individual assays were carried out in 
triplicate (errors are SEM). Percentages are calculated as the average of 
percentage stimulation from each separate experiment with basal PDE 
activity representing 100%, assayed with IpM  cyclic AMP.
214
I
J
«
Table A 
Total PDE 
activity
anti-CD3 
%age zero 
activity
+ Staurosporine 
%age zero 
activity
0 100+/-5 1 0 0 + /-6
;v.
30 150+/-6 104+/-9
■ii
■f
Table B 
PDE4 activity
anti-CD3 
%age zero 
activity
+ Staurosporine 
%age zero 
activity
0 100+A5 100+/-7
30 184+/-7 94+/-10
Table 5.3. PDE2 activity upon stim ulation vpith anti-CD3  
antibodies and/or PMA in the presence of 
various inhibitors.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5p.g/ml) for 30 minutes, in the presence of various 
inhibitors. The antibody used was directed against the e chain of the 
CD3 complex (Philips et al. 1991). PDE activities were assessed with 
l|iM  cyclic AMP substrate in the presence of stimulatory concentrations 
of cyclic GMP (lOpM), and the magnitude of the increase in PDE 
activity elicited by cyclic GMP is shown. This is taken to serve as an 
index of PDE2 activity. In this regard it must be taken as an 
underestimate as it does not take into account the basal activity of the 
enzyme. However, given the magnitude of the stimulation by cyclic 
GMP, then such a basal component is likely to be small. This approach 
has the advantage in that it solely represents PDE2 activity. Inhibitors 
used are chelerythrine (lOpM), staurosporine'(lOOnM), PMA (lOOnM), 
okadaic acid (lOOnM), H89 (200nM), Genistein (lOjiM and lOOpM), 
tyrophostin 1 (lOOpM) and tyrophostin 25 (lOOjiM), actinomycin D 
(lOOpg/ml) and cyclohexamide (IpM). These experiments were carried 
out on a ‘mixed’ population of cells as described in ‘Materials and 
Methods.’ The data shown is an average of three separate experiments. 
Individual assays were carried out in triplicate (errors are SEM). 
Percentages are calculated as the average of percentage stimulation 
from each separate experiment with basal PDE activity representing 
100%, assayed with l|iM  cyclic AMP.
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PDE2 activity
Cells stimulated with anti-
CD3 antibodies +/- PMA
Omin.
(1 0 0%)
30min.
%age of Omin. ,;3
anti-CD3 antibodies 100 +/- 5 90 +/- 4
Chelerythrine + anti-CD3 100  +/- 10 94 +/- 3
antibodies
Staurosporine + anti-CD3 100 +/- 9 103 +/- 1
antibodies
H89 + anti-CD3 100 +/- 5 94 +/- 8 fantibodies ;S
PMA 100  +/- 8 104 +/- 1 1
i
;PMA + anti-CD3 100  +/- 1 96 +/- 7
antibodies
Okadaic acid + anti-CD3 100  +/- 8 89+/- 3
antibodies
Genistein (10|LiM) + anti- 100 +/- 14 81 + /-7
CD3 antibodies
Genistein (100|J,M) + anti- 100+/- 13 78 +/- 7
CD3 antibodies ;
Tyrophostin A1+ anti- 100 +/- 9 109 +/- 2
CD3 antibodies
::Tyrophostin A25 + anti- 100+/- 13 106 +/- 10
CD3 antibodies '.'4:
Actinomycin D + anti- 1 0 0 +/- 11 8 1 + A 3
CD3 antibodies
Actinomycin D + PMA 100+/- 15 96 +/- 2 ' := 
%Actinomycin D + anti- 100+/- 13 102  +/- 22
CD3 antibodies + PMA
Cyclohexam ide + anti- 100  +/- 8 1 1 0 +/- 12
CD3 antibodes
Cyclohexam ide + PMA 1 0 0 +/- 11 80 +/- 5
Cyclohexam ide + anti- 100  +/- 12 127 +/- 22
CD3 antibodies + PMA
1
: J
Table 5.4. PDE4 activities upon incubation with inhibitors
alone.
PDE4 activities were assessed upon incubation of murine 
thymocytes with various inhibitors for 30 minutes, at IpM  cyclic AMP 
substrate. Inhibitors used are chelerythrine (lOpM), staurosporine 
(lOOnM), PMA (lOOnM), okadaic acid (lOOnM), H89 (200nM), 
Genistein (lOpM and 100|iM), tyrophostin A l (lOOjiM) and tyrophostin 
A25 (lOOpM), actinomycin D (100|ag/ml) and cyclohexamide (l|iM ). 
These experiments were carried out on a ‘mixed’ population of cells as 
described in ‘Materials and Methods.’ The data shown is an average 
o f three separate experiments. Individual assays were carried out in 
triplicate (errors are SEM). Percentages are calculated as the average of 
percentage stimulation from each separate experiment with basal PDE 
activity representing 100%, assayed with l|iM  cyclic AMP.
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:PDE4 activity 
-anti-CD3 antibodies
Omin.
10 0%
30min.
%age of Omin.
Incubation 100  +/- 10 1 1 7 +A5
Chelerythrine 100 +/- 9 91 +/- 4
Staurosporine 100 +/- 5 116+/- 11
H89 100  +/- 10 100  +/- 6
Okadaic acid 1 0 0 + /-1 2 119+/- 14
Genistein (lOjiM) 100  +/- 8 94 +/- 3
Genistein (lOOjiM) 100  +A 10 95 +/- 7
Tyrophostin A l 100 +/- 9 86  +/- 7
Tyrophostin A25 100 +/- 7 77 +/- 5
Actinomycin D 100 +/- 15 93 + /-2
Cyclohexam ide 100 +/- 4 89 +/- 9
Table 5.5. PDE2 activities upon incubation with inhibitors
alone.
PDE2 activities were assessed upon incubation of murine 
thymocytes with various inhibitors for 30 minutes, at l|iM  cyclic AMP 
substrate in the presence of stimulatory concentrations of cyclic GMP 
(lOjiM). Inhibitors used are chelerythrine (lOjiM), staurosporine 
(lOOnM), PMA (lOOnM), okadaic acid (lOOnM), H89 (200nM), 
Genistein (lOpM and lOOjiM), tyrophostin A l (100p,M) and 
tyrophostin A25 (lOOjiM), actinomycin D (100|ag/ml) and 
cyclohexamide (IjiM). These experiments were carried out on a ‘mixed’ 
population of cells as described in ‘Materials and Methods.’ The data 
shown is an average of three separate experiments. Individual assays 
were carried out in triplicate (errors are SEM). Percentages are 
calculated as the average of percentage stimulation from each separate 
experiment with basal PDE activity representing 100%, assayed 
with l|iM  cyclic AMP.
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PDE2 activity 
- anti-CD3 antibodies
Omin.
(1 0 0%)
30min.
%age of Omin.
Incubation 100 +/- 5 105 +/- 9
Chelerythrine 100  +/- 10 92 +/- 10
Staurosporine 100 +/- 9 94 +/- 1
H89 100 +/- 5 100  +/- 10
Okadaic acid 100  +/- 8 107+/- 2
Genistein (lOpM) 100 +/- 14 91 +/ -9
Genistein (lOOjiM) 100+/- 13 96 +/- 9
Tyrophostin A l 100 +/- 9 84 +/- 7
Tyrophostin A25 100+/- 13 93 +/- 9
Actinomycin D 1 0 0 +/- 11 97 +/- 2
Cyclohexam ide 100  +/- 8 107 +/- 8
î
3
Table 5.6. PDE4 activity upon stim ulation of murine 
thym ocytes with anti-CD3 monoclonal antibodies, in the 
presence of PTK inhibitors.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (Spg/ml) for 30 minutes, after a pretreatment of 1 hour with 
lOOfiM tyrophostin 1 and tyrophostin 25, and genistein (lOjiM and 
100|lM). The antibody used was directed against the e chain of the CD3 
complex (Philips et al. 1991). PDE activities were assessed with IpM  
cyclic AMP substrate. The tables show a) total PDE activity as a 
percentage of the basal, and b) the fraction of activity inhibited by lOp-M 
rolipram, expressed as a percentage of the PDE4 basal activity. These 
experiments were carried out on a ‘mixed’ population of cells as 
described in ‘Materials and Methods.’ The data shown is an average 
of three separate experiments. Individual assays were carried out in 
triplicate (errors are SEM). Percentages are calculated as the average of 
percentage stimulation from each separate experiment with basal PDE 
activity representing 100%, assayed with IjxM cyclic AMP.
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Figure 5.1. Structures of the serine/threonine protein kinase
inhibitors chelerythrine, staurosporine and H89.
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Figure 5.2. Structures of the protein tyrosine kinase
inhibitors genistein, tyrophostin A l and tyrophostin A25.
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Figure 5.3. Structure of the protein phosphatase inhibitor 
okadaic acid.
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Figure 5.4. PDE4 activity in murine thymocytes upon
stimulation with anti-CD3 monoclonal antibodies.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5|Xg/ml) for up to 30 minutes as indicated. The antibody 
used was directed against the e chain of the CD3 complex (Philips et al. 
1991). The total PDE activity observed in the presence of IpM  cyclic 
AMP as substrate (circles) is shown. Also given is that fraction of 
activity (squares) which is inhibited by lOpM rolipram. This is not the 
residual rolipram-insensitive fraction, but the fraction of PDE activity 
which was inhibited by rolipram and, as such, can be taken as an index 
of PDE4 activity. These experiments were carried out on a ‘mixed’ 
population of cells as described in ‘Materials and Methods.’ These data 
show results typical of experiments carried out five times. Assays were 
carried out in triplicate (errors are SEM). PDE activity is expressed as 
pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 5.5. PDE2 activity in murine thymocytes upon
challenge with anti-CD3 monoclonal antibodies.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5pg/ml) for up to 30 minutes as indicated. The antibody 
used was directed against the e chain of the CD3 complex (Philips et a l  
1991). Shown is the total PDE activity (diamonds) observed in the 
presence of stimulatory concentrations of cyclic GMP (10|iM) and IjiM  
cyclic AMP as substrate. Also given is the magnitude of the increase in 
PDE activity elicited by cyclic GMP (triangles); this is taken to serve as 
an index of PDE2 activity. In this regard it must be taken as an 
underestimate as it does not take into account the basal activity of the 
enzyme. However, given the magnitude of the stimulation by cyclic 
GMP, then such a basal component is likely to be small. This approach 
has the advantage in that it solely represents PDE2 activity. These 
experiments were carried out on a ‘mixed’ population of cells as 
described in ‘Materials and Methods.’ These data show results typical 
of experiments carried out at least four times. Assays were carried out in 
triplicate (errors are SEM). PDE activity is expressed as pmols cyclic 
AMP hydrolysed/min/mg protein.
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Figure 5.6. PDE4 activity in murine thymocytes upon
stimulation with anti-CD3 monoclonal antibodies in the
presence of PKC inhibitor, chelerythrine.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5|ig/ml) for up to 30 minutes as indicated, in the presence of 
lOpM chelerythrine. The antibody used was directed against the e chain 
o f the CD3 complex (Philips et al. 1991). The graphs show; a) the total 
PDE activity observed in the presence of IjiM  cyclic AMP as substrate 
(inverted triangles), compared with that fraction of activity (squares) 
which is inhibited by lOfxM rolipram. This is not the residual rolipram- 
insensitive fraction, but the fraction of PDE activity which was inhibited 
by rolipram and, as such, can be taken as an index of PDE4 activity, 
b) This graph compares the PDE activity upon stimulation of the cells with 
anti-CD3 antibodies in the absence (circles) and presence (inverted triangles) 
of chelerythrine. These experiments were carried out on a ‘mixed’ 
population of cells as described in ‘Materials and M ethods.’ These data 
show results typical of experiments carried out five times. Assays were 
carried out in triplicate (errors are SEM). PDE activity is expressed as 
pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 5.7. PDE4 activity in murine thymocytes upon
stimulation with PKC activator, PMA.
Thymocytes were stimulated with lOOnM PMA. The graphs 
show; a) the total PDE activity observed in the presence of IjiM cyclic 
AMP as substrate (inverted triangles), compared with that fraction of 
activity (squares) which is inhibited by lOjiM rolipram. This is not the 
residual rolipram-insensitive fraction, but the fraction of PDE activity 
which was inhibited by rolipram and, as such, can be taken as an index 
of PDE4 activity, b) This graph compares the PDE activity upon 
stimulation of the cells with anti-CD3 antibodies (circles) or PMA 
(inverted triangles). These experiments were carried out on a ‘mixed’ 
population of cells as described in ‘Materials and Methods.’ These data 
show results typical of experiments carried out four times. Assays were 
carried out in triplicate (errors are SEM). PDE activity is expressed as 
pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 5.8. PDE4 activity In murine thymocytes upon
stimulation with anti-CD3 monoclonal antibodies in the
presence of PKC activator, PMA.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5p.g/ml) for up to 30 minutes as indicated, in the presence of 
lOOnM PMA. The antibody used was directed against the £ chain of the 
CD3 complex (Philips et al. 1991). The graphs show; a) the total PDE 
activity observed in the presence of IpM  cyclic AMP as substrate 
(inverted triangles), compared with that fraction of activity (squares) 
which is inhibited by 10{iM rolipram. This is not the residual rolipram- 
insensitive fraction, but the fraction of PDE activity which was inhibited 
by rolipram and, as such, can be taken as an index of PDE4 activity, 
b) This graph compares the PDE activity upon stimulation of the cells 
with anti-CD3 antibodies in the absence (circles) and presence (inverted 
triangles) of PMA. These experiments were carried out on a ‘mixed’ 
population of cells as described in ‘Materials and Methods.’ These data 
show results typical of experiments carried out four times. Assays were 
carried out in triplicate (errors are SEM). PDE activity is expressed as 
pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 5.9. PDE4 activity in murine thymocytes upon
stimulation with anti-CD3 monoclonal antibodies in the
presence of PKA inhibitor, H89.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5p.g/ml) for up to 30 minutes as indicated, in the presence of 
200nM H89. The antibody used was directed against the e chain of the 
CD3 complex (Philips et a i  1991). The graphs show; a) the total PDE 
activity observed in the presence of l|iM  cyclic AMP as substrate 
(inverted triangles), compared with that fraction of activity (squares) 
which is inhibited by lOjiM rolipram. This is not the residual rolipram- 
insensitive fraction, but the fraction of PDE activity which was inhibited 
by rolipram and, as such, can be taken as an index of PDE4 activity, 
b) This graph compares the PDE activity upon stimulation of the cells 
with anti-CD3 antibodies in the absence (circles) and presence (inverted 
triangles) of H89. These experiments were carried out on a ‘mixed’ 
population of cells as described in ‘Materials and Methods.’ These data 
show results typical of experiments carried out three times. Assays were 
carried out in triplicate (errors are SEM). PDE activity is expressed as 
pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 5.10. PDE4 activity in murine thymocytes upon
stimulation with anti-CD3 monoclonal antibodies in the
presence of PPT inhibitor, okadaic acid.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5p.g/ml) for up to 30 minutes as indicated, in the presence of 
lOOnM okadaic acid. The antibody used was directed against the e 
chain of the CD3 complex (Philips et al. 1991). The graphs show; a) 
the total PDE activity observed in the presence of IjiM cyclic AMP as 
substrate (inverted triangles), compared with that fraction of activity 
(squares) which is inhibited by lOp-M rolipram. This is not the residual 
rolipram-insensitive fraction, but the fraction of PDE activity which was 
inhibited by rolipram and, as such, can be taken as an index of PDE4 
activity, b) This graph compares the PDE activity upon stimulation of the 
cells with anti-CD3 antibodies in the absence (circles) and presence 
(inverted triangles) of okadaic acid. These experiments were carried out 
on a ‘mixed’ population of cells as described in ‘Materials and Methods.’ 
These data show results typical of experiments carried out three times. 
Assays were carried out in triplicate (errors are SEM). PDE activity is 
expressed as pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 5.11. PDE4 activity in murine thymocytes upon
stimulation with anti-CD3 monoclonal antibodies in the
presence of RNA synthesis inhibitor, actinomycin D.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5jig/ml) for up to 30 minutes as indicated, after a 
preincubation of 45 minutes in the presence of lOOpg/ml actinomycin D. 
The antibody used was directed against the e chain of the CD3 complex 
(Philips et al. 1991). The graphs show; a) the total PDE activity 
observed in the presence of IpM  cyclic AMP as substrate (filled), 
compared with that fraction of activity (hatched) which is inhibited by 
lOpM rolipram. This is not the residual rolipram-insensitive fraction, 
but the fraction of PDE activity which was inhibited by rolipram and, as 
such, can be taken as an index of PDE4 activity, b) This graph compares 
the PDE activity upon stimulation of the cells with anti-CD3 antibodies 
in the absence (spots) and presence (filled) of actinomycin D. These 
experiments were carried out on a ‘mixed’ population of cells as described 
in ‘Materials and Methods. ’ These data show results typical of experiments 
carried out three times. Assays were carried out in duplicate (range >12%). 
PDE activity is expressed as pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 5.12. PDE4 activity in murine thymocytes upon
stimulation with PKC activator, PMA, in the presence of
actinomycin D.
Thymocytes were stimulated with lOOnM PMA in the presence 
o f lOOpg/ml actinomycin D. The graphs show; a) the total PDE activity 
observed in the presence of lp,M cyclic AMP as substrate (filled), 
compared with that fraction of activity (hatched) which is inhibited by 
lOjiM rolipram. This is not the residual rolipram-insensitive fraction, 
but the fraction of PDE activity which was inhibited by rolipram and, as 
such, can be taken as an index of PDE4 activity, b) This graph compares 
the PDE activity upon stimulation of the cells PMA in the absence (spots) 
or presence (filled) of actinomycin D. These experiments were carried 
out on a ‘mixed’ population of cells as described in ‘Materials and 
Methods.’ These data show results typical of experiments carried 
out three times. Assays were carried out in duplicate (range >12%).
PDE activity is expressed as pmols cyclic AMP hydrolysed/min/mg 
protein.
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Figure 5.13. PDE4 activity in murine thymocytes upon
stimulation with anti-CD3 monoclonal antibodies in
the presence of PMA and actinomycin D.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5|ig/ml) and PMA (lOOnM) for up to 30 minutes as 
indicated, after a preincubation of 45 minutes in the presence of 
lOOjig/ml actinomycin D. The antibody used was directed against the e 
chain of the CD3 complex (Philips et al. 1991). The graphs show; a) 
the total PDE activity observed in the presence of l|iM  cyclic AMP as 
substrate (filled), compared with that fraction of activity (hatched) which 
is inhibited by 10|iM rolipram. This is not the residual rolipram- 
insensitive fraction, but the fraction of PDE activity which was inhibited 
by rolipram and, as such, can be taken as an index of PDE4 activity, 
b) This graph compares the PDE activity upon stimulation of the cells 
with anti-CD3 antibodies and PMA in the absence (spots) and presence 
(filled) of actinomycin D. These experiments were carried out on a ‘mixed’ 
population of cells as described in ‘Materials and Methods.’ These data 
show results typical of experiments carried out three times. Assays were 
carried out in duplicate (range >11%). PDE activity is expressed as 
pmols cyclic AMP hydrolysed/min/mg protein.
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Figure 5.14. Cyclic AMP PDE activity in murine thymocytes 
upon stim ulation with anti-CD3 monoclonal antibodies and/or 
PM A in the presence o f protein synthesis inhibitor, 
cycloh exam id e.
Thymocytes were stimulated with anti-CD3 monoclonal 
antibodies (5|ag/ml) and/or PMA (lOOnM) for up to 30 minutes as 
indicated, after a preincubation of 45 minutes in the presence of IjiM  
cyclohexamide. The antibody used was directed against the e chain 
o f the CD3 complex (Philips etal. 1991). The graphs show the total 
PDE activity observed with IjuM cyclic AMP as substrate in the presence 
(filled) and absence (spots) of lp.M cyclohexamide. Graph:
a) thymocytes are stimulated with anti-CD3 antibodies; b) thymocytes 
are stimulated with PMA; and c) thymocytes are stimulated with both 
anti-CD3 antibodies and PMA. These experiments were carried out 
on a ‘mixed’ population of cells as described in ‘Materials and 
Methods.’ These data show results typical of experiments carried 
out three times. Assays were carried out in duplicate (range >15%).
PDE activity is expressed as pmols cyclic AMP hydrolysed/min/mg 
protein.
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6. Discussion
This study has illuminated some exciting points regarding the expression 
and regulation of cyclic AMP PDEs in T cells from different sources. It has been 
determined that: (i) the profile of cyclic AMP PDE isoforms varies between 
different species, (ii) differential regulation of cyclic AMP PDE activities and cyclic 
AMP levels occur upon stimulation of murine thymocytes with the TCR ligating 
mitogenic lectin, PHA or anti-CD3/anti-TCR antibodies, (iii) anti-CD3 stimulated 
changes in PDE4 activity appear to be mediated by a PKC-dependent pathway, 
involving rapid induction of a PDE4 activity.
6.1. Im plications of different PDE activities in T cells.
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Ca VCaM-stimulated, PDEl activity has not been found to be present in 
either primary murine lymphocytes, thymocytes or human tonsillar T cells. This 
finding is supported by other investigations which indicate the absence of type-I 
PDE activity in human and bovine peripheral blood lymphocytes (Hurwitz et a l,
1990; Robicsek et a l ,  1989; Thompson et al., 1976), rat thymocytes (Marcoz et 
a l,  1993) or rat splenic lymphocytes (Hait and Weiss, 1976). However this 
activity does appear to be present in Jurkat cells and other proliferating lymphoid 
cell lines (Epstein e ta l ,  1987). Furthermore, expression can be induced by
,mitogenic stimulation of primary T cells (Hurwitz et a l, 1990). This indicated that 
Ca^VCaM-stimulated, PDEl activity may have a role in proliferating cells. These 
studies demonstrate a possible regulatory interface for the metabolism of calcium 
and cyclic nucleotides during lymphocyte mitogenesis.
It has been demonstrated that cyclic GMP-stimulated, PDE2 activities exist 
in primary murine thymocytes, T3.2 thymoma cells and the human T cell line,
Jurkat. From the studies presented above and others (Franks and MacManus,
1971; Meskini et a l,  1992; Robicsek et a l ,  1989; Valette et a l, 1990) it is clear that 
cyclic GMP may play a very influential role in the regulation of hydrolysis of cyclic 
AMP. In murine thymocytes it is evident that upon increasing cyclic GMP levels
there is an enormous increase in cyclic AMP breakdown. In future studies, it 
would intriguing to study the effects of increasing cyclic GMP concentrations with 
the use of sodium nitroprusside, an activator of guanylyl cyclase activity, or cyclic 
GMP analogues on cyclic AMP levels and PDE activities within the murine 
thymocytes. It has been previously found in studies on rat thymocytes, that 
inhibiting PDE3 in conjunction with PDE4 had anti-proliferative effects on the 
proliferation of rat thymocytes (Marcoz et al., 1993). This effect was mirrored by 
inhibiting the PDE4 activity and elevating cyclic GMP with sodium nitroprusside, 
indicating that cyclic GMP has a role as a negative effector in lymphocyte mitogenic 
response. However the effect was not seen when 8-bromo-cyclic GMP, a potent 
activator of PKG, was used to elevate cyclic GMP levels. Due to the predominance 
of PDE2 activity in murine thymocytes, and the apparent lack of PDE3 activity, it 
would be interesting to investigate PDE2 function in relation to proliferation within 
murine thymic organ cultures. These studies may illuminate key differences in the 
control of cyclic AMP homeostasis between murine and rat models.
As eluded to above, rat thymocytes have been shown to contain both cyclic 
GMP-inhibited and cyclic GMP-stimulated PDE activities (Franks and MacManus, 
1971; Valette et al., 1990), implying that there is a complex control of cyclic GMP 
regulation of cyclic AMP PDE activities. The investigations here suggest an 
absence of cyclic GMP-inhibited PDE3 activity in murine thymocytes, 
demonstrating that there are species specific differences in PDE expression. In 
systems where both cyclic GMP-stimulated, and cyclic GMP-inhibited PDE 
isoforms exist, differential regulation of these PDEs may occur with differing levels 
of cyclic GMP. At low concentrations of cyclic AMP, the cyclic GMP-inhibited 
PDE activity would predominate whereas, if levels were to increase, cyclic GMP 
stimulated PDE activity would be activated in the presence of cyclic GMP (Franks 
and MacManus, 1971).
T3.2 thymoma cells give an interesting comparison to murine thymocytes, 
as the predominant PDE activity in this murine cell line is not the cyclic GMP
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stimulated PDE. Indeed these cells appear to express a cyclic GMP-inhibited PDE3 
activity and therefore appear to be more similar to rat thymocytes (Valette et al.,
1990), Jurkat cells and primary human lymphocytes (Meskini et al., 1992;
Robicsek etal., 1991), with regard to the complement of cyclic AMP PDEs 
expressed. This difference may relate to the prominence of a particular 
developmental stage within the cell line, in contrast to thymocyte preparations 
which are made up of cells from several different maturation stages. Unlike Jurkat 
cells where PDE3 activity is dominant at basal levels, PDE4 is the predominant 
activity in T3.2 cells. This implies that in the absence (or at sub-micromolar 
concentrations) of cyclic GMP, T3.2 cells will behave in a similar manner to that of 
primary murine thymocytes in a similar situation with regard to PDE activities. The 
situation changes dramatically however, upon introduction of cyclic GMP. It is 
likely that cyclic AMP catabolism would increase dramatically within primary cells, 
but would not be affected considerably in the proliferating cell line. It would be of 
interest, therefore, to study the effects of cyclic GMP and cyclic AMP elevating 
agents on this cell line in parallel with studies carried out on thymic cultures. This 
would be particularly exciting, as it is known that upon stimulation of these cells 
with Con A, PHA and ionomycin there is an induction of apoptosis. However, this 
does not occur upon stimulation with PMA or anti-CD3 antibodies, unless the cells 
are sufficiently cross-linked (R. Zamoyska personal communication). This points
.
to a difference in signalling networks between this cell line and primary thymocytes 
(Shi eta l., 1991; Smith et a i,  1989; Ta.y\or et al., 1984).
cells upon stimulation of soluble guanylyl cyclase in the brain. The generation of 
NO could be important in controlling apoptosis (Genaro et al., 1995), which is 
particularly relevant in the thymic environment, where 95% of developing T cells 
apoptose, with the remaining 5% entering the periphery (Hueber et al., 1994; Kaye 
and Ellenberger, 1992). It would therefore be of interest to study the effect of nitric
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Nitric oxide may have an important influence on cyclic AMP concentrations 
within cells, as it has been shown to elevate cyclic GMP levels within and between
oxide on cyclic AMP metabolism, particularly in T3.2 cells, in order to identify a 
possible link between nitric oxide and T cell apoptosis.
PDE4 activities appeared to be apparent in all of the cells looked at in this 
study, dominating the PDE activities of murine thymocytes and T3.2 thymomas in 
the absence of cyclic GMP. Thus indicating the importance of this isozyme in the 
homeostasis of cyclic AMP in lymphoid cells. However, in Jurkat cells there 
appeared to be an IBMX insensitive activity present also. Without further analysis 
of these cells it cannot be defined as a PDE7 activity, although it is interesting to 
note that Ichimura et al. (1993) have reported a high affinity PDE activity in Jurkat 
cells, and other T cell lines that is insensitive to cyclic GMP and rolipram. This 
activity is absent from B cell lines, illustrating a lineage-specific difference in PDE 
expression in cells of lymphoid origin.
It was rather surprising to find that 'in vfro-activated’ and ‘resting’ 
populations of thymocytes have a similar basal PDE activity in the absence and 
presence of stimulatory concentrations of cyclic GMP. This was not found to be 
the case with murine lymphocytes, where the activated populations of cells were 
seen to have higher PDE activities. This is consistent with studies carried out on 
leukemic cells, where PDE activities are seen to be enormously elevated in 
comparison to normal peripheral blood lymphocytes (Epstein and Hachisu, 1984;
Epstein et a i,  1977; Hait and Weiss, 1976). A possible reason for the difference 
between thymocytes and lymphocytes could be that 'in viVo-activated’ thymocytes 
isolated on the basis o f their buoyant density may reflect a population of ‘activated 
thymocytes’ that are undergoing activation-induced cell death, rather than 
proliferation, thus having unaltered PDE activities.
The pattern of PDE expression and activities have been observed to undergo 
profound changes after stimulation and during cell differentiation in cells such as 
Sertoli cells (Conti et a i,  1982; Swinnen et al., 1989b), 3T3-L1 cells (Manganiello 
et al., 1983), fibroblasts (Manganiello and Vaughan, 1972) and lymphoma cells 
(Bourne et a l, 1974). This indicates that changes in the pattern of cyclic AMP
I
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degradation may be an integral part of the cells long term response to stimulation 
and possibly of the differentiating process. Indeed, PDE activity has also been seen 
to be elevated in Jurkat cells after stimulation with cyclic AMP elevating agents are 
applied for three hours (S. Erdogan, personal communication).
6.2. Cyclic AMP PDE activities on stimulation with TCR ligating  
ag en ts .
Cyclic AMP PDE activities are differentially regulated upon stimulation of 
thymocytes with PHA or with monoclonal antibodies directed against the TCR/CD3 
complex. One of the main reasons for this could be the complement of cell surface 
receptors which are being ligated by these agents. PHA is known to coligate CD2 
and the TCR/CD3 complex (O’Flynn et al., 1985), therefore it would be interesting 
to try ligating CD2 alone with antibodies raised against specific epitopes of this 
molecule, to ascertain the effects on PDE activities. There is a range of anti-CD2 
monoclonal antibodies available, whose effects ai'e dependent on the pairing of 
antibodies used, from unresponsiveness to proliferation (Yang et al., 1986).
Another reason for the differing effects of these agents may be that CD2 is 
present at the early stages of thymocyte differentiation, being expressed on 85-95% 
of all developing T cells (Fox et a l ,  1985; Lanier et a l,  1986; Sewell et a l, 1986). 
This suggests that a greater proportion of the cells will be ligated by PHA than with 
monoclonal antibodies directed against the TCR. Anti-CD3/anti-TCR antibodies 
will target the more mature populations of cells, thus opening the possibility of 
different signalling. Cyclic AMP has been implicated in early thymocyte 
differentiation (Bach et a l ,  1975; Scheid et a l ,  1975) and stimulation of thymic 
apoptosis (Kaye and Ellenberger, 1992; McConkey et a l,  1990a); two very 
divergent physiological events. Tliis indicates that at different developmental 
stages, cyclic AMP signalling mediates a different end result. In order to study 
this, it may be possible to study sub-populations of cells within the thymus, in 
order to ascertain how the PDE activities are regulated following stimulation with
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PHA. This would have the advantage of studying a more homogeneous population 
of cells. It was hoped that these studies could be carried out on the T3.2 thymoma 
cell line, but the PDE activities expressed within the cells meant that comparisons 
between this cell system and primary thymocytes may be difficult.
In these studies it was interesting that upon ligation of TCR/CD3 complex 
there was a 2-fold increase in PDE4 activity within 20 minutes of incubation with 
anti-CD3/anti-TCR antibodies. This was accompanied by a rise in cyclic AMP 
concentration. It is known that ligating CD3 in thymocytes leads to apoptosis in 
vitro (Smith e ta i ,  1989) and in vivo (Shi e ta l ,  1991), whereas thymocytes
respond mitogenically to co-stimulation with lectins and PMA (Taylor et al., 1984). 
Indeed, Con A has been found to cause proliferation of rat thymocytes, with PDE4
being essential for this mitogenic response (Marcoz et a l,  1993). This indicates
that sustained elevations of cyclic AMP are inhibitory to proliferation, and that
PDE4 activities are central to controlling cyclic AMP levels within thymocytes 
(Marcoz et al., 1993). In mature lymphocytes it is tempting to suggest that cyclic 
AMP levels are important in the control of proliferation, as basal PDE activities are 
elevated in 'in vzvo-activated’ populations of cells.
Cyclic AMP homeostasis may play a role in controlling adhesion of T 
lymphocytes to accessory cells. This would occur in a form of ‘inside-out’ 
signalling, where cyclic AMP produced intracellularly would signal an increase in 
adhesiveness extracellularly (Hahn et a l ,  1993). Indeed this has been suggested to 
occur upon ligation of the CD2 molecule (Hahn et a l,  1993), increasing its avidity
for its natural ligand LEA-3 and may be of importance in the thymic selection, 
upon  stimulation of murine thymocytes with PHA, a rapid transient increase in 
cyclic AMP was observed, possibly mediated through CD2 (Carrera e ta l ,  1988; 
Hahn et a l,  1991). It may be the case that the elevation of cyclic AMP is 
compartmentalised, thus giving a very high local concentration of cyclic AMP 
sufficient to trigger localised membrane signalling events. Indeed, cyclic AMP has 
been shown to play a central role in controlling the mobility of cell surface
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receptors, polarising cell surface molecules to the point of interaction of the cell
(Kammer et a l,  1988).
6.3. M echanism  of regulation.
The mechanisms involved in mediating the rapid changes in PDE2 and 
PDE4 activity upon stimulation of the thymocytes with PHA may involve an 
alteration o f phosphorylation status. In this regard, increased activity correlating
■:p
with PDE phosphorylation, has been noted for particular splice variants of PDE4D 
(Sette et a l  1994a) and for a PDE4 activity found in hepatocytes (Marchmont et a l,
1981; Pyne et a l ,  1989). No studies, however, have thus far characterised any 
phosphorylation of PDE2, although it has been suggested that insulin may lead to 
transient activation of this activity in hepatocytes (Pyne and Houslay, 1988). It is 
possible that the transient decrease in PDE activity might ensue by virtue of a 
dephosphorylation event rather than any phosphorylation. It would therefore be |
interesting to study the mechanism behind the stimulation of, PHA. Although, this IIresearch may be difficult due to the differing complement of cell surface receptors
being ligated in addition to the TCR/CD3 complex
The mechanism by which anti-CD3 antibody stimulation leads to PDE4 
induction appears to be mediated by PKC, as selective inhibitors of PKC inhibit 
this increase, and the phorbol ester, PMA replicates the elevation of PDE4 activity i?;Iobserved upon stimulation with anti-CD3 antibodies. In contrast to this, there is 
evidence which shows that phorbol ester treatment can cause a rapid and profound
=;|:inhibitory effect on PDE activity in hepatocytes, modulation which presumably soccurs through the action of protein kinase C (Irvine et a l ,  1986). However, PMA 
appears to cause an immediate increase in PDE4 activity, whereas anti-CD3-
mediated PDE4 elevation is preceded by an slight decrease in PDE activity. This is I1exciting, as it may imply that PDE4 activity is regulated by two pathways upon
ligation of the TCR/CD3 complex, one of which is inhibitory to PDE4 activity and
the other which is stimulatory. This is supported by the observation that upon t|
I
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addition of chelerythrine, there was not only a block of the rise in PDE4 activity, 
but a decrease in PDE activity. Furthermore, addition of PTK inhibitors also 
abrogated the elevation of PDE4 activity. This implied that a tyrosine 
phosphorylation-mediated event might also be involved in the stimulation of PDE4 
activity. Indeed, tyrosine phosphorylation has previously been shown to activate 
the peripheral plasma membrane PDE (PDE4) in intact hepatocytes, upon 
stimulation o f the cells with insulin (Pyne et a l,  1989). At this stage, it is 
impossible to assess whether the activation of PDE4 activity in murine thymocytes 
is due to a tyrosine or a serine/threonine kinase-mediated pathway. However, it is 
tempting to suggest that early activation of PDE4 may be due at least partially to the 
PTK-mediated activation of PLC-yl and the subsequent activation of PKC (Secrist 
et al., 1991). Further studies in this area should illuminate the pathway from the 
TCR/CD3 complex to PDE4 activation.
The situation described here differs from that seen by Sette et al. (1994b)
where PKA has been shown to mediate the expression of certain splice variants of
PDE4D (PDE4D3.1 and PDE4D3.2), whilst increasing activity pf PDE4D3.3 by
phosphoylation in réponse to thyroid-stimulating hormone. This investigation
demonstrated that splice variants from the same locus could be differentially
regulated on stimulation of the cell by a particular hormone. An elevation of cyclic
AMP has also been shown to cause to an increase in ratPDE3 (PDE4D) expression
in immature Sertoli cells on stimulation with FSH (Monaco et al., 1994; Sette et al.,
1994b; Swinnen etal., 1991b), in cardiac myoblasts (Kovala etal., 1994) and in
Jurkats (Engels et al., 1994). It would be of interest to see whether different PDE4
activités are regulated by different signalling networks. At this stage, it is not
.known which PDE4 is present, or induced in murine thymocytes. Studies are 
cmrently underway in the laboratory to investigate this further.
The induction of the PDE4 is extremely fast, indicating that its gene 
expression, like that of c-jun (Angel et al., 1988) may be controlled by a d^-acting 
TRE to which AP-1 transcription factors bind. This rapid induction is supported by
, a r
work carried out on the induction of PDEl in CHO cells (Spence et al., 1995). The 
PDEl induction process occurred within 25 minutes of phorbol ester treatment of 
the cells, and could also be achieved by over-expression of selected isoforms of 
PKC (a  and e) within the cells. Both of these PKC isoforms are found to be 
present in T cells, and are implicated in the early events of T cell activation (Szamel 
and Resch, 1992). Indeed, PKCe is found to be expressed at high concentrations 
in murine thymocytes (Strulovici et al., 1991).
6.4. Prospects.
It is becoming increasingly evident that cyclic AMP PDEs play an active role 
in regulating the metabolism of cyclic AMP (Conti et a l,  1995b; Houslay and 
Kilgour, 1990). Recently, it has become clear that at least PDE4 sub-families have
:
the ability to be specifically targetted to the plasma membrane by virtue of an 
alternatively spliced N-teiminal domain (Shakur e ta l ,  1995). Research is currently 
underway which suggests that the PDE4A splice variant (RPDE6) binds via a 
proline/arginine rich region in its N-terminal tail to SH3 domains of the non­
receptor tyrosine kinase w-src, p56^ ^^  ^and p50^‘^  ^(McCallum et a l ,  1995). The 
importance of these kinases is well appreciated in T cell activation, implying that 
cyclic AMP PDEs may be centrally located to participate in T cell signalling. Indeed 
the results presented here suggest that PDE4 activity may be regulated by a PTK- 
mediated pathway.
Recent research has rekindled interest in cyclic AMP signalling pathways 
with the observation that cyclic AMP can inhibit raf-1 kinase actvity in fibroblasts 
(Cook and McCormick, 1993; Hafner et a l,  1994; Wu et a l,  1993). This protein 
kinase is a central player in the activation of the MAP kinase signalling cascade 
(Gupta e ta l ,  1994). Raf-1 kinase has recently been found associated with the 
TCR/CD3 complex (Loh et a l ,  1994). In addition, PKA type I isoform as been 
found to be associated with the TCR/CD3 complex (Skalhegg et a l ,  1994). PKA 
is known to mediate stimulatory as well as inhibitory effects on lymphocyte
242
proliferation (see section 1.6). It has been suggested that cyclic AMP-mediated 
stimulation of PKAI may release this kinase activity from the TCR/CD3 complex, 
and through phosphorylation uncouple the TCR from intracellular signalling 
pathways (Skalhegg et aL, 1994). The finding that PDE4 isoforms may be 
localised to this area of the cell by their association with ^rc-family non-receptor 
PTKs, indicates that cyclic AMP PDEs may play a positive role in T cell 
proliferation pathways. These findings could be the basis of a molecular 
mechanism for the modulatory effects of cyclic AMP in T cell biology.
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